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p-ABSA  para-acetamidobenzenesulfonyl azide 
Ac   acetyl 
AIBN   2,2’-azobisisobutyronitrile 
APT   attached proton test 
9-BBN   9-borabicyclo[3.3.1]nonane 
(R)-BINAP  (R)-(-)-2,2’-bis(diphenylphosphino)-1,1’-binaphthaline 
(S)-BINOL  (S)-(-)-1,1’-bi-2-naphtol 
Bn   benzyl 
Boc   tert-butyloxycarbonyl 
b.p.   boiling point 
Bu   butyl 
tBu   tert-butyl 
tBuOH   tert-butyl alcohol 
CAN   ceric ammonium nitrate 
calc.   calculate 
Cbz   benzyloxycarbonyl 
COSY   corelated spectroskopy 
m-CPBA  meta-chloroperoxybenzoic acid 
CSA   10-camphorsulfonic acid 
Cy   cyclohexyl 
de   diastereomeric excess 
DEPT   distortionless enhancement by polarization transfer 
DDQ   2,3-dichloro-5,6-dicyano-1,4-benzoquinone 
DHP   dihydropyran 
DIBAL   diisobutylaluminium hydride 
4-DMAP  dimethylaminopyridine 
DMF   N,N-dimethylformamide 
DMSO   dimethyl sulfoxide 
Dppf   1,1’-bis(diphenylphosphanyl)ferrocene 
EDC   1-(3-dimethylaminopropyl)-3-ethylcarbodiimide 
EI   electron-impact 
eq.   equivalent 
ESI   electrospray ionization 
EtOH   ethanol 
FAB   fast-atom bombardment 
 ii 
FD   field-desorption 
FT-ICR  Fourier transform ion cyclotron resonance 
GC   gass chromatography 
glyme   1,2-dimethoxyethane 
GTP   guanosine triphosphate 
HMBC   heteronuclear multiple bond correlation 
HMDS   bis(trimethylsilyl)amide 
HMPA   hexamethylphosphoric triamide 
HPLC   high performance liquid chromatography 
HRMS   high resolution mass spectrometry 
HSQC   heteronuclear single quantum coherence 
HYTRA  2-hydroxy-1,2,2-triphenylethyl acetate 
Ipc   isopinocampheyl 
IR   infrared 
LDA   lithium diisopropyl amide 
MAPs   microtubule-associated proteins 
MeOH   methanol 
MOM   methoxymethyl 
m.p.   melting point 
MS   mass spectrometry 
NBS   N-bromosuccinimide 
NIS   N-iodosuccinimide 
NMO   N-methylmorpholine N-oxide 
NMR   nuclear magnetic resonance 
NOESY  nuclear Overhauser effect spectroskopy 
OTf   trifluoromethanesulfonate 
PCC   pyridinium chlorochromate 
PG   protecting group 
Ph   phenyl 
Piv   pivaloyl 
PMB   para-methoxybenzyl 
PPTS   pyridinium-4-toluenesulfonate 
i-Pr   isopropyl 
Py   pyridine 
rBSM   recovered based starting material 
RCM   ring closing metathesis 
Rf   retention factor 
 iii 
SAMP   (S)-(-)-1-amino-2-(methoxymethyl)pyrolidine 
TBAF   tetra-n-butylammonium fluoride 
TBDMS  tert-butyldimethylsilyl 
TBDPS  tert-butyldiphenylsilyl 
TEMPO  2,2,6,6-tetramethylpiperidine-1-oxyl 
TFA   trifluoroacetic acid 
THF   tetrahydrofuran 
TIPS   triisopropylsilyl 
TLC   thin layer chromatography 
TOCSY  total corelation spectroscopy 
TPAP   tetra-n-propylammonium perruthenate 
Troc   2,2,2-trichloroethyl oxycarbonyl 
Ts   para-toluenesulfonyl, “tosyl” 
pTsOH  para-toluenesulfonic acid 
UV   ultraviolet 
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1 Introduction 
 
Since the earliest time mankind was using extracts from natural sources like plants, 
animals and fungi for treatment of different diseases without knowing the relation between 
chemical structures and biological activity. During the enlightenment many of the old 
therapy methods were condemned but with the further development of the modern natural 
sciences it was found out that many of the earlier used natural extracts contain in fact 
biological active compounds which can be used as drugs or therapeutics and applied in 
medicine. An important milestone was the discovery of penicillin in 1928 by Sir Alexander 
Fleming.[1] Since this time isolation, characterization and finally synthesis of natural 
molecules with biological activity became one of the main aims in modern organic 
chemistry. 
In the present work two topics concerning natural product synthesis are discussed. 
The first topic represents a novel convergent synthetic way to epothilone analogues, 
whereas the second has as purpose the synthesis of cyclohexenylamines which 
represents a formal total synthesis of the alkaloid epibatidine. 
Since the discovery that the epothilones (see Scheme 1.1) possess a very high 
activity against cancer cells,[2] as well as some advantages compared to the billion dollar 
anticancer drug Taxol® in terms of potency and effectiveness against drug-resistant tumor 
cells, their total synthesis, structural modification and biological investigation became a 
very interesting synthetic target for many scientists all over the world. The epothilones and 
their analogues appeared as the most promising candidates for cancer chemotherapy in 
the present days. 
Cancer is a group of diseases characterized by the uncontrolled growth and spread of 
abnormal cells that invade and disrupt other tissues and spread to other areas of the 
body. If the spread is not controlled, it can result in death. There are two classes of 
factors, which can be responsible for the development of cancer, external factors (for 
example, chemicals, radiation, and viruses) and internal factors (for example, hormones, 
immune conditions, and inherited genes). Causal factors may act together or in sequence, 
to initiate or promote carcinogenesis.[3] 
At the beginning of the last century the word “cancer” was not even mentioned as a 
known disease in medicine, but today cancer is a growing public health problem, and in 
middle Europe and USA it is the second leading cause of death, after the cardiovascular 
diseases.[4] According to studies of the American Cancer Society (ACS) in 1997 in the 
USA died alone around 560 000 people of different cancer diseases. That is more than 1 
500 people a day, averaging approximately one death per minute.[5] These fearful facts 
motivated many research groups around the world to search, to investigate, and to 
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produce drugs against these diseases in an intradisciplinary and intensive way. Very often 
the quantity of biologically active products obtained from natural sources is not enough, 
that’s why the main task of the synthetic chemists is to develop and to optimize 
convergent total syntheses with maximum yields, good stereoselectivity and the fewest 
possible reaction steps. Through a convergent synthesis it is possible to keep the basic 
structure of the desired molecule and at the same time to introduce new functional groups, 
which can promote a higher biological activity. An important issue in the synthesis of 
natural products is furthermore the stereoselectivity. Quite often enantiomeric molecules 
show different biological activities. One example for this, which became known to the 
public in an extreme dramatical way, was the CONTERGAN-affair in 1961. The active 
compound of the analgesic CONTERGAN was thalidomide[6] a chiral molecule, which was 
used as racemic mixture in this drug. Whereas one enantiomeric form had the desired 
activity, the other form damaged very seriously human embryos. Many children born by 
women who had used this analgesic during pregnancy stayed handicapped for their whole 
life. 
In completion to the known ways of epothilone synthesis, the new alternative 
synthetic route, represented in this work, allows the insertion of an additional number of 
different residues in the epothilone scaffold. This will be important for the finding of the 
epothilone analogue with the most suitable properties to become a drug. 
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Scheme 1.1: Structures of the natural occurring epothilones A-F. 
 
 
The second part of this work represents a formal total synthesis of the natural alkaloid 
epibatidine through a straightforward synthesis of cyclohexenylamine as starting material. 
Epibatidine (see Scheme 1.2) occurs as a very potent analgesic agent which shows in two 
assays about 200-500 times stronger activity than those of morphine. The most interesting 
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fact found for this compound is that epibatidine posses a non-opiate mechanism of 
action.[7] Because of the undesired strong side effects known for opiates used as 
analgesic agents, the interest in epibatidine as a potential drug was extremely growing in 
the last ten years. The epibatidine can be isolated from the natural source in very small 
amounts (1mg isolated from the skin of 750 frogs), which stimulated considerable interest 
in its total synthesis. 
 
(-) - epibatidine
N
H N Cl
 
 
Scheme 1.2: Structure of the natural compound (-)-epibatidine. 
 
 
Both classes of compounds represented in this work have several stereocenters 
which play an important role for their biological activity (epothilone has seven, epibatidine 
has three stereocenters). Therefore a main focus was directed on the stereoselective 
synthesis of these compounds and their analogues. 
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2 The Family of Epothilones 
 
2.1 The Macrolactones Epothilone A and B 
 
The epothilones A and B (see Scheme 1.1) were discovered in the late 1980s, by 
Höfle, Reichenbach, and their coworkers at the Gesellschaft für Biotechnologische 
Forschung (GBF) in Braunschweig, Germany.[8] These compounds were isolated from 
culture extracts of the cellulose-degrading myxobacterium Sorangium cellulosum 
(Myxococcales; strain So ce90), first found in soil collected from the banks of the Zambesi 
River in South Africa. Initially the investigations of these compounds were focused on the 
activity of the epothilones against fungi, bacteria, and a variety of animal cell lines.[9] It was 
found that the pure substances show a large spectrum of activity against eukaryotic cells 
whereupon the epothilone B was more active than epothilone A, minimum with factor 2 in 
the most cases. The studies revealed only a narrow spectrum of antifungal activity and the 
field experiments indicated a rather high phytotoxicity of the epothilones.[8-10] These facts 
discouraged an early interest in the epothilones as pesticide agents as well as their 
potential application in agriculture. 
Some years later in 1995, a team from MERCK in the USA independently isolated 
epothilones A and B and they found that these compounds kill tumor cells through a 
mechanism of action similar to that of taxol (paclitaxel), namely through induction of 
tubulin polymerization to microtubules and microtubule stabilization.[2] Thereafter this 
observation was confirmed by the GBF scientists.[9] A special merit in this work had D. M. 
Bollag and coworkers, who established a new very sensitive filtration-calorimetric assay to 
detect microtubule nucleating activity.[2] During a high-throughput screening program to 
discover taxol-like tubulin polymerization agents, the MERCK group subjected tens of 
thousands of compounds to biological assays and their only hits were epothilones A and 
B.[2] So the interest of the family of epothilones resumed, this time with much more 
excitement and momentum. 
Nearly twenty years after the discovery of the mechanism of action of taxol by Horwitz 
et al. (1979)[11] this new class of cytotoxic agents, the epothilones, were found which 
exhibit an almost identical biological activity. By comparison of this activity, it was 
established that the potency of epothilones as tubulin polymerization agents is higher than 
this of taxol (epothilone B > epothilone A > taxol). Both compounds, epothilone and taxol, 
probably compete for the same receptor and replace each other.[2, 12] They are 
“equipotent” in in vitro tests (filtration, light scattering, sedimentation, and electron 
microscopy), show similar kinetics, and provide closely similar microscopic pictures of 
microtubule structure and cell damage. Perhaps the most exciting property of the 
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epothilones is their superiority over taxol as a killer of tumor cells, particularly multiple 
drug resistant (MDR) cell lines, including a number resistant to taxol.[2, 12] Additionally, they 
are slightly soluble in water, while the insolubility of taxol is notorious, which may also 
prove an advantage in their clinical application. MERCK scientists found in displacement 
experiments that epothilones A and B were competitive inhibitors of [3H]-labelled taxol with 
almost identical IC50 values (inhibiting concentration which stops growth in 50% of cells) to 
that of non-labelled taxol, from which it may be deduced that the binding site for 
epothilones is located on the β–tubulin subunit as it is in the case of taxol.[2, 12] In some of 
the cytotoxicity experiments, epothilone B demonstrated a 2000–5000-fold higher potency 
than taxol.[2] For example, Table 2.1 shows some test results from treating of tumor cells 
with epothilones and taxol. The cytotoxicity is determined based on the growing rate of 
human leukemia cells CCRF-CEM as well the taxol resistant subtribe CCRF-CEM/VBL 
and the etoposide resistant subtribe CCRF-CEM/VM1.[13] 
 
Table 2.1: Activity of epothilones and taxol against human leukemia cells. 
Compound 
CCRF-CEM 
IC50 (µM) 
CCRF-CEM/VBL 
IC50 (µM) 
CCRF-CEM/VM1 
IC50 (µM) 
Epothilone A 
Epothilone B 
Epothilone C 
Epothilone D 
Taxol® 
0.003 
0.022 
0.0004 
0.009 
0.002 
0.020 
0.012 
0.003 
0.017 
3.390 
0.003 
0.013 
0.002 
0.014 
0.002 
 
 
Although the chemical structures of the epothilones were reported in the first papers 
by Höfle et al.[8] in 1993 as well as by the MERCK group[2] in 1995, the absolute 
stereochemistry of these natural products was not explained until July 1996.[9] The 
structural assignments were made on the basis of spectroscopic[9, 14] and X-ray 
crystallographic data,[9] and the compounds were named epothilones after their structural 
subunits, epoxide, thiazole and ketone. The determination of the absolute configuration of 
the seven stereocenters in epothilone B was made through X-ray measurements (Figure 
2.1) and chemical degradation of the fragment C13-C16 to (S)-hydroxy succinic acid. As it 
is possible to see from Figure 2.1, the carbon backbone of the macrocycle is largely flat, 
and the side-chain with the thiazol moiety adopts an equatorial position. 
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Figure 2.1: X-ray structure of epothilone B and chemical structures of the 
natural epothilones. 
 
 
Because of the assumption that the epothilones have the same or partly the same binding 
position on tubulin as the taxol, some structural similarities, in spite of their significant 
differences were investigated. Several pharmacophore models, have been formulated to 
explain the interaction of epothilone and tubulin at an atomic level.[15] Based on 
conformational analysis Winkler and Axelsen have developed a model for the taxol-
epothilone-pharmacophore (see Figure 2.2).[16] 
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Figure 2.2: Pharmacophore-model studies based on conformational analysis. 
 
 
2.2 Biological Properties of Epothilones 
 
The cytoskeleton of eukaryotic cells is an extremely complex system possessing a 
multitude of individual components with a whole range of different functions. It is not only 
principally responsible for cell shape, but also plays an essential part in cell movement, in 
nuclear and cell division, and in intracellular transport processes. It is involved in the 
reception of signals from the cell’s environment, as well as for their transformation into 
chains of intracellular signals. Basically the cytoskeleton consists of two distinct but 
mutually interacting and complementary systems, the actin skeleton and the tubulin 
skeleton. In the case of epothilone, it is principally the tubulin skeleton, which is affected. 
The tubulin skeleton is formed through polymerization of protein dimers, consisting of 
one molecule each of globular α- and β–tubulin subunits. Dimer and polymer are in a state 
of dynamic equilibrium, so that the network can respond flexibly and quickly to functional 
requirements. The polymer forms a fine, unbranched cylinder, usually with internal and 
external diameters of 14 and 28 nm, respectively, the so-called microtubule.[17, 18] 
Assembly is initiated by the association of α/β–tubulin dimers to form short protofilaments, 
thirteen of which – as a rule – subsequently arrange themselves side by side and bind to 
form the microtubule (Figure 2.3).[18] 
 
THEORETICAL PART 8 
α-tubulin
 β-tubulin
Heterodimer
Formation
α/β-tubulin
dimer
Microtubules
28 nm
Protofilaments 14 nm
(-)-end 
(less  growth)
(+)-end
(more  growth)
Stabilized
microtubules
Taxol or 
Epothilone
Elongation
Stabilized
nucleation
centers
Elongation  in
presence of
Taxol or
Epothilone
Nucleation
Nucleation in
presence of
Taxol or
Epothilone
 
 
 
Figure 2.3: Schematically representation of the microtubule formation from α- 
and β- tubulin proteines. 
 
 
Formation of microtubules proceeds by a nucleation-elongation mechanism.[19, 20] 
Nucleation is the initial phase of the process in which preformed heterodimers of α- and β- 
tubulin assemble in the presence of magnesium ions, guanosine triphosphate (GTP), and 
microtubule-associated proteins (MAPs). This process is relatively slow until a short 
microtubule is formed. Thereafter follows the much faster elongation phase, which 
involves extension of the microtubule nucleus at both ends by a reversible, noncovalent 
addition of tubulin heterodimers to form polymers. The α/β–tubulin dimers within the 
protofilaments are held together by stronger bonds compared to the ones formed during 
the microtubule assembly between the single protofilaments. The structure of the 
microtubules is dipolar, containing (+)-end, which is kinetically more dynamic, and (-)-end, 
which is less dynamic. Although both ends can either grow or dissociate, it is the (+)-end 
that usually grows faster than the (-)-end, and net growth occurs at the (+)-end, while net 
shortening takes place at the (-)-end.[21] 
THEORETICAL PART 9 
Subsequent growth of the microtubules occurs through the addition of further dimers, 
which involves GTP molecules. Each tubulin dimer carries two GTP molecules, but only 
the one on the β-subunit appears to function.[22] The growth and the dissolution of 
microtubules are regulated by adding (for growth) or hydrolyzing (for shrinkage) GTP on 
the ends of the microtubule. Consequently, microtubules are in a constant state of flux 
responding to the needs of the cell. This state is called “dynamic instability” and is 
controlled by regulatory processes within the cell.[19, 23] Thus, microtubule growth is 
promoted in a dividing or moving cell, but more controlled in a stable polarized cell. The 
half-life of microtubules is about 10-20 min. 
The tubulin skeleton appears to be modulated at two levels. On the one hand there 
are a number of different genes for tubulin, at least five of which are expressed in the 
mammalian brain, and which are possibly activated according to the tissue or organ they 
occur in, or depending on the stage of development, so that from situation to situation it 
may react differently to the signals it receives. In addition, there are a number of proteins, 
the MAPs, which bind to microtubules and affect their behavior. Varying expression and 
constitution of MAP patterns facilitate the cell’s differential influence over its tubulin 
skeleton in different tissues, organs and stages of development.[17] 
As major components of the cellular apparatus known as the mitotic spindle, the 
microtubules play an important role in the mitosis, the process during cell replication in 
which the duplicated genetic material in the form of chromosomes is partitioned equally 
between the two daughter cells.[24] During the transition from metaphase to anaphase, in 
the stage of the active cell division, the fast growing microtubules literally pull the cell 
chromosomes apart pushing them into the two emerging daughter cells. Because of the 
rapid dynamic growth of the microtubules (length increases by 20- to 100-fold compared 
with the interphase) during the active phase, their sensitiveness is extremely high against 
compounds, which can interact with the tubulin.[23, 25] Such antimitotic agents, which take 
action in these stage of the cell cycles inhibit mitosis and lead to cell death (apoptosis). 
A wide range of compounds, including a number of natural products interact with the 
tubulin system, of which some have found practical application. They bind either to the 
tubulin itself or to the MAPs. The antimitotic agents known so far can be classified in four 
main classes, based on their binding place as well as on their mechanism of action: 
 
Class I: Colchicine like binding agents 
This group of compounds include the well-established chemotherapeutic agents 
colchicine,[26] and colcemide,[27] obtained from meadow saffron Colchicum antumnale (see 
Scheme 2.1). Colchicine first binds to free tubulin and the formed complexes are 
incorporated into the microtubules at the growing ends in relatively low concentrations, but 
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show profound effects on the microtubule dynamics, and inhibit the formation of the 
mitotic spindle. 
MeO
MeO
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OMe
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R
O
Colcemide    (R = Me)
Colchicine    (R = Ac)
 
 
Scheme 2.1: Cholchicine like binding agents promoting depolymerization of 
tubulin. 
 
 
Class II: GTP binding agents 
Here belongs the group of the vinca alkaloids, like vinblastine and vincristine [19, 28] 
(see Scheme 2.2), which were isolated from the plant Catharanthus (formerly Vinca) 
roseus. Their binding place is central situated near to the GTP-binding place of the β–
tubulin, whereby the tubulin polymerization is prevented. The vinca alkaloids have been 
used for many years in cancer therapy. 
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Vincristine     (R = CHO)
Vinblastine    (R = Me)
 
 
Scheme 2.2: GTP binding agents promoting depolymerization of tubulin. 
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Class III: Microtubules stabilizing agents 
The most known substance in this class of compounds is Taxol® (registered with the 
trade mark from Bristol-Myers Squibb) as well known as paclitaxel, which was discovered 
from the Pacific Yew Tree (Taxus brevifolia) in 1971.[29] In the meantime this compound is 
also semi-synthetically available and is mainly used for the treatment of a variety of solid 
tumors commonly encountered with ovarian and breast cancer.[30] In contrast to the 
antimitotic drugs described above, taxol disturbs the polymerization-depolymerization 
dynamics of microtubules in vitro. The mechanism of action is based on a stabilization of 
the microtubules against depolymerization so that the mitosis cannot take its regular 
course, which finally results in apoptosis. To this class of compounds belong also the 
epothilones A-F,[31] discodermolide,[32] eleutherobin,[33] sarcodictyn A,[34] and laulimalide[35] 
(see Scheme 2.3). Although the epothilones displace taxol from its receptor, they must 
bind in a slightly different manner to microtubules as suggested by their action against 
taxol-resistant tumor cells, which contain mutated tubulin. 
 
Class IV: Microtubules-Network-destabilizing agents 
To this class belong for example the ecteinascidin 743, isolated from snails, which 
reorganize completely the microtubules-network which leads to cell death. 
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Scheme 2.3: Selected natural products with tubulin polymerization and 
microtubule stabilization properties. 
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2.3 Structure and Activity Relationships of Epothilones 
 
Through investigations of the isolated natural epothilones as well as their synthetically 
obtained large number of derivates, it was possible to find and to explain some structural 
requirements for the biological activity within the epothilone structure.[31] The cytotoxicity 
data for many of the epothilone analogues were compatible with those of the natural 
epothilones, which hold a considerable promise to find the compounds with the best 
properties as a drug candidates. The cytotoxicity investigations were made by 
measurements of the tubulin polymerization through Filtrations-Colorimetric-Assays 
methods.[2, 36] On Figure 2.4 is represented the chemical structure of epothilone, divided 
on four regions A-D, which may easier to explain many relationships between the 
structure and the effect on biological action. 
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Figure 2.4: Structure and activity releationships of the epothilones. 
 
 
Region A includes the C7-C11 part from the carbon skeleton and is relative sensitive 
against modifications. For example the change of the ring size or the stereochemistry of 
C8, as well as the addition or removal of a methyl group on this position, resulted in 
considerable loss of biological activity. 
In contrast, changes in region B (C12-C15) are well tolerated. It was found that the 
absolute configuration of the epoxides had a small influence on the biological activity and 
that both stereoisomers exhibit actually high activity. The derivates of epothilones C and D 
with a double bound are also active and additionally it was proved that changes in the 
geometry of the double bound as well as the epoxide derivates obtained from an E-olefin, 
had little effect on the activity. Since the discovery that epothilone B is more active than A, 
the role of the C12 substituent was extensively studied, whereby other alkyl substituents 
were also accepted and the resulting derivates showed high activity. The (S)-configuration 
at C15 seems to play an important role, because inversion of this configuration leads to a 
significant decrease of tubulin polymerization activity. 
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Modifications in region C reveal less tolerance than in region B. Specifically, depletion 
or direct attachment of the aromatic moiety at C15, as well as replacement of the C20 
methyl group with bulkier alkyl or aryl substituents, resulted in a loss of cytotoxic 
properties. On the other hand only a hydrogen atom as a substituent at C20 lead to a 
small positive changes in the activity. Furthermore, replacement of the C16 methyl group 
with an ethyl group, and the thiazole ring by a number of structurally diverse aromatic 
moieties turned out to be, in general, detrimental to biological activity. The only exceptions 
were N-containing aromatic compounds like oxazoles, 2-pyridyl or 2-thiazoyl-containing 
compounds, where the nitrogen is on the same position as in the natural epothilones and 
the properties of these analogues are comparable to those of the natural products. 
The region D is also relative sensitive towards structural changes. For example, 
inversion of the C3 stereochemistry resulted in significantly reduced potency, as did a 
cyclopropane substitution on C4-position instead of geminal dimethyl moiety. Similar loss 
of activity was observed, when the C5, C6 and C7 sbstituents were removed or when the 
ketone at C5 was reduced. An interesting fact was found when an E-olefin was introduced 
at C2-C3 bound. The resulting compounds retained considerable potency. 
 
 
2.4 Chemistry of the Epothilones 
 
Soon after the recognition of the importance of the epothilones, a number of groups 
around the world began to pursue strategies for their total synthesis. Only few months 
after the structure of these macrolides was published the working groups of S. J. 
Danishefsky,[37] K. C. Nicolaou,[38] and D. Schinzer[39] were able to present independently 
successful total syntheses of epothilones A and B. In the following time many other 
working groups have published contributions to the existing synthetic strategies as well as 
new total syntheses, and essays[31, 40] about the biological role of epothilones. 
Within the scope of the general introduction of this thesis it is not possible to present 
the entire existing literature on this field. Therefore only a short selection of the first total 
syntheses is compiled. For a more comprehensive representation of the chemistry and 
biological activity of epothilones the review of K. C. Nicolaou[31] is recommended. 
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2.4.1 The Danishefsky Strategies to the Synthesis of Epothilones 
 
The first total synthesis of both epothilones A and B including their desoxy precursors 
epothilones C and D respectively, were carried out in the working group of S. J. 
Danishefsky, who made major contributions in the field of epothilone research. In the 
published synthesis a number of interesting reactions and sequences were used as a 
means to install functionality and control stereochemistry. For the construction of the 
macrocycle, Danishefsky and co-workers applied three main strategies, which include a 
macroaldolization reaction,[41] an olefin metathesis approach[42] and a macrolactonization 
procedure.[41] In their first published total synthesis of epothilone A and later also of 
epothilone B two key-step reactions were employed, namely a stereospecific SUZUKI-type 
cross-coupling for combining two synthetically obtained fragments, and a 
macrocyclization-aldol reaction for the ring formation (see Figure 2.5). This synthesis was 
taken as an example and is schematically presented in the following discussion. 
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Figure 2.5: Strategic bond disconnections applied in the total syntheses of 
epothilone A and B by Danishefsky et al. 
 
 
The synthesis of fragment C3-C11 was started with formation of the dihydropyran ring 
A3 by a Lewis acid catalyzed stereoselective cyclocondensation of the enatiomerically 
pure aldehyde A1 with the Danishefsky diene A2 (see Scheme 2.4). The chirality of 
aldehyde A1 determines the configuration of the new stereocentres in the condensation 
product A3. Thereafter followed a stereoselective reduction of the keto group with lithium 
aluminium hydride and the double bound was converted via a SIMMONS-SMITH reaction to 
the cyclopropane derivative A4. The opening of the cyclopropane ring was done with N-
iodosuccinimide (NIS) in methanol, which leads to product A5. Compound A6 was 
obtained after subsequent radical dehalogenation of iodide A5 followed by protection of 
the hydroxy moiety, and thioacetalization of the intermediary formed aldehyde. The 
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product A6 includes the centers C6 and C8, which were prepared in the correct 
configuration, as it was necessary according to the structure of the target molecule. 
Additionally, A6 was a key building block, because it was also suitable for the alternative 
synthetic routes to epothilone and its analogues, reported later by Danishefsky et al. 
Further silyl protection of the new formed hydroxyl group in A6, followed by cleavage of 
the benzyl group, then SWERN oxidation and WITTIG reaction transformed the key building 
block A6 to the methoxyvinyl ether A7. Later this vinyl ether was hydrolysed with p-
toluenesulfonic acid to the aldehyde which was reacted with methlytriphenyl-phosphonium 
bromide and through a subsequent transacetalization the acetal A8 was obtained. 
Compound A8 represents the C3-C11 fragment of the desired carbon skeleton, which is 
one of the two main building blocks necessary for the synthesis of the epothilone A and B 
as well. Sequential formation and opening of the dihydropyran system was the key tactic 
for introduction of the stereochemistry into the final open-chain intermediate A8. 
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Scheme 2.4: Synthesis of the C3-C11 key fragment A8. 
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The second building block C12-C15, employed in the macroaldolization strategy of 
Danishefsky et al, contained the side chain with the aromatic moiety. Initially for the 
synthesis of epothilone A the (R)-glycidol (A9) was used as a starting material, where the 
hydroxyl group was protected with dihydropyran (see Scheme 2.5). Subsequent opening 
of the epoxide leads to a secondary alcohol, which was protected as methoxymethyl ether 
and the compound A10 was formed. After cleavage of the tetrahydropyrane moiety, 
followed by SWERN oxidation and subsequent GRIGNARD reaction the methylketone A11 
was obtained. This compound was reacted with the EMMONS reagent A12 and the silyl 
group was replaced with iodine with the help of N-iodosuccinimide. Thereafter followed 
hydroboration whereby the (Z)-iodoalkene A13 was received. At the end, the 
methoxymethyl ether A13 was cleaved, and the resulting compound was acetylated to 
give the product A14. The desired stereochemistry of the C12-C15 fragment was 
established through the use of the enantiomerically pure starting material A9. 
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Scheme 2.5: Synthesis of the C12-C15 key fragment A14. 
 
 
Short time after the successful synthesis of epothilone A, Danishefsky et al. have 
published also a convergent total synthesis of epothilone B, in which they applied the 
same macroaldolization strategy for the ring formation. This time, the second building 
block C12-C15 was synthesized starting from the aldehyde A15, which was reacted with 
allyltributyltin under enantioselective catalysis and subsequently acetylated to give the 
compound A16 (see Scheme 2.6). Thereafter this compound was dihydroxylated and after 
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glycol cleavage transferred to the vinyl iodide A17 by WITTIG reaction. The product A17 
was an analogue to the above described compound A14 and had an additional methyl 
group at C12, which was obligatory for the synthesis of epothilone B. 
 
1. OsO4, NMO
2. Pb(OAc)4
3. Ph3PC(I)CH3
A17
12
13
14
15
S
N
OAc
I
A16
S
N
OAc
A15
OHC
S
N 2. Ac2O, Et3N, DMAP
1. allyltributyltin, 
(S)-(-)-BINOL, Ti(OiPr)4
 
 
Scheme 2.6: Synthesis of olefin A17 as a starting material for the Suzuki-
coupling. 
 
 
In assembling both fragments, a stereospecific SUZUKI coupling allowed the union of 
intermediates A8 and A14 for epothilone A or A8 and A17 for epothilone B to form after 
an acetal cleavage compound A18 or A19, respectively (see Scheme 2.7). These 
intermediates underwent a stereoselective ring closure through an intramolecular aldol 
reaction to give the desired macrocycles A20 with yield of 51% (stereoselectivity ca. 6:1) 
and A21 with yield of 64% (stereoselectivity ca. 3:2), respectively. Subsequent functional 
group transformations led to the desoxy precursors epothilone C and D, and finally after 
stereoselective epoxidation the epothilones A and B were obtained. 
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Scheme 2.7: Suzuki-coupling and macroaldolization reaction for preparation of 
epothilone A and B. 
 
 
The already mentioned olefin metathesis strategy to obtain epothilone B starts also 
from the key building block A6 (see Scheme 2.8). After removing of the benzyl group the 
hydroxy moiety was oxidized to obtain an aldehyde, which appeared as a starting material 
for the chain elongation. In this way compound A22 was synthesized in several steps. 
Coupling of A22 with compound A16 via aldol addition results in compound A23. After 
several modifications the ring was closed through an olefin metathesis reaction and the 
macrocycle A24 was obtained. For the olefin metathesis the molybdenum-based 
SCHROCK catalyst was used.[43] In this case, however, the C12-C13 double bond was 
formed as a mixture of Z:E isomers in an approximately 1:1 ratio. After cleavage of the 
protecting groups, epothilone D was obtained and final stereoselective epoxidation led to 
epothilone B. 
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Scheme 2.8: Synthesis of epothilone B through an olefin metathesis approach. 
 
 
Because of the low stereoselectivity in the olefin metathesis approach, as well as the 
poor yields in the case of the macrocyclization-aldol reaction, there was a high motivation 
in establishing alternative methods for ring closure.[44] The third route established by 
Danishefsky et al. was the macrolactonization strategy. For that purpose compound A25 
was synthesized (see Scheme 2.9). The most remarkable part of this route was the 
subsequent regio- and stereoselective NOYORI reduction[45] of the keto moiety at C3 to 
obtain compound A26. This was carried out by the use of a ruthenium-binaphtol-complex 
as a catalyst under a hydrogen pressure of 85 atm. The stereoselectivity was higher than 
95%. From compound A26, the epothilones were prepared in several steps including the 
macrolactonization reaction. 
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Scheme 2.9: Regio- and stereoselective Noyori-reduction. 
 
 
2.4.2 The Nicolaou Strategies to the Synthesis of Epothilones 
 
On the field of epothilone synthesis K. C. Nicolaou and co-workers have made a 
remarkable work. The special merits of Nicolaou et al. were to establish different synthetic 
routes not only to the known natural epothilones A-F, but also to a big number of 
epothilone analogues. Additionally, in the working group of Nicolaou experiments on solid 
phase for the construction of epothilone libraries were carried out.[46] Through 
combinatorial methods it was possible to synthesize different single fragments, which 
were used later for the formation of the macrocycles. The synthesis of a big number of 
epothilone derivatives allowed the investigation and understanding of the relationships 
between structure and biological activity. 
Amongst many strategies, Nicolaou et al. considered the olefin metathesis 
approach[47] for constructing of the macrocycle and simultaneously applied as well a 
second strategy based on macrolactonization[38, 46]. Both methods were similar to that 
presented in the work of Danishefsky et al. The first total synthesis made in the working 
group of Nicolaou led to epothilone A and its desoxy precursor epothilone C employing 
the olefin metathesis strategy (see Figure 2.6). 
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Figure 2.6: Strategic bond disconnections applied in the total synthesis of 
epothilone A by Nicolaou et al. 
 
 
After a retrosynthetic analysis the target molecule was divided in three key building 
blocks, which were synthesized independently, following different synthetic pathways than 
the ones described by Danishefsky et al. The C7-C12 building block A29 was obtained 
starting from N-propionyl bornyl sulfonamide A27, which was alkylated with ω-iodo-
pentene and the resulting product was subsequently reduced to alcohol A28 by cleavage 
of the bornyl sulfonamide residue (see Scheme 2.10). Further oxidation with N-
methylmorpholin-N-oxide and tetra-n-propylammoniumperruthenate led to aldehyde A29. 
The synthesis of the C1-C6 fragment A32 began with the stereoselective allylation of the 
keto aldehyde A30 using the BROWN reagent allylisopinocamphenylborane. The new-
formed hydroxy moiety was protected with a silyl group and the compound A31 was 
obtained. An oxidative degradation of the double bound to a carboxyl group provided the 
desired product A32. The thiazol-fragment A35 was synthesized starting from the 
carboxylic ester A33, which was reduced with diisobutylaluminium hydride to the 
corresponding aldehyde. Subsequent WITTIG olefination gave the aldehyde A34, which 
was further transformed through a BROWN allylation[48] to the compound A35. 
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Scheme 2.10: Synthesis of the key fragments for the olefin metathesis approach 
of Nicolaou et al. 
 
 
The two fragments A29 and A32 were combined through an aldol condensation with 
lithiumdiisopropyl amide (LDA) to form the acid A36, which through an esterification with 
the thiazol alcohol A35 gave the starting material A37 for the olefin metathesis reaction for 
constructing of the macrocycle (see Scheme 2.11). For the ring closing metathesis (RCM), 
Nicolaou et al. used the GRUBBS catalyst [RuCl2(=CHPh)(PCy3)2].[49] Thereafter, similar to 
the methods established from Danishefsky et al., the double bound of the desoxy 
THEORETICAL PART 24 
precursor epothilone C was stereoselectively oxidized to an epoxide, to give the end 
product, in this case epothilone A. As stereoselective oxidation reagents were applied 3,3-
dimethyldioxirane (65% yield, diastereoselectivity ca. 3:1), 3,3-methyl-(triflouromethyl)-
dioxirane (75% yield, diastereoselectivity ca. 5:1), or m-chloroperbenzoic acid (48% yield, 
diastereoselectivity ca. 3:1). 
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Scheme 2.11: Aldol reaction and olefin metathesis for preparation of epothilone A. 
 
 
Short time after establishing the first strategy for the building of the ring system, 
Nicolaou and co-workers published their second route, which applied an YAMAGUCHI 
macrolactonization procedure[50] for the ring formation. In this way they carried out the 
stereoselective syntheses of both epothilones A and B, whereas here is schematically 
presented the synthesis of epothilone B. The construction of the carbon-chain starts with 
the formation of the fragments C1-C6 A38 and C7-C15 A43, which were assembled 
through an aldol reaction with LDA to give the ring closure precursor A44. The first 
building block C1-C6 A38 was synthesized starting from compound A31. After ozonolysis 
of A31 followed by reduction to the corresponding alcohol, which was further protected, 
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the key fragment C1-C6 A38 was obtained. For the formation of the other building block 
C7-C15 A43, the alcohol A35 was used as a starting material. In three steps, including an 
oxidation, A35 was transformed to the thiazol aldehyde A39 (Scheme 2.12). Thereafter, 
followed a Z-selective WITTIG reaction with the ylide A40 which lead to the chain-
elongated product A41. The ester function was reductively removed and after a 
hydroboration of the terminal double bond, the primary-formed hydroxy function was 
replaced by iodine to give A42. The configuration at C7 was controlled by a 
stereoselective ENDERS alkylation with SAMP-hydrazone A43.[51] After an oxidative 
cleavage of the chiral auxiliary group and subsequent reduction the desired key building 
block A44 was obtained. 
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Scheme 2.12: Preparation of the C7-C15 fragment A44 for further synthesis of 
epothilone B. 
 
 
The applied aldol reaction for formation of compound A45 with the new stereocenters 
at C7 and C6 occurs with a stereoselectivity of approximately 3:1 (Scheme 2.13). 
Thereafter the ring closure precursor A45 was transformed in several steps to the 
carboxylic acid A46. The macrolactonization was carried out using the YAMAGUCHI 
procedure. After cleavage of the silyl protecting groups in A47 the desoxy precursor 
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epothilone D was received. By the following stereoselective epoxidation to obtain the end-
product epothilone B, diastereoselectivity of approximately 5:1 was achieved. 
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Scheme 2.13: Ring formation via Yamaguchi macrolactonization. 
 
 
2.4.3 The Schinzer Strategies to the Synthesis of Epothilones 
 
Another working group with big contributions in the field of the epothilone synthesis is 
the group of D. Schinzer. At the beginning of 1997, Schinzer et al. published their 
independently developed olefin metathesis approach to epothilones A and C.[39] Their 
design required three key intermediates A50, A29 and A35, which were obtained by 
asymmetric synthesis (see Scheme 2.14). Compounds A29 and A35 were also used in 
the total synthesis of Nicolaou et al. The formation of the single (6R,7S) diastereomer in 
the aldol condensation of the ethyl ketone A50 with the aldehyde A29 under the influence 
of LDA was most impressive, and was attributed to the influence of the acetonide moiety. 
Attachment of the side-chain A35 by esterification, ring closure through olefin metathesis, 
and epoxidation with 3,3-dimethyldioxirane, led to the desired products epothilone C and 
A respectively. Like Nicolaou et al., the group of Schinzer also applied the GRUBBS 
catalyst [RuCl2(=CHPh)(PCy3)2], for the ring closing metathesis reaction. 
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Scheme 2.14: The Schinzer et al. strategic bond disconections and retrosynthetic 
analysis for preparation of epothilone A. 
 
 
In 1998, Schinzer et al. established as well a new synthetic route[52] to epothilone B 
using also the macrolactonization strategy as a key reaction step for the ring formation, 
which is presented in the following. The most innovative steps in this synthesis are the 
successful introduction of the correct chiralities at the stereocentres C3, C6 and C7 via 
stereoselective aldol reactions. The main key intermediates were the C1-C6 fragment A50 
and the C7-C15 fragment A58. 
The synthesis of the C1-C6 fragment was started from the α-bromoester A48, which 
was condensed through a REFORMATSKY reaction with pentane-3-one (see Scheme 2.15). 
After subsequent reduction and oxidation the coupling product was transformed to the 
appropriate aldehyde A49. Thereafter followed a stereoselctive aldol reaction with (S)-
HYTRA [(S)-2-hydroxy-1,2,2-triphenylethylacetate] according to the method of M. Braun[53] 
and the correct chirality at C3 was introduced. The condensation product was further 
reduced, the resulting 1,3-diol moiety was protected as an acetal and the double bound 
was ozonized to give the key compound A50. 
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Scheme 2.15: Synthesis of C1-C6 building block A50. 
 
 
The synthesis of the C7-C15 fragment was beginning from the (S)-hydroxy succinic 
acid derivative A51, which after reduction and cleavage of the protecting group was 
transformed to the hydroxy butyrolactone A52 (see Scheme 2.16). Further silyl protection 
of the hydroxy moiety, ring opening with methyl lithium and subsequent protection of the 
resulting hydroxyl group led to the ketone A53. The thiazol-containing residue was 
introduced by a WITTIG-WADSWORTH-HORNER reaction with A54, and after deprotection of 
the chain-elongated product, the compound A55 was obtained. DESS-MARTIN oxidation 
and WITTIG reaction gave the vinyl iodide A56. Thereafter followed a palladium-catalyzed 
coupling of A56 with the alkyl zinc compound A57 and the resulting product was 
deprotected and oxidized to give the desired C7-C15 key fragment A58. The coupling 
reaction presented by Schintzer et al. appeared as an alternative to the SUZUKI-cross 
coupling used by Danishefsky et al. 
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Scheme 2.16: Synthesis of C7-C15 building block A58. 
 
 
The alkyl zinc compound A57 contains the stereocenter C8 in the later macrocycle 
(see Scheme 2.17). The synthesis of A57 began with the EVANS auxiliary A59, which 
allowed the introduction of the correct chirality.[54] For that purpose the EVANS auxiliary 
A59 was combined in a stereoselective reaction with allyl iodide and the compound A60 
was obtained. The oxazolidinone group was cleaved by reduction with lithiumaluminium 
hydride and after protection of the resulting hydroxy moiety, the terminal double bond was 
degraded by using a mixture of borane-THF complex, iodine chloride and sodium acetate 
and the corresponding iodide A61 was obtained. Compound A61 was coupled with zinc-
copper mixture to the alkyl zinc compound A57. 
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Scheme 2.17: Synthesis of compound A57. 
 
 
The compound A62 was formed via stereoselective aldol reaction with LDA of the C7-
C15 fragment A58 with the C1-C6 fragment A50 (see Scheme 2.18). This reaction step 
introduced the correct configurations at C6 and C7 stereocenters. The high 
stereoselectivity (de 9:1) was reached by the chelation ability of the C1-C6 fragment, 
because of the acetal-protecting group. After cleavage of the acetal group the synthesis to 
epothilone B proceeded similar to the synthesis presented in the work of Nicolaou et al. 
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Scheme 2.18: Aldol reaction and macrolactonization for synthesis of epothilone B. 
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2.4.4 Further Strategies to the Synthesis of Epothilones and Analogues 
 
As it was mentioned already there are plenty of publications in the field of epothilones 
syntheses and it is not possible to discuss all of them in the present thesis. Therefore, 
only a short overview of some important publications is given in the following in addition to 
the first three important strategies described schematically above. 
Similar to the strategy of Schinzer and Nicolaou, the working group of Mulzer 
described independently their syntheses of epothilones.[55] Herein, the key reaction steps 
were also an aldol reaction and macrolactonization. However, for highly stereoselective 
construction of the carbon chain they have used an asymmetric MUKAIYAMA aldol reaction. 
The further synthesis was carried out according to the strategy of Nicolaou et al., whereby 
the KECK-variant of the STEGLICH esterification was applied for the macrolactonization. 
The chiral hydroxyl group at C3-atom from the carbon skeleton was introduced by BROWN 
allylation. The main difference between the strategy of Mulzer compared to the earlier 
published syntheses was the formation of the oxirane ring before the final 
macrocyclization reaction. This allowed a better determination of its absolute 
configuration. 
Furthermore, the total synthesis of S. Sinha and R. A. Lerner has to be mentioned in 
which aldol and retroaldol reactions was used by employing monoclonal aldolase-
antibodies.[56] Another total synthesis was presented also from the working group of P. A. 
Grieco which is based on the olefin metathesis strategy from Danishefsky et al., and the 
correct configuration at C7 and C8 stereocenters was introduced via a ROUSH 
crotylation.[57] A further interesting total synthesis of epothilone B was presented by J. D. 
White, whereby the hydroxyl group at C15-stereocenter was built through an 
oxazolidinone-controlled hydroxylation reaction by using the DAVIS reagent which allows 
the reaction to proceed with high stereoselectivity.[58] One of the newest work concerning 
the syntheses of epothilone A and B was published by Carreira et al.[59] Here, a C13-C15 
bridging nitrile oxide unite plays the central role. 
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3 The Natural Alkaloid Epibatidine 
 
3.1 Isolation and Biological Activity 
 
The alkaloid (-)-epibatidine (see Scheme 3.1) was isolated for the first time in 1992 
from Daly and co-workers[60] from the skin of the Ecuadorian poison frog Epipedobates 
tricolor. This amphibian belongs to the family Dendrobatidae that inhabits the rain forest of 
South and Central America. To this family belong approximately 160 species and more 
than 200 different alkaloids were isolated from the skin of these small, often colorful 
frogs.[61] Most of these alkaloids show strong pharmacological activity against muscle cells 
and the nervous system.[62] For this reason the skin-secret from these animals has been 
used, until the present days, by the native people in the tropic regions of America as a 
source for their arrow poisons. Presumably the biological occurrence of these often 
extremely poisonous compounds is for the passive protection of the frogs against 
rapacious animals or as well for protection of their humid and sensitive skin against 
microbes.[63] However, the amounts of the alkaloids isolated from the natural sources are 
very low. For example for the isolation of 80 mg of a mixture of alkaloids, the skins of 750 
frogs from Epipedobates tricolor was necessary, whereby the amount of the alkaloid 
epibatidine only, was below 1 mg.[60] 
Initially, the crude alkaloid mixture isolated from the Epipedobates tricolor was 
investigated because of the observed STRAUB-phenomenon, when mice were treated with 
this skin-extract.[64] In general it was known, that when the STRAUB-phenomenon 
appeared an opiate-like analgesic activity should be expected. Actually it was found, that 
the special activity of the crude alkaloid mixture is due to the natural substance 
epibatidine.[60] In the applied mice Hot-Plate Test, epibatidine showed about 200-fold 
higher activity than morphine.[65] However, further pharmacological investigations were 
made, which assumed that the natural product epibatidine is a very potent analgesic 
agent and has a non-opiate mechanism of action.[66] Strong hints for this were the facts 
that the general opiate-antagonist naloxone is ineffectual against the symptoms caused by 
epibatidine and that the affinity of epibatidine to the known natural opiate receptors is 
2000 times lower than those of morphine.[66] 
The chemical structure of epibatidine represents an azabicyclic system and contains 
the 7-azabicyclo[2,2,1]heptane unit with an exo-oriented 5-(2-chloropyridyl) substituent 
(see Scheme 3.1).[61, 67, 68] The structure and activity relationship studies show that the 
nucleophilic character of the nitrogen and the configuration of the aromatic substituted 
carbon play a crucial role for the high biological activity.[69] This was proven by comparing 
the activity data of the N-acetyl derivative B1, the N-methyl derivative B2, and the endo-
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epimer of epibatidine B3 with those from the natural compound. The activity, tested on 
mice, was almost the same in the case of epibatidine and its N-methyl derivative B2, 
whereas the N-acetyl derivative B1 and the endo-epimer B3 were inactive. A less 
important role for the biological activity plays the configuration of the bridged carbons on 
the molecule. The activity of non-natural (+)-epibatidine was nearly the same as of its 
natural enantiomer. 
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Scheme 3.1: The natural alkaloid (-)-epibatidine and structurally related 
compounds. 
 
 
In the case of mice the subcutaneous dose of 10 µg/kg epibatidine leads to poisoning 
symptoms like cramps and difficulties in breathing, whereas higher than 10-fold doses are 
lethal. The same doses of the inactive endo-epimere B3 and N-acetyl epibatidine B1 
cause no poisoning symptoms or other effects.[69] 
Qian et al.[70] pointed out the structural similarities of epibatidine with nicotine and 
compared their activities. In fact epibatidine was 120 times more active than nicotine. 
Furthermore, it was found out that epibatidine shows a selective and the strongest so far 
known affinity to the acetylcholine receptors, which are the targets of nicotine as well.[70, 71] 
The acetylcholine receptors play an important role in many diseases like PARKINSON- and 
ALZHEIMER- disease, addiction to nicotine, special forms of colon inflammation and various 
disorders of the central nervous system.[72] Therefore, selective agonists of the 
acetylcholine receptors like epibatidine are promising candidates for the use in therapy of 
these diseases. In spite of symptoms like decrease of body temperature, cramps and 
difficulties in breathing observed in the animal tests, the epibatidine plays also an 
important role as a lead structure for the development of new, extremely effective 
analgesics. Bannon et al.[73] were able to demonstrate that the analgesic activity of 
epibatidine can be partly separated from the undesired side effects. Herewith it was 
proved that the analgesic activity is not a fictitious activity or a consequence of poisoning. 
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3.2 Chemistry of the Epibatidine 
 
The synthesis of 7-azabicyclo[2.2.1]hepta-2,5-diene, 7-azabicyclo[2.2.1]hept-2-ene, 
and 7-azabicyclo[2.2.1]heptane (see Figure 3.1) systems has been the subject of 
numerous synthetic studies which have resulted in the development of several methods 
for the construction of these novel azabicyclic systems.[74] The synthesis of such bicyclic 
structures was only of academic interests until no natural occurring compound was known 
that contains this ring systems.[61, 67] Due to the novel biological activity associated with 
epibatidine and its paucity in nature its total synthesis has aroused the interest of many 
working groups around the world. 
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Figure 3.1: 7-azabicyclo[2.2.1]heptane derivatives. 
 
 
The first total synthesis was achieved by Broka and co-workers[75] and was published 
in 1993, nearly one year after the discovery of epibatidine by Dally et al.[61] Thereafter, 
almost simultaneously were reported several synthetic approaches to the epibatidine 
structure from different working groups. Because the absolute configuration of epibatidine 
was not determined until this point many of the publications described the synthesis of the 
both possible enantiomers (±)-epibatidine.[74] The basic strategies used for the epibatidine 
total syntheses are presented in Scheme 3.2. 
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Scheme 3.2: Retrosynthetic pathways to epibatidine. 
 
 
1) DIELS-ALDER reaction between an activated pyrrole derivate and an activated 
alkyne. The pyridyl residue can be introduced by using a suitable activated pyridyl 
alkyne[76, 77] or by subsequent reductive HECK reaction with a 3-metallated 
pyridine.[78, 79] 
2) 1,3-Dipolar cycloaddition of an azomethine ylide to an activated pyridyl alkene.[80] 
3) Ring contraction of 8-azabicyclo[3.2.1]octane derivative to give 7-
azabicyclo[2.2.1]hept-2-ene. The pyridyl residue was introduced via a reductive 
Pd-catalyzed HECK-type coupling.[81] 
4) Addition of 3-metallated pyridine to 7-azabicyclo[2.2.1]hept-2-one, which was 
obtained from a 3,4-epoxycyclohexane derivative.[62, 82, 83] 
5) Ring closure of 2-pyridyl cyclohexylamine with a suitable leaving group (X) at C4 
(transannular cyclization reaction).[75, 84-88] 
 
 
THEORETICAL PART 36 
From the big amount of published total syntheses of epibatidine only the total 
synthesis of Fletcher et al.[68] is discussed in the present work. This synthetic strategy 
includes the preparation of N,N-benzyltrifluoroacetyl-3-cyclohexenylamine B5 (see 
Scheme 3.3) which was as well one of the target compounds in our straightforward 
synthesis of cyclohexenylamines by olefin metathesis reaction (compound 63d, see 
Section 6.3). In this context our synthetic pathway represent also a formal total synthesis 
of epibatidine. 
 
 
3.2.1 The Fletcher Strategy to the Synthesis of Epibatidine 
 
In the following the total synthesis of epibatidine by Fletcher et al.[68] is presented 
which at first applied the synthetic strategy described above in point 4. Additionally it has 
to be mentioned that in 1993 Fletcher et al. first reported the absolute configuration of the 
natural (-)-epibatidine and determined it to be 1R,2R,4S.[82] 
This synthesis used as starting material the racemic N-trifluoroacetyl-3-
cyclohexenylamine B4 (see Scheme 3.3) which was obtained from 4-
cyclohexenylcarboxylic acid chloride via a CURTIUS-degradation reaction. Compound B4 
was protected at the N-H by reaction with benzyl bromide under basic conditions to give 
N,N-benzyltrifluoroacetyl-3-cyclohexenylamine B5. Epoxidation with m-CPBA led to 
epoxide B6. Basic hydrolysis and subsequent transannular cyclization reaction in the 
polar solvent 1-methyl-2-pyrrolidinone gave the desired N-benzyl-7-aza-2-hydroxy 
bicyclo[2.2.1]heptane B7. Reductive cleavage of the benzyl group followed by introduction 
of the tert-butyloxycarbonyl moiety provided compound B8. Thereafter followed a SWERN 
oxidation which gave the ketone B9. The subsequent reaction with 5-lithium-2-chloro 
pyridine proceeded stereoselective and only the endo-alcohol B10 was obtained. The 
compound B10 was then converted to the coresponding S-methyl xanthate by treatment 
with potassium hydride, carbon disulfide and methyl iodide and thereafter thermolysis in 
toluene resulted in elimination to give the bicyclic olefin B11. After catalytic hydrogenation 
a mixture of two products was obtained, namely the N-protected natural epibatidine (the 
exo-isomer) B12 and the N-protected endo-epibatidine B13, in approximately 1:4 ratio. 
Epimerisation of compound B13 to compound B12 was achieved in 50% yield by longer 
heating (30 h) of the reaction mixture in tert-butanol in the presence of potassium tert-
butoxide. Then the Boc protecting group was cleaved by using hydrogen chloride in 
ethylacetate and the racemic epibatidine was obtained in quantitative yield. 
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Scheme 3.3: The Fletcher et al. total synthesis of epibatidine. 
 
 
It was reported that epibatidine analogues were also prepared from the key 
intermediate ketone B9 following the same synthetic route. Nevertheless, a mixture of 
exo/endo products was always obtained which requires a separation and subsequent 
epimerization of the endo-isomer. 
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Scheme 3.4: Determination of the absolute configuration of epibatidine. 
 
 
To investigate the absolute configuration of the natural product, Fletcher et al.[82] have 
transformed compound B8 to the corresponding Moscher’s esters B14 and B14a using 
(R)-(-)-Mosher’s acid chloride (see Scheme 3.4). The resulting diastereomeric mixture 
was separated by HPLC and the absolute configuration of the natural compound was 
determined to be (-)-(1R,2R,4S)-epibatidine. Confirmation for this was obtained by X-ray 
analysis of the crystalline compound B14a and the subsequent transformation reactions 
which led to the non-natural (+)-epibatidine. 
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4 Formulation of the Problem 
 
Within the scope of the present work two different projects are independently 
presented. The first and as well the main part of the following work concerns the 
development of an alternative strategy to epothilone analogues. Epothilones and their 
related compounds are promising candidates to become chemotherapeutics with 
outstanding relevance, because of their high biological activity against tumour cells and 
interesting mechanism of action as microtubule-stabilizing agents. The structures of 
epothilones are considerably less complex than that of taxol. Nevertheless, the 
epothilones posed a considerable challenge to synthetic chemist and, most importantly, 
offered opportunities for the discovery and development of new synthetic technologies 
and strategies. Variation of the different functional groups in the natural molecule should 
make it possible to find an analogue with higher activity and/or easier applicability for 
large-scale synthesis. 
The purpose of our project is the development of a synthetic strategy that also allows 
rapid access to epothilone analogues.[31] A key feature is the creation of stereocenters by 
aldol reactions. In searching for new and alternative reactions for the synthesis of the 
target molecule it was generally noticed that until now in the all published total syntheses 
the coupling of the key building blocks was accomplished mainly between C6 and C7 
using an aldol reaction. Thereby the desired configuration of the methyl group at C6 was 
often obtained with low stereoselectivity, and the methyl group at C8 had normally to be 
introduced in advance trough a stereoselective alkylation reaction. Therefore we wanted 
to apply a new strategy using an asymmetric EVANS aldol reaction[89] for formation of the 
C7-C8 bond, whereby it would be possible to establish the new stereocenters at C7 and 
C8 with higher stereoselectivity (Scheme 5.1). One of the key fragments should carry the 
methyl group at C6 with the desired configuration, which could be achieved also with an 
asymmetric aldol reaction. For the ring formation we planned to use the YAMAGUCHI 
macrolactonization,[50] which seemed to be the best method for obtaining the 16-
membered macrolide. 
 
As it was mentioned above, in the present work is also discussed a second project 
which includes the straightforward synthesis of cyclohexenylamines by ring closing 
metathesis reaction (RCM) of 4-amino-1,7-octadiene derivatives.[90] This route would 
provide a valuable alternative to the DIELS-ALDER strategy to cyclohexenes with an 
electron donating substituent in the homoallylic position. It was planned to study a 
transannular cyclization reaction for obtaining of bicyclic structures which appear often in 
natural products. Additionally, the present work also constitutes a formal total synthesis of 
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racemic epibatidine,[91] because the compound 63d obtained by our new synthetic route 
using the RCM, has been already used in the total synthesis of this alkaloid.[68] Epibatidine 
is a natural product which is a very potent analgesic agent and its chemical structure 
contains a 7-azabicyclo[2.2.1]heptane ring plus a 5-(2-chloropyridyl) substituent.
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5 Synthetic Pathway for Preparation of Epothilone 
Analogues 
 
5.1 Retrosynthetic Analysis 
 
According to the other published total synthesis of epothilones we have also planned 
to introduced the epoxide function at a late stage of the synthesis by a conformationally 
controlled reaction. Molecular modelling indicates that the epoxide is exposed to the 
outside of the macrocycle. A similar conformation is found also for the corresponding cis-
olefin. 
In our initial retrosynthetic analysis for constructing of the epothilone core structure 
were planned three key reaction steps namely a WITTIG reaction for formation of the 
double bound which would represent later the desoxy precursor epothilone C; then an 
asymmetric aldol reaction for formation of the C7-C8 bond, which required the synthesis 
of the two key fragments C1-C7 and C8-C15; and macrolactonization reaction for 
formation of the macrocycle, whereupon a YAMAGUCHI procedure was envisioned (see 
Scheme 5.1). The attachment of the thiazol ring was planned to be done using a 
palladium-catalyzed cross-coupling reaction between a vinylmetal species and a 4-bromo-
thiazole. This approach would allow for the preparation of aryl analogous of the target 
molecule. The vinylmetal species in turn would arise from a carbometallation reaction.[92] 
For this purpose it would be necessary to introduce the alkyne moiety using the 
SEYFERTH/GILBERT reagent.[93] One could also think about putting on the thiazole at an 
earlier stage of the synthesis. Selective removal of the PMB group, oxidation, epoxidation 
of the double bond, and final deprotection would provide the title compound, namely 
epothilone A. 
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Scheme 5.1 Retrosynthetic analysis for synthesis of epothilone A. 
 
 
After opening of the macrolactone to the hydroxy acid 55 a retrosynthetic cut between 
atoms 7 and 8 by a stereoselective aldol reaction leads to compounds such as 22 and 31. 
Thus, the methyl group at C8 would originate ultimately from a carboxylic group.[94] 
Compounds 22 and 31 represent the two key fragments in our retrosynthesis. The C6 and 
C3 stereocenters in the originally assigned aldehyde 31 might be established by an 
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acylation and subsequent stereoselective aldol reaction. However, according to our 
experiments, it became necessary to replace the initially chosen aldehyde 31 with an 
analogue aldehyde 44 which contains only the stereocenter C6.  
The alkyne moiety in the C8-C15 key fragment would be obtained through reaction of 
the appropriate aldehyde with the SEYFERTH/GILBERT reagent. The cis double bond of the 
oxazolidinone 22, in turn would be fashioned by a WITTIG reaction between a 6-carbon 
building block and the aldehyde 7. This aldehyde contains the future C15 stereocenter of 
the target molecule which might be obtained starting from the optically pure and 
commercially available D-arabinose (1). The choice of protecting groups is not casual and 
suited to the further planned selective deprotections and the oxidation at the end of the 
synthesis. 
 
 
5.2 Synthesis of the C8-C15 Fragment 
 
5.2.1 Preparation of 2-Deoxy-3-O-(4-methoxybenzyl)-4,5-O-isopropylidene-D-
erythro-pentose (7) 
 
The first step in our research work was to obtain the aldehyde 7, which was later used 
as a precursor for the chain elongation through a WITTIG olefination reaction. As a starting 
material we used the optically pure D-arabinose (1), which can function as a source of the 
desired chirality for the stereocenter C15 in the target product. According to the 
literature[95] the aldehyde function of D-arabinose (1) was converted to a dipropyl 
mercaptal, through reaction with 2 equivalents of propyl mercaptan in concentrated 
hydrochloric acid and compound 2 was obtained in 71% yield (see Scheme 5.2). The 
reason for the use of the dipropyl instead of the more common diethyl mercaptal was the 
considerably reduced solubility of the D-arabinose dipropyl mercaptal which makes 
purification by recrystallization easier.[95] The hydroxyl groups of the resulting tetraol were 
protected as acetals, which led to compound 3. For this purpose, a standard procedure 
under acidic conditions and acetone was applied. Treatment of compound 3 with 1.5 
equivalents of potassium tert-butoxide in water free THF/DMSO (3:1) mixture resulted in 
abstraction of the acidic hydrogen and concomitant elimination of acetone to give the 
ketene dithioacetal 4 in 80% yield. 
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Scheme 5.2: Synthesis of 2-deoxy-4,5-O-isopropylidene-D-erythro-pentose di-1-
propyl dithioacetal (5). 
 
 
Because of the instability of 4 under acidic conditions,[96] for the further reduction 
lithium aluminum hydride in dry THF instead of the known protonation hydride transfer 
sequence with trifluoroacetic acid / triethyl silane was used.[97] Compound 5 was obtained 
after work up under aqueous conditions in excellent yield of 98%. In the mechanism of this 
reduction, aluminum coordinates to the oxygen of the free hydroxyl group and a five 
membered cyclic transition state is formed in which the hydride is transferred to the 
carbon of the double bond.[98] 
Thereafter followed a protection of the free hydroxy moiety of 5 and compounds 6a-d 
were obtained (see Scheme 5.3). For that purpose were made several experiments with 
different protecting groups. The interesting fact however was, that in the case of benzyl 
(Bn) and tert-butyl(diphenyl)silyl (TBDPS) protecting groups the yields were very poor, 
whereas with p-methoxybenzyl (PMB) and tert-butyl(dimethyl)silyl (TBDMS) groups the 
yields were nearly quantitative. According to our initial synthetic strategy the PMB-ether 
6a was used for the next studies, which would allow a selective deprotection at the end of 
the synthesis. In a later phase of this synthetic route, during an aldol reaction for 
combining the two key fragments, we observed that the PMB protecting group was not 
stable and we had to exchange it with the more bulky triisopropylsilyl (TIPS) group (see 
Section 5.2.4). Further experiments with the TBDMS-ether 6b, were also made until the 
first key reaction, namely the WITTIG reaction for the chain-elongation, whereupon after 
working up and/or purification a substantial part of the desired product decomposed and 
the yield unfortunately was only 5%. 
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Scheme 5.3: Protection of the hydroxy moiety of compound 5. 
 
 
The desired 2-deoxy-3-O-(4-methoxybenzyl)-4,5-O-isopropylidene-D-erythro-pentose 
(7), was obtained after dithioacetal cleavage of 6a, with mercuric (II) chloride and calcium 
carbonate in a mixture of acetonitrile / water (4:1) using the known procedure of Kende et 
al.[99] The aldehyde 7 was obtained in 84% yield as a pure product and further purification 
was not necessary (see Scheme 5.4). 
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Scheme 5.4: Cleavage of the dithioacetal to aldehyde 7. 
 
 
5.2.2 WITTIG Reaction for Formation of the Carboxylic Acid 9 
 
To form the double bound it was planned to apply a WITTIG olefination, which was as 
well our first key reaction for the preparation of the chain-elongated product 9, containing 
the C8-C15 part of the carbon skeleton of the 16-membered macrocycle. For that purpose 
the aldehyde 7 was reacted with the non-stabilized ylide, prepared in advance from (5-
carboxypentyl)triphenylphosphonium bromide (8) and sodium bis(trimethylsilyl)amide (see 
Scheme 5.5).[100] The phosphonium bromide 8 was easily synthesized by heating 
equimolar quantities of triphenylphosphine and 6-bromohexanoic acid in toluene for 24 h 
and under inert atmosphere.[101] 
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Scheme 5.5: Chain elongation by WITTIG reaction. 
 
 
The resulting unsaturated carboxylic acid 9 was obtained in an excellent yield of 99% 
as a single isomer. Unfortunately it was not possible to confirm the Z-configuration by 1H 
NMR, because both signals from the olefinic protons were overlapping and therefore the 
value of the coupling constant could not be determined. For proving isomeric purity, the 
product 9 was treated with diazomethane to give the corresponding methyl ester and after 
GC-MS only one product was detected. Based on literature precedence it was assumed to 
be the Z-isomer. 
Thus, it is known from the literature that non-stabilized triphenylphosphorus ylides 
generally react with aldehydes to afford mainly Z-alkenes, by a process suggested to 
involve oxaphosphetane intermediates.[102] The stereochemistry of the WITTIG reaction can 
be affected by solvent, cation, temperature, and type of aldehyde. Z stereoselectivity is 
maximized by polar aprotic solvents, exclusion of lithium salts, and low reaction 
temperatures.[100] To explain the stereochemistry it is necessary to look at the mechanism 
of the WITTIG olefination reaction (see Scheme 5.6).[103] At the beginning occurs a [2+2]-
cycloaddition of the ylide to the aldehyde, which can result in a cis- or trans-configuration 
of the oxaphosphetane. Because of the 4 participating electrons, the thermal cycloaddition 
has to occur via a MÖBIUS transition state or a [π2s + π2a] approach, respectively. The two 
double bonds approach each other in a perpendicular fashion with the R groups as far as 
possible apart from each other. Therefore, the transition state leading to the cis-
oxaphosphetane is favored. The four-membered ring collapses to give the alkene and 
triphenylphosphine oxide. Triphenylphosphine oxide is exceptionally stable, and the 
conversion of triphenylphosphine to triphenylphosphine oxide provides the driving force 
for the WITTIG reaction. The collapse of the four-membered ring is stereoselective and the 
cis-oxaphosphetane exclusively forms a cis-olefin, and respectively the trans-
oxaphosphetane forms only a trans-olefin. The formation of the 1,2-substituted 
oxaphosphetane is kinetically controlled. This process is very fast and irreversible. When 
stabilized ylides are used the thermodynamic stability of the resulting oxaphophetanes is 
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increased and therefore, the selectivity to form the cis-oxaphosphetane is decreased. 
Consequently, in this case the E-alkene can be obtained also, whereas non-stabilized 
ylides, especially under lithium salt-free conditions, give Z-alkenes with high selectivity. 
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Scheme 5.6: Mechanism of the WITTIG reaction. 
 
 
5.2.3 Introduction of the EVANS Auxiliary and Synthesis of Compound 18 
 
With the WITTIG olefination the carbon skeleton of the C8-C15 fragment was 
complete. Because of the subsequently planned stereoselective EVANS aldol reaction[104] 
for combining the two key fragments, it was necessary to introduce a chiral auxiliary in the 
molecule. In the present work two alternative routes for introducing the EVANS auxiliary, 
namely the oxazolidinone moiety, are presented. Additionally, the acetal group was 
cleaved and the terminus modified to obtain an alkyne residue, which is needed for the 
future attachment of the thiazole group by a cross-coupling reaction. 
Route A: Removal of the isopropylidene group from the unsaturated acid 9 was 
achieved using 5 equivalents of copper(II) chloride dihydrate in refluxing methanol for 1.5 
h (see Scheme 5.7). Additionally, as a side effect of this reaction, esterification of the free 
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carboxyl group was observed and the dihydroxyester 10 was obtained. Subsequent glycol 
cleavage was carried out by using of sodium(meta)periodate in 60% aqueous acetonitrile 
solution to give the unstable aldehyde 11, which was used immediately for the next 
reaction step. According to the literature[99] the aldehyde was used directly without further 
purification, because otherwise an undesired racemization at C15 has to be expected. 
Small racemization was always observed, which was evident from GC-MS at the stage of 
compound 22 and thereby the ratio was determined to be approximately 96:4. Thereafter 
the aldehyde moiety was transformed to an alkyne group by using the SEYFERTH/GILBERT 
reagent 15,[93] and potassium tert-butoxide as a base.[105] The reaction was carried out at –
78°C in anhydrous THF and under inert atmosphere and the desired product 16 was 
obtained in excellent yield of 96%. Further saponification of the methyl ester with lithium 
hydroxide at room temperature in a mixture of THF/H2O/MeOH (6:3:2) gave the alkynoic 
acid 17 as colorless oil in 77% yield. Thereafter followed the attachment of the chiral 
auxiliary, which was done with the EVANS’s protocol.[106, 107] Thus, the chiral oxazolidinone 
37 was deprotonated with n-butyllithium at –78°C in THF and the resulting lithio derivative 
was reacted at –78°C with the mixed anhydride derived from the alkynoic acid 17, pivaloyl 
chloride, and triethylamine. The desired carboximide 18 was obtained after a silica gel 
chromatography in 52% yield. 
RESULTS AND DISCUSSIONS 49 
 
37
18
OPMB
H
N
O
O
O
Bn
52%
2. 
1. Piv-Cl, Et3N, THF
HN
OO
Bn
LiN
OO
Bn
n-BuLi, THF
-78°C
HO
OH
OPMB
COOMe
9
10
OHC
OPMB
COOMe
11
96%
KOtBu, (MeO)2P(O)CHN2 (15),
THF
98%
NaIO4,
60% aq. CH3CN
16 17
OPMB
H COOH
OPMB
H COOMe 77%
LiOH.H2O,
THF/H2O/MeOH (6:3:2)
57%
1. CuCl2.2H2O, MeOH, reflux
2. NaHCO3, H2O
 
 
Scheme 5.7: Route A for formation of compound 18.  
 
 
The dimethyl(diazomethyl)phosphonate (15) (SEYFERTH/GILBERT reagent) was 
synthesized in advance[93] and it turned out that the reagent was stable for a longer time, 
when stored under inert atmosphere and at –18°C. For the preparation of the 
SEYFERTH/GILBERT reagent the commercially available dimethyl methylphosphonate (12) 
was used, which was temporarily trifluoroacetylated to give the intermediate 13, existing 
as a ketone hydrate (see Scheme 5.8). This was used directly without purification in the 
diazo/trifluoroacetyl exchange to give the dimethyl(diazomethyl)phosphonate (15). 
According to the original literature the most convenient reagent for the diazo/trifluoroacetyl 
exchange was the p-acetamidobenzenesulfonyl azide (14) (p-ABSA) and the reaction was 
performed at 0°C in acetonitrile with triethylamine as a base.[108] Comparable to the WITTIG 
reaction the SEYFERTH/GILBERT reagent forms with the aldehyde in the first step an 
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oxaphosphetane, which collapses under loss of dimethyl phosphate to give the unstable 
diazo alkene. The diazo alkene decomposes to nitrogen and a vinylidene carbene 
intermediate, which stabilizes itself through a migration of the alkyl residue to the 
electrophilic carbon and formation of a triple bond. 
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Scheme 5.8: Preparation of the SEYFERTH/GILBERT reagent and mechaism of the 
alkyne formation. 
 
 
Route B: In comparison to route A, the introduction of the EVANS auxiliary was done 
at the first step after the WITTIG olefination reaction. This had as advantage the formation 
of the caboximide function at the beginning, which prevented the methyl ester formation 
and the saponification step was not necessary. The introduction of the oxazolidinone 
auxiliary was made using the EVANS procedure as was described above whereupon the 
mixed anhydride was prepared this time from the carboxylic acid 9, pivaloyl chloride and 
triethylamine (see Scheme 5.9). The desired product 19 was purified by silica gel 
chromatography and was obtained in 78% yield as a colorless oil. The isopropylidene 
group was removed as before using 5 equivalents of copper(II) chloride dihydrate in 
refluxing methanol and the glycol 20 was obtained in 88% yield. Subsequent treatment of 
20 with sodium(meta)periodate in 60% aqueous acetonitrile solution gave the aldehyde 21 
as a highly viscous oil, which was used directly without further purification for the same 
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reason as it was described above, namely undesired racemization at C15. Thereafter 
followed reaction of the aldehyde 21 with the SEYFERTH/GILBERT reagent 15 for formation 
of the alkyne moiety and the oxazolidinone 18 was obtained in 60% yield. 
 
18
9
60%
KOtBu, (MeO)2P(O)CHN2 (15),
THF
OHC
OPMB
O
O O
N
Bn
21
78%
37
2. 
1. Piv-Cl, Et3N, THF
HN
OO
Bn
LiN
OO
Bn
n-BuLi, THF
-78°C
19
O
O
OPMB
O
O O
N
Bn
HO
OH
OPMB
O
O O
N
Bn
2088%
1. CuCl2.2H2O, MeOH, reflux
2. NaHCO3, H2O
96%
NaIO4,
60% aq. CH3CN
 
 
Scheme 5.9: Route B for formation of compound 18. 
 
 
5.2.4 Protecting Group Exchange 
 
Compound 18, which carries the chiral oxazolidinone moiety, was the starting 
material for the subsequent stereoselective aldol reaction. For this aldol reaction we used 
the conditions established by Evans et al. with n-Bu2BOTf as a Lewis acid and 
triethylamine or diisopropylethyl amine (HÜNIG base) as a base.[104] Unfortunately, the 
experiments with this substrate and different test aldehydes were not successful and a 
mixture of recovered starting material and deprotected product was always obtained. 
That’s why we considered a new strategy, where the PMB group was exchanged with the 
more bulky TIPS protecting group. For this purpose compound 18 was treated with 3 
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equivalents of ceric ammonium nitrate in acetonitrile / water (3:1) mixture and the desired 
deprotected product 22 was obtained in almost quantitative yield (99%) as a colorless oil, 
which solidified on standing as a white solid (see Scheme 5.10).[99] Here it is important to 
mention that the work up and the purification of this reaction step have to be done 
immediately, because otherwise decomposition of the product was observed. The 
secondary hydroxyl group of 22 was further protected with triisopropylsilyl chloride in 
anhydrous CH2Cl2 in the presence of imidazole as a base and dimethylaminopyridine as a 
catalyst. The reaction was followed by TLC and after 3 days no more starting material was 
presented and compound 23 was obtained in excellent yield of 95% as a colorless oil. 
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Scheme 5.10: Protecting group exchange for obtaining the suitable C8-C15 
fragment 23. 
 
 
The TIPS protected β-keto imide 23 represents the fragment C8-C15 of the target 
carbon skeleton from the natural epothilones and is the first key intermediate applied in 
our synthesis. 
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5.3 Synthesis of the C1-C7 Fragment 
 
5.3.1 Initial Experiments for Synthesis of the Aldehyde 31 
 
The fragment C1-C7 was actually an aldehyde molecule, which according to the 
carbon skeleton of the natural product required an anti-relationship between C3 and C6, 
and a protecting group at C5 that can be removed selectively. We have thought of several 
options to reach a compound like 31. Our initial route was thought to start from 
oxazolidinone 24, which had to be acetylated to the keto imide 25 (see Scheme 5.11). A 
subsequent aldol reaction with the aldehyde 26 in presence of stannous triflate should 
give compound 27 with the indicated stereochemistry.[109, 110] Treatment of 27 with 
triacetoxyborohydride[111] would lead to the anti-1,3-diol 28. Although the compound 28 
carries two similar hydroxyl groups, a regioselective monosilylation could be expected 
according to the literature.[110] After that, it was planned to convert 28 via a transamination 
to the WEINREB amide 29, protect the remaining hydroxyl function and finally to reduce the 
WEINREB amide 30 with DIBAL, to provide the aldehyde 31. 
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Scheme 5.11: Initial considerations for synthesis of aldehyde 31. 
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Following this synthetic strategy compound 25 was obtained in excellent yield (90% 
over two steps) after an asymmetric EVANS aldol reaction with n-Bu2BOTf and 
triethylamine, and subsequent oxidation of the new formed hydroxyl group with SO3-Py 
complex in anhydrous DMSO.[109] The first problem appeared during the aldol reaction in 
the presence of stannous triflate for preparation of compound 27. Unfortunately, all the 
experiments with different aldehydes and different Lewis acids for obtaining the desired 
product 27 were not successful and in all cases oxazolidinone cleavage, followed by 6-
membered lactone formation was observed (see Scheme 5.12). It seems likely that the 
lactonization is favored by the geminal dialkyl effect of the substrate. The structures of the 
resulting products were determined by NMR- and MS analysis.  
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Scheme 5.12: Observed lactonization by using compound 25 as a starting material 
for aldol reaction. 
 
 
From the NMR spectroskopic data it can be assumed, that the keto form is the mainly 
occurring one. The 13C shifts of the carbonyl signals C1 and C3, as well as the C2 signal 
gave no hints for enolization. This is also confirmed by the integration of the signal of the 
acidic proton at C2 from the 1H-NMR spectra. As an example, the NMR data of compound 
32a are presented in Table 5.1. 
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 Table 5.1: NMR data of compound 32a. 
Position 1H [ppm] 13C [ppm] 
1 - 169.9 
2 3.56 (q, 1H, J = 7 Hz) 49.3 
3 - 207.6 
4 - 46.3 
5 4.64 – 4.68 (m, 1 H) 78.1 
7 1,28 (d, 3 H, J = 7 Hz) 8.1 
8, 8´ 1.08 ; 1.04 (s, 2 x 3 H) 21.3 ; 18.0 
9 1.72 –1.79 (m, 2H) 31.7 
10 4.64 - 4.68 (m, 2H) 58.4 
11, 11´ 0.01 (s, 6H) -5.2 
12 - 18.3 
12
O
O
O
O
Si
12
3
4 5
7
8 8'
9 10
11'
11
13
13'
13"
 
13, 13´, 13´´ 0.84 (s, 9H) 25.9 
 
 
To circumvent this problem, we have thought of an alternative way to reach the anti-
I,3-diol 28 by applying an Evans aldol reaction between the oxazolidinone 24 and the 
ketoaldehyde 33 (see Scheme 5.13). Unfortunately, the synthesis of the ketoaldehyde 33a 
was also problematic. For its preparation a MUKAIYAMA cross-aldol reaction between the 
silyl enol ether 34 and a C3-aldehyde, for example 26a, was examined.[112] It was not 
possible to purify the resulting aldol product. Therefore, the subsequent DESS-MARTIN 
oxidation was performed on the crude product. However, only decomposition was 
observed. Therefore, this rout was not further investigated. 
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Scheme 5.13: Further considerations for obtaining aldehyde 33 through 
MUKAIYAMA aldol reaction. 
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From the experiments toward an aldehyde of type 31 the following conclusions could 
be drawn. First, a free hydroxyl group at C3 (epothilone numbering) is not possible with a 
carboxylic group at C7 due to lactonization. Second, an aldol reaction forming the C5-C6 
bond is very difficult due to steric hindrance (quaternary center at C4, see Figure 5.1). 
Thus, other routes were developed.[113] In this work, we therefore concentrated on a less 
complicated C1-C7 fragment. 
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Figure 5.1: Steric hindrance between the methyl groups at C4 and C6 in the 
assumed transition state. 
 
 
5.3.2 Preparation of Aldehyde 44 
 
After the unsuccessful experiments for the synthesis of aldehyde 31 we chose a third 
option this time for preparation of the analogue compound 44. For that purpose we started 
again from the carboximide 24, which was synthezised from (S)-phenylalanine (35), 
according to the EVANS procedure,[114] as it is shown on Scheme 5.14. The (S)-
phenylalanol (36) was obtained in 78% yield after a direct reduction of the α-amino acid 
with a borane. The resulting β-amino alcohol 36 can be transformed into oxazolidinone 37 
using 2 equivalents of diethylcarbonate and catalytic amounts of potassium carbonate. 
Further depotonation with n-butyllithium at –78°C and subsequent acylation with freshly 
distilled propionyl chloride gave the desired carboximide 24 in 98% yield. 
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Scheme 5.14: Preparation of oxazolidinone 24 and aldehyde 40 as a starting 
materials for the further synthesis of C1-C7 fragment. 
 
 
The C1-C7 chain from the desired molecule was built through a syn-aldol reaction 
with the formed titanium enolate of 24 and the aldehyde 40, whereby as a base the 
commercially available (-)-spartein was used (see Scheme 5.15).[115] The aldol product 41 
was obtained as a single diastereomer in excellent yield of 98%. The stereochemical 
outcome of this reaction is discussed in the next Section 5.4. The aldehyde 40 was 
obtained in two steps starting from 1,5-pentanediol (38), which was monosilylated 
according to the literature[116] to give the compound 39. Subsequent SWERN oxidation with 
oxalyl chloride, anhydrous DMSO and triethylamine led to the aldehyde 40 (see Scheme 
5.14). 
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Scheme 5.15: Synthesis of C1-C7 fragment 44. 
 
 
Thereafter was prepared in situ a dimethylaluminum amide intermediate by treatment 
of N,O-dimethylhydroxylamine hydrochloride (WEINREB salt) with trimethylaluminum and 
evolution of methane was an evident. This reagent was necessary for converting the 
oxazolidinone moiety of the aldol product 41 to the WEINREB amide 42 (see Scheme 
5.15). The free hydroxyl function was than protected with chloromethyl methyl ether in the 
presence of diisopropylethylamine to give the MOM-ether 43 in 97% yield. This protecting 
group was chosen because the experiments for introduction of the more convenient PMB-
group were unsuccessful and always led to unknown products, either using the standard 
procedure with NaH in dry DMF or applying the procedure with p-methoxybenzyl 
trichloroacetimidate[117] and trifluoromethanesulfonic acid as a catalyst.[118] Further 
reduction of the protected WEINREB amide 43 with DIBAL gave the desired end-aldehyde 
44 in almost quantitative yield as a colorless syrup. The mechanism of this transformation 
is represented on the following Scheme 5.16. The WEINREB amide is attacked by a 
metallorganic compound (methyllithium or DIBAL) which leads to formation of a stable 
tetrahedral-intermediate, whereas (MeO)MeN- - moiety represents an extremely bad 
leaving group. At the same time the metal atom is chelated by the methoxy group which 
additionally stabilizes the Weinreb-intermediate. Thus, the two-fold reaction by excess 
amounts of metallorganic reagent is prevented. The intermediate collapses to the 
corresponding aldehyde or ketone after work up under aqueous conditions. 
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Scheme 5.16: Mechanism of the WEINREB amide reduction . 
 
 
The aldehyde 44 represents our simplified C1-C7 key fragment that was used in the 
main asymmetric aldol reaction for the combination of the two fragments. Comparing with 
the structure of the natural product, here the methyl group at the C3 stereocenter is 
missing as well as the two methyl groups at C4, which will lead to the synthesis of an 
epothilone analogue. 
 
 
5.4 Combination of the Fragments via an Asymmetric Aldol 
Reaction 
 
One of the most important reactions used in our work was the asymmetric EVANS 
aldol reaction[89] for formation of a new C-C bond and two new stereocenters. This type of 
reaction was applied two times in our synthetic strategy. Once it was used in the synthesis 
of the C1-C7 fragment and as a key reaction for combination of the two fragments C1-C7 
and C8-C15 which formed the precursor for the further macrocyclization step. 
To explain the stereochemical outcome of this reaction it is necessary to present its 
mechanism. The aldol reactions are one of the most common reactions that utilize enolate 
chemistry. A substituted carbonyl compound can form to enolates, the Z- or E-enolates 
(neglecting regioisomers). Each isomer then reacts with the electrophile (re- or si-face 
attack) to give two different products. The geometry of the resulting enolate plays an 
important role in determining the stereochemical outcome of the aldol reaction, which 
proceeds via a cyclic transition state (Zimmerman-Traxler-model). In general, the Z-
enolate reacts further with the aldehyde to produce syn-products whereas the E-enolate is 
responsible for the formation of the anti-products (see Scheme 5.17). 
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Scheme 5.17: (Z)- and (E)-enolate formation and the corresponding 
stereochemical outcome after aldol reaction. 
 
 
Within syn- or anti-aldol products, enantioselection can be obtained via a chiral 
auxiliary or a chiral ligand based enolate. A good chiral auxiliary should have the following 
properties: to be suitable for easy introduction with high yield and high optical purity; 
stable under enolate reaction conditions; to induce high diastereofacial selectivity; and to 
be easily removed and when possible recovered.[89] The most popular auxiliary which was 
used also in our synthesis, is the EVANS oxazolidinone prepared from an α-amino acid as 
it was described above in Section 5.3.2. 
For a typical EVANS aldol reaction, the starting carbonyl derivative reacts at -78°C with 
n-Bu2BOTf and Et3N or i-Pr2NEt as a base to give the Z-enolate which further reacts with 
the aldehyde to give the syn-aldol product (commonly known as “Evans” syn) with a high 
diastereofacial (>250:1, >99% de) selectivity.[104] The favored formation of the Z-enolate 
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can be explained by the fact, that the intarmolecular steric hindrance between the auxiliary 
group and the reasidue R is much bigger in the transition state which leads to the E-
enolate compared to this which results in Z-enolate. The reaction is believed to proceed 
via a Zimmerman-Traxler-type cyclic transition state, in which the re-face of the enolate is 
hindered by the chiral auxiliary leading to attack from the si-face of the enolate giving 
“Evans” syn product. The unfavored transition state leads to the “non-Evans” syn product 
(see Scheme 5.18). For electronic reasons (dipol alignment) the C=O of the oxazolidinone 
and the C-O of the enolate point in opposite directions. 
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Scheme 5.18: Transition states of the EVANS aldol reaction. 
 
 
Titanium[118-120] and tin[121] metal centers have also been reported to be effective in 
creating well-ordered transition states for aldol reactions. Because in our particular 
synthetic route the experiments with n-Bu2BOTf were in a large part unsuccessful, as it is 
described later, we have looked for an alternative way to obtain the same stereoselective 
results in agreement with the stereochemistry of the target molecule. For this purpose we 
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used TiCl4 as a Lewis acid and (-)-sparteine as a base even though it was reported that 
titanium enolates of the EVANS acyl oxazolidinones are less selective than the boron 
enolates.[122] According to the literature[115] the transition state has been proposed for the 
titanium enolate to give the “Evans” syn aldol product. An additional important point is that 
TiCl4 and (-)-sparteine could be used directly as received without further purification in 
contrast with n-Bu2BOTf, which was prepared in advance in two steps[123, 124] (see 
Experimental part) and even freshly distilled was stable only for a short time as a 1M 
solution in anhydrous CH2Cl2. 
In our synthesis the first test EVANS aldol reactions were studied with the building 
block 19, which carries the isopropylidene moiety and the PMB-ether functionality using a 
freshly prepared n-Bu2BOTf and Et3N or HÜNIG base in presence of different aldehydes 
(see Table 5.1). Unfortunately, the isopropylidene and the PMB groups were not stable 
under different reaction conditions and in all cases no desired products were obtained. 
Then we have thought to apply the asymmetric aldol reaction after modification of the 
isopropylidene group to a triple bond but our test experiments failed again and a mixture 
of recovered starting material and starting material with cleaved PMB group was always 
obtained (Table 5.2). To circumvent the problems with the cleavage of the PMB group we 
exchanged it with the more bulky TIPS group as it was described above in Section 5.2.4, 
and the desired boron enolate mediated aldol reaction was applied again whereby only 
deprotection was observed (Table 5.2). 
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Table 5.2: Studies on test aldol reactions. 
 
Starting 
material 
 
Reagent and reaction 
conditions 
 
Aldehyde 
 
Remarks 
O
O
O
R
PMB
19  
 
 
1.2 eq. n-Bu2BOTf, 
1.3 eq. Et3N 
in CH2Cl2 
0°C → -78°C, 30 min 
 
 
CHO
BnO
(1.5 eq)  
-78°C → 0°C, 1h 
 
decomposition 
19 
1.2 eq. n-Bu2BOTf, 
1.3 eq. i-Pr2EtN 
in CH2Cl2 
0°C, 45 min 
 
 
CHO
(1.5 eq)  
-78°C, 30 min; RT, 2h 
 
decomposition 
19 
1.2 eq. n-Bu2BOTf, 
1.3 eq. i-Pr2EtN 
in CH2Cl2 
0°C, 45 min 
 
 
(1.5 eq)
CHO
TBDMSO
 
-78°C, 30 min; RT, 2h 
 
decomposition 
PMBO
R
H 18  
1.2 eq. n-Bu2BOTf, 
1.3 eq. Et3N 
in toluene 
-60°C, 1h → -38°C, 
1.5 h 
 
 
CHO
(1.5 eq)  
-78°C → RT, 2 d 
 
recovered 
starting material 
(93%) 
and 
cleavage of the 
PMB-group (7%) 
18 
1.2 eq. n-Bu2BOTf, 
1.3 eq. i-Pr2EtN 
in CH2Cl2 
0°C, 45 min 
 
 
(1.5 eq)
CHO
TBDMSO
 
-78°C, 30 min; RT, 2h 
 
recovered 
starting material 
(100%) 
18 
3 eq. n-Bu2BOTf, 
3.3 eq. Et3N 
in CH2Cl2 
0°C, 2 h 
 
 
(1.5 eq)
CHO
TBDMSO
 
-78°C, 1 h; RT, 2h 
 
cleavage of the 
PMB-group 
(100%) 
23
O
O
O
R
TIPS
 
7.5 eq. n-Bu2BOTf, 
8.25 eq. Et3N 
in CH2Cl2 
0°C, 1 h 
 
 
CHO
BnO
(1.5 eq)  
-78°C, 1 h; RT, 2h 
 
cleavage of the 
TIPS-group 
and 
decomposition 
23 
1.2 eq. n-Bu2BOTf, 
1.3 eq. i-Pr2EtN 
in CH2Cl2 
0°C, 2 h 
 
 
(1.1 eq)
OHC
OTIPS
OMOM
44
 
-78°C, 1 h; RT, 2h 
 
cleavage of the 
TIPS-group 
(100%) 
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Summarising this results we came to the conclusion that our particular substrates 
including the C8-C15 part of the main carbon skeleton and the oxazolidinone chiral 
auxiliary, are not suitable for this reaction using the standard EVANS procedure, because 
of the deprotection of the hydroxyl group at C15, which interferes with the boran enolate 
formation or aldol reaction. 
To solve this problem, we then exploited a recent modification of the EVANS 
procedure in the aldol addition which according to the literature also results in “Evans”-
type syn products.[115]. Enolization of the C8-C15 key fragment 23 with (1 eq.) TiCl4, and 
(2.5 eq.) (-)-sparteine at –78°C, followed by addition of the freshly prepared (1.2 eq.) 
aldehyde 44 (the C1-C7 building block), produced the desired aldol adduct 45 with 
excellent diastereoselectivity (>95% de) (see Scheme 5.19). This established the C7 and 
C8 stereocenters for the future analogues of the target natural compound. The two 
diastereomers could be separated by flash column chromatography and the yield was 
51% based on recovered starting material. 
 
O O
N
Bn
Xq  =
OTIPS
H
OTIPS
OH
XqO
OMOM
51%
TiCl4, (-)-sparteine, CH2Cl2
44
H
O
OTIPS
OMOM
,
45
OTIPS
H
N
O
O
O
Bn
23
 
 
Scheme 5.19: Combination of the fragments C1-C7 and C8-C15 via aldol reaction. 
 
 
To confirm this stereochemical outcome some investigations on test aldol reactions 
with aldehyde 44 were made by using either the (S) or the (R) enantiomer of the 
oxazolidinone auxiliary, namely compound 24 and 24a respectively. In both cases we 
made the boron enolate following the EVANS protocol[104] with n-Bu2BOTf and HÜNIG base, 
and additionally the titanium enolate formation with TiCl4 and (-)-sparteine. According to 
the literature for obtaining “Evans” syn product an equimolar amount of TiCl4 and 2.5 eq. 
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of (-)-sparteine was employed.[115] The summarised results are presented on Scheme 
5.20. In all cases we obtained single aldol products with exception of the example where 
the titanium enolate of the (R)-auxiliary was used in presence of (-)-sparteine. Here a 
mixture of aldol products and undetermined by-products was obtained which could be 
separated by flash column chromatography. 
 
S
NO
O
Bn
O
24
NO
O
Bn
O OH OMOM
OTIPS
46
[α]24.7D = +21.8 (c 1.00, CH2Cl2)
[α]25.8D = +20.8 (c 1.00, CH2Cl2)
60% (+ bRSM)
aldehyde 44,
TiCl4, (-)-sparteine,
CH2Cl2
n-Bu2BOTf, i-Pr2EtN,
aldehyde 44,
CH2Cl2
66% (+ bRSM)
NO
O
Bn
O OH OMOM
OTIPS
46
[α]25.2D = -31.2 (c 1.00, CH2Cl2)
[α]25.0D = -46.1 (c 1.00, CH2Cl2)
R
NO
O
Bn
O
24a
NO
O
Bn
O OH OMOM
OTIPS
46a
62% (+ bRSM)
aldehyde 44,
TiCl4, (-)-sparteine,
CH2Cl2
n-Bu2BOTf, i-Pr2EtN,
aldehyde 44,
CH2Cl2
10% (+ bRSM)
NO
O
Bn
O OH OMOM
OTIPS
46b
? ?
 
 
Scheme 5.20: Test aldol reactions for investigation of the stereochemical outcome. 
 
 
When the (S)-auxiliary was used the same aldol product was obtained by applying 
both different conditions. Within the scope of measurement accuracy the optical rotation 
values were the same, and 1H- and 13C-NMR spectra were identical. Different results were 
observed when the (R)-auxiliary was applied. Because of the obviously different optical 
rotation values measured from the two received compounds we concluded that the 
obtained compounds from this aldol reactions are different. This result was difficult to 
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confirm by 1H-NMR, because the significant signals were overlapped and by 13C-NMR it 
was not possible to determine clear differences in the chemical shifts. However, it was 
visible from the NMR-experiments, that the compounds obtained from the (R)-auxiliary are 
definitively different from the compound resulting from the (S)-auxiliary. It is difficult to 
explain the seemingly strange result from the two aldol reactions with the (R)-auxiliary. 
One might speculate that the different stereochemical outcome when using TiCl4 and (-)-
sparteine is due to the chiral nature of the base. The low yield obtained in this aldol 
reaction as compared to the otherones can serve as a hint for a low compatibility of the 
base to the (R) auxiliary. It is known from various investigations reported in the 
literature[104] that when n-Bu2BOTf and HÜNIG base are used an “Evans” syn product can 
be expected. Based on this and comparing our results it can be assumed that when the 
titanium enolate of the (S)-auxiliary was formed in presence of (-)-sparteine, the “Evans” 
syn product is also obtained whereas the titanium enolate of the (R)-auxiliary gives under 
the same conditions the “non-Evans” syn product or an anti product. Further investigations 
concerning the stereochemical outcome in the case of the (R)-auxiliary were not made 
within the scope of the present work. 
 
 
5.5 Further Synthesis and Final Macrolactonization 
 
The next task was the generation of the methyl group from the side chain which 
carries the chiral auxiliary and this was accomplished as follows. At first the oxazolidinone 
moiety from the aldol product 45 was reduced to the primary alcohol 47 (see Scheme 
5.21). The best yield (80%) was obtained with lithium borohydride in anhydrous THF and 
traces of absolute methanol,[125] whereas by using a system of absolute ether and traces 
of water the maximum obtained yield was only 56%.[126] The primary hydroxyl group was 
further tosylated with p-toluenesulfonyl chloride, triethylamine and catalytic amounts of 
DMAP to give the product 48 as a colorless oil in 68% yield. Very important for the 
performance of this reaction was the presence of the catalytic amounts of DMAP, because 
in the experiments without it, only recovered starting material was isolated, even after 
longer reaction time (more than 24 h). Thereafter it was planned to apply the standard 
procedure for reduction of the tosylate to a methyl group with the superhydride 
triethyllithium borohydride in anhydrous THF.[126] However, this reaction always resulted in 
a mixture of unknown cyclization by-products and a small amount of the desired product 
(14% yield). This forced us to search for a new method for preparation of this compound 
and we found that when a mixture of 10 eq. zinc dust and 5 eq. sodium iodide refluxing in 
glyme for 2.5 h[127] was used, the desired product 49 was obtained without any problems 
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in quantitative yield. Thus, compound 49, which carries the methyl group, was always 
obtained as a single product according to the 1H- and 13C-NMR, and therefore was used 
without further purification for the next step. 
To continue the synthesis it was necessary to protect the free secondary hydroxyl 
group resulting from the syn-aldol reaction. According to our initial considerations, the 
requirements for the new protecting group were to be stable under acidic conditions, 
which does not allow to use a PMB group (not stable at pH ≤ 2[128]); to be stable under the 
conditions for cleavage of the already existing MOM group; to be different from a silicone 
group, because of the necessary selective deprotection of the TIPS moiety; and to be 
possibly to be removed without disturbing the later formed macrolactone. Consequently 
we chose the 2,2,2-trichloroethyl carbonate (Troc) group. For this reason compound 49 
was treated with 2,2,2-trichloroethyl chloroformate at 0°C in the presence of absolute 
pyridine and catalytic amounts of DMAP to give the Troc-protected product 50 in excellent 
yield of 99% (see Scheme 5.22).[129] Thereafter, as it is described also in the literature the 
silicone protecting groups can be removed selectively.[130] Thus, treatment of 50 with HF in 
pyridine liberated the primary hydroxyl group and compound 51 was obtained in 56% yield 
together with recovered starting material (42%). Subsequent oxidation of the primary 
hydroxyl group with aqueous sodium hypochlorite solution in acetone / 5% aqueous 
NaHCO3 mixture and in presence of potassium bromide and TEMPO provided the desired 
carboxylic acid 52.[131] This reaction also gave an unknown by-product, which could not be 
separated at this step of the synthesis. Therefore, the whole crude material was used for 
the desilylation of the secondary TIPS-protecting group with 1M solution of TBAF in THF. 
The reaction was successful and gave the hydroxy acid 53 in 30% yield (over two steps). 
Here, it was possible to isolate the by-product and after some investigations, we 
concluded that during the oxidation step a concurrent reaction appeared, probably 
involving an addition of chlorine and water to the triple bond resulting in an α-chloroketone 
moiety. Evidence for this was the disappearance of the alkyne signals at 66.3, 85.0 ppm in 
the 13C NMR and the appearance of an additional carbonyl signal at 210.0 ppm. The ESI-
MS spectrum shows the typical isotopes pattern of a molecule containing four chlorines 
instead of the corresponding three chlorines from the Troc-moiety. The molecule peak [M-
H+] measured by the HRMS (FT-ICR-ESI) was found to be 609.1194910 m/z, which fits 
well with the theoretical mass of 609.1197172 m/z for the assumed by-product 
C24H37O9Cl4 [M-H+]. 
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Scheme 5.21: Synthesis of the hydroxy acid 53 as precursor for the 
macrolactonization. 
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Nevertheless, with the obtained purified product 53 in hands we made our next key 
reaction toward formation of the macrocycle via the very efficient YAMAGUCHI 
macrolactonization method.[130] For that purpose we used the commercially available 
YAMAGUCHI reagent (2,4,6-trichlorobenzoyl chloride), which formed with our starting 
material the mixed anhydride in the presence of a base. The lactonization by means of the 
mixed anhydride consists of two steps: the formation of the mixed anhydride, and the 
alcoholysis of the anhydride. Normally the reaction is performed when the solution of the 
mixed anhydride was diluted with toluene and added slowly to a hot solution of DMAP in 
toluene [refluxing or as in our particular case 80°C (see the Experimental section)] under 
high-dilution conditions to prevent the unwanted formation of polymers. In our case after 
flash column chromatography the expected 16-membered ring lactone 54 was isolated in 
excellent yield of 83% as colorless oil (see Scheme 5.22). 
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Scheme 5.22: YAMAGUCHI macrolactonization to epothilone analogue 54. 
 
 
Compound 54 was the target molecule in the represented synthetic strategy for 
preparation of epothilone analogues. After some functional group transformations, which 
include the cleavage of the MOM ether, subsequent oxidation and removal of the Troc-
moiety an epothilone analogue compound should be obtained. 
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5.5.1 Characterization of the Macrolactone 54 and Conformational Studies 
 
For characterization of the macrolactone 54 two-dimensional NMR experiments, such 
as H-H COSY, TOCSY, HMBC, HSQC and NOESY were used. In the following the H-H 
COSY and the NOESY are presented. As it is possible to see from the H-H COSY (Figure 
5.2), all expected couplings between protons bounded to neighbouring carbons could be 
confirmed in accordance to the structure. For conformational analysis the macrolactone 
54 was investigated by NOESY (Figure 5.3). Besides the expected interactions between 
vicinal and geminal protons, the most remarkable result was the prominent NOESY cross-
peak observed between H-2/H-5. 
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Figure 5.2: H-H COSY of compound 54. 
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Figure 5.3: NOESY of compound 54. 
 
 
For a better understanding of the topology of the single conformations of compound 
54 a conformational search was carried out by using MacroModel 7.0 (10 000 starting 
conformations, 50 kJ/mol cutoff, MM* force field). From the obtained set of conformations 
the five energy-minimised average conformations with the lowest energies were selected 
and presented on Figure 5.4. Comparison of the topology of this conformations shows, 
that the conformations E1 (97.98 kJ/mol), E2 (98.02 kJ/mol) and E3 (101.79 kJ/mol) 
differs only in the alignment of side chains, but not in the topology of the cyclic system. 
54
O
O
H
O
O O
O
Cl
Cl
Cl
O
1 2 3 4 5 6
7
8
9
10
11
12
13
1415
17 18
19
20
21
222324
25
RESULTS AND DISCUSSIONS 72 
E1 = 97.979 kJ/mol
E4 = 101.94 kJ/mol E5 = 101.95 kJ/mol
E3 = 101.79 kJ/mol
E2 = 98.020 kJ/mol
Accordances in the topology of the cyclic system were found also for the conformations 
E4 (101.94 kJ/mol) and E5 (101.95 kJ/mol). 
In all cases, the distances between the protons at C2 and C5 were found to be < 3 Ǻ. 
Therefore, interaction between this protons can be observed for all examined 
conformations. The results of the NOESY are in accordance to the global minimum 
conformation E1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4: Calculated conformations of 54. 
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6 Synthetic Pathway for Preparation of Functionalized 
Cyclic Olefins by RCM 
 
6.1 Retrosynthetic Analysis 
 
The natural alkaloid epibatidine contains a 7-azabicyclic structure which provided our 
initial interest to this type of compounds. After a retrosynthetic analysis we have 
determined our synthetic route for preparation of 7-azabicyclo[2.2.1]hept-2-enes (see 
Scheme 6.1). It was planned to apply an elimination reaction of the appropriate 7-
azabicyclo[2.2.1]heptane derivative, which in turn would be fashioned by a transannular 
cyclization reaction of cyclohexenylamines with possibilities for using different protecting 
groups for the amine function. The cyclic structure would be obtained by performing a 
RCM reaction of the appropriate dienes. An allylation reaction would be used to obtain the 
protected homoallyl amines, possibly applying a one-pot synthesis with 5-pentenaldehyde, 
appropriate carbamates and the commercially available allyl(trimethyl)silane under the 
influence of borontrifluoride etherate. 
 
N
PG
N
PG
R
R
N
PG
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PG
PG = Cbz, Boc, COCF3, Tos
elimination
transannular
cyclization
HN
PG
CHO R1 H2N PG+ +
RCM allylation
 
 
 
Scheme 6.1: Retrosynthetic analysis for 7-azabicyclo[2.2.1]heptane derivatives. 
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6.2 Preparation of Diene Intermediates as Precursors for the RCM 
 
For the planned allylation reaction it was necessary first to synthesized the 5-
pentenaldehyde 58. For this purpose, according to the literature,[132] allyl alcohol was 
reacted with triethyl ortoacetate in the presence of catalytic amounts of o-nitrophenol at 
140°C and the desired ester 56 was obtained after distillation in 86% yield (see Scheme 
6.2). Thereafter followed reduction of the ester function with LiAlH4 in anhydrous THF and 
the primary alcohol 57 was obtained as a colourless liquid in 70% yield. Subsequent 
oxidation with PCC in presence of anhydrous sodium acetate gave the desired aldehyde 
58 in 40% yield.[133] The low yield can be explained with the high volatility of this product. 
 
OH CH3C(OEt)3+
OEt
O84%
NO2
OH
140°C
OH CHO
70%
LiAlH4, THF
PCC, NaOAc,
CH2Cl2
40%
56
57 58  
 
Scheme 6. 2: Preparation of 4-pentenal (58). 
 
 
The corresponding substrates, 1-allyl-4-pentenylamines were available by addition of 
an allyl anion equivalent to a suitable 4-pentenylimine. According to this strategy, the 1,7-
octadien-4-amine derivatives 59a-d were prepared. The urethanes 59a,b were 
synthesized in analogy to a published procedure (see Scheme 6.3).[134] Thus, addition of 
borone trifluorid etherate to a mixture of 4-pentenal (58), benzyl carbamate and 
allyl(trimethyl)silane followed by stirring of the reaction mixture over night gave the 
urethane 59a in 60% yield. In a similar manner the urethane 59b was prepared by using 
tert-butyl carbamate instead. However, when trifluoroacetamide was used as starting 
material for the same reaction with aldehyde 58, no product was obtained. 
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Scheme 6.3: One-pot synthesis of protected homoallyl amines. 
 
 
It was also of interest to study the influence of different substituents at the amino 
function upon the further planned RCM reaction. Therefore the secondary amine 59c was 
synthesized in a simple two-step operation by first converting the aldehyde 58 with 
benzylamine to the corresponding imine followed by addition of allyl(tributyl)stannane and 
trifluoroacetic acid.[135, 136] Treatment of the benzyl amine 59c with triflouroacetic acid 
anhydride in the presence of triethylamine furnished the protected aminodiene 59d (see 
Scheme 6.4). 
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Scheme 6.4: Synthesis of protected homoallyl amines by using allyl(tributyl) 
stannane. 
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6.3 Synthesis of Cyclohexenylamines by Ring Closing Metathesis 
 
The ring closing methatesis (RCM) is one of a few reactions that form a double bond 
in the cyclization step (see Scheme 6.5). In contrast to the intramolecular WITTIG reaction 
or the MCMURRY cyclization, the starting materials, acyclic nonconjugated dienes, are 
stable entities and usually easily accessible. It is thus logical that the RCM reaction has 
found widespread use[137] since the discovery of carbene complexes that are able to 
mediate this reaction efficiently. In addition, some of these complexes are easily 
available.[138] The RCM reaction allows the formation of cyclic olefins with various ring 
sizes. However, as with other cyclization reactions, entropic factors and ring strain make 
the formation of medium-sized cycloolefins by this route difficult. Other well-known ways 
to some cyclic olefins include cycloaddition reactions. While, for example, cyclohexenes 
can be obtained by DIELS-ALDER reactions, not all substitution patterns are suitable for this 
strategy. Examples include cyclohexenes with a hetero atom at the homoallylic position. 
They require the use of special dienophilles, such as vinylboranes[139] or rearrangement 
reactions on a carboxylic substituent.[140] A grate advantage of the RCM is the involvement 
of relatively stable double bonds. This facilitates synthesis and handeling of the cyclization 
precursors. 
 
+ H2C CH2
catalyst *
high dilution
* metal-carbene compelex  
 
Scheme 6.5: Ring closing metathesis (RCM) 
 
 
The commonly used catalysts for the RCM reaction are the ruthenium carbene 
complexes 60 and 61 developed by Grubbs,[138] and the Schrock molybdenum-based 
catalyst 62 (see Figure 6.1).[141] The GRUBBS catalyst 60 is very easy to prepare, 
commercially available, and air stable. On the other hand, the preparation of the SCHROCK 
catalyst 61 is a more elaborate undertaking, but is also commercially available. Recently, 
novel air- and water-tolerant ruthenium complex like 62 were introduced and shown to 
exhibit increased methatesis activity as compared to 60.[142] These complexes are even 
able to induce cyclization to tetrasubstituted cycloalkenes. 
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Figure 6.1: Metal carbene complexes as catalysts for RCM. 
 
The RCM reaction is generally believed to proceed via a sequence of formal [2+2] 
cycloaddition and cycloreversion steps between metal alkylidene and metallacyclobutane 
species (see Scheme 6.6).[137] In the first turn of the catalytic cycle, the alkene cut-off by-
product depends on the substituent in the original catalyst, while in second and 
subsequent catalytic cycles it depends on the substrate. For terminal alkene substrates 
the reaction by-product is ethene, and a partial vacuum may be used to drive the reaction 
to completion. Alkene substitution in both substrate and product can dramatically influence 
the reaction rate and outcome. Fürstner and co-workers have found some key parameters 
for successful proceeding of the RCM reaction.[143] These are: the presence of a functional 
group which serves as a relay entity that assembles the reacting sites; an appropriate 
distance between this polar group and the reacting alkenes; and low steric congestion 
near the double bonds. 
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Scheme 6.6: Mechanism of RCM. 
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In the present work the crucial RCM reactions were performed by stirring a solution of 
the dienes 59a-d in CH2Cl2 in presence of 3 mol% of the GRUBBS ruthenium carbene 60 
catalyst at room temperature for 24 h. As can be seen from Scheme 6.7, the 1,7-
octadiene-4-amine derivatives 59a,b and 59d cyclized in almost quantitative yield to the 
coresponding cyclohexenylamines 63a,b and 63d. In contrast, the unprotected amine 59c 
was recovered unchanged. This negative result supports the observation of Fürstner et 
al., mentioned above that a chelating substituent in close proximity to one of the double 
bonds shuts down the catalytic cycle.[143] 
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Scheme 6.7: Preparation of cyclohexenylamines 63a-d via RCM. 
 
 
Since compound 63d had been used in the total synthesis of the alkaloid epibatidine 
by Fletcher et al.[68] (compound B5, see Section 3.2.1) the present work also constitutes a 
formal total synthesis of racemic epibatidine (Scheme 6.8).[91] 
 
NCF3
Bn
O
64d = B5 (-)-epibatidine
N
NCl
HHN
N Cl
S
R
R
(+)-epibatidine
(1R,2R,4S)  
 
Scheme 6.8: Formal total synthesis of racemic epibatidine according to the 
synthesis of Fletcher et al. 
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6.4 Transannular Cyclization 
 
To achieve structural analogues of the natural compound epibatidine, we continued 
our experiments with an epoxidation reaction according to the total synthesis of Fletcher 
et al.[68] The substrates 63a,b,d, dissolved in anhydrous dichloromethane, were treated 
with m-CPBA at 0°C and the desired products 64a,b,d were obtained (see Scheme 6.9). 
 
64d
64b
64a
R1 yield (%)product
starting
material R2
74
35
55
F3CCO
Boc
Cbz
H
H
Bn
63a
63b
63d
63
N
R1
R2 O
64
N
R2
R1
m-CPBA, CH2Cl2
0°C-RT, 8 h
 
 
Scheme 6.9: Epoxidation for obtaining precursors for the  transannular 
cyclization reaction. 
 
 
Thereafter it was planned to perform an transannular cyclization reaction for 
constructing of the bicyclic system. The mechanism of this reaction is presented in 
Scheme 6.10. As can be seen there are two cyclization modes, exo and endo, which can 
be involved in this mechanism. By ring opening of an anti-epoxide the nucleophilic attack 
of the nitrogen occurs from the back side and the mechanism is proposed to be 
concerted. Therefore the anti-epoxide leads to an endo-product, whereas the exo-product 
can be obtained from the corresponding syn-epoxide. The mechanism of this cyclization is 
believed to proceed through a opening of the epoxide function to give a carbenium ion. 
Such examples have been relative rarely reported[144] and one of them was presented by 
Fletcher et al.[68] in the total synthesis of epibatidine. 
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Scheme 6.10: Mechanism of the transannular cyclization. 
 
 
The transannular cyclization reaction used by Fletcher et al. was performed with 
compound 64d at 180°C for 16 h in presence of a catalytic amount of 1-methyl-2-
pyrrolidinone. In our synthetic route the same reaction conditions were also applied to 
substrates 64a and 64b, but no products were obtained even after prolongation of the 
reaction time. Another possibility to establish this bicyclic structure is the use of 
transannular cyclization reaction of cyclic olefins involving electrophilic halogen atoms. 
The proposed mechanism is present in Scheme 6.10 and is similar to the one described 
above. However, treatment of cyclohexenylamine derivative 63b with 1.2 eq. N-
bromosuccinimide (NBS) in dichloromethane[145] provided the bicyclic urethane 65a in 
good yield instead of the initially assigned 7-azabicyclo[2.2.1]heptane derivative (see 
Scheme 6.11). Similarly, reaction of 63b with 2 eq. iodine and 2 eq. potassium carbonate 
in diethyl ether gave the corresponding iodo compound 65b.[146] 
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Scheme 6.11: Bicyclic urethanes 65a,b obtained by transannular cyclization. 
 
 
However, from the observed results it has to be considered that the nitrogen itself 
dose not react as nucleophile. Instead, the oxygen of the carbamate moiety functions as 
nucleophile because of the good leaving group properties of Boc and Cbz groups. 
Therefore another bicyclic system was obtained containing a six- and an eight-membered 
ring. This method represents another alternative way for obtaining bicyclic structures. 
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7 Summary and Conclusion 
 
The first goal of the present thesis was to find an efficient approach to epothilone 
analogues. Herein was described the formal synthesis of epothilone A analogue as 
exemplified with compound 54. The present synthetic route contains in the longest 
reaction sequence 22 isolated intermediates and represents a novel strategy for 
generation of epothilone analogues. The overall yield was determined to be 1.3%, which 
corresponds to an average yield of 82% per reaction step. 
The innovative step in this synthesis was the formation of the C7-C8 bond via a 
stereoselective aldol reaction between the key fragments C1-C7 (compound 44) and C8-
C15 (compound 23) with de > 95%. This required the synthesis of two building blocks. As 
it was mentioned already, the so far published total syntheses of epothilones and 
analogues describe the formation of the C-C bond through an aldol reaction only between 
C6 and C7 atoms of the main carbon-skeleton. The cyclization step was made via an 
YAMAGUCHI macrolactonization reaction and the end product 54 from our synthesis was 
obtained. Unfortunately, the small amount of this product has limited our practical 
possibilities for continuing the further planned synthetic strategy for obtaining the 
completely deprotected and oxidized compound. Nevertheless, compound 54 might show 
already some biological activity. Further experiments and investigations are planned. It 
should be mentioned that the present work illustrates a flexible and convergent synthetic 
route to epothilone analogues. 
The use of optically pure and commercially available D-arabinose as a starting 
material had the purpose to introduce the desired chirality at C15 of the main carbon-
skeleton. The cis double bond of the C8-C15 building block 23 was obtained by a WITTIG 
reaction and contained the EVANS auxiliary, which was necessary for the asymmetric aldol 
reaction. The product 23 carries also a triple bond which was introduced through a 
SEYFERTH/GILBERT reagent. This should make possible the attachment of the thiazol 
moiety through a palladium-catalysed cross-coupling reaction and would allow the 
preparation of aryl analogues of the natural compound. An EVANS-type modified aldol 
reaction was used for the synthesis of the C1-C7 building block 44, which determined the 
stereochemistry of the methyl group at C6. The desired configuration of C7 and C8 
stereocenters also was secured by a stereoselective EVANS type aldol reaction. Here it is 
necessary to mention that the natural compound contains 7 stereocenteres, whereas our 
expected product would have 5. Another synthetic strategy for obtaining a derivative with 
7 stereocenters is currently by developed. 
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The second goal of the present thesis was the synthesis of cyclohexenylamines by 
ring closing metathesis reaction. This method represents a useful alternative to the DIELS-
ALDER strategy. Such cyclohexenes are of interest for the synthesis of bicyclic 
heterocycles by transannular reactions (see Scheme 7.1). 
 
X
H XH X
E
E+[Ru] CHPh
X = O, NR  
 
Scheme 7.1: Synthesis of bicyclic heterocycles by transannular reactions from 
cyclohexenes. 
 
 
The combination of the RCM reaction with transannular cyclization should provide 
access to interesting natural products. It should be mentioned that our synthetic route to 
compound 63d represents a formal total synthesis of the alkaloid epibatidine. In addition, 
the bicyclic urethane 65a obtained by electrophilic transannular cyclization reaction has 
been of interest to the National Cancer Institute (NCI) and was tested in a disease-
orientated in vitro anticancer screening program.[147] The compound 65a has been 
evaluated in a one-dose primary anticancer assay[148] against a 3 cell line panel consisting 
of MCF7 (Breast), NCI-H460 (Lung), and SF-268 (CNS), but unfortunately the activity was 
found to be too low for further investigations. 
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8 Experimental Part 
 
8.1 General Remarks 
 
8.1.1 Chemicals and Working Technique  
 
All required fine chemicals were received from the firms ACROS (Ulm), ALDRICH 
(Steinheim), FLUKA (Buchs, Switzerland) and MERCK (Darmstadt). They were used directly 
without further purification if nothing else was mentioned. All solvents were distilled and/or 
dried before use. The applied petrol ether fraction had a b.p. of 40-60°C. Anhydrous 
solvents were obtained as follows: THF, diethyl ether and toluene by distillation from 
sodium and benzophenone; dichloromethane and chloroform by distillation from calcium 
hydride; dimethylformamide and dimethylsulfoxide by vacuum distillation from calcium 
hydride; acetone by distillation from phosphor(V)-oxide. Absolute triethylamine and 
pyridine were distilled from calcium hydride prior to use. Hünig’s base was stored over 
potassium hydroxide and was used without further distillation. Aqueous sodium 
hypochlorite (6-14% active chlorine, «RIEDEL-DEHAEN» Sigma Aldrich Laborchemikalien) 
was calculated as a 2M aqueous solution. For preparation of phosphate buffer (pH 7) was 
used a standard procedure: 85.0 g KH2PO4 and 14.5 g NaOH in 1 l H2O. 
Unless mentioned, all the reactions were carried out under an argon atmosphere and 
the glass material was pre-dried by flame drying under high vacuum (oil pump RV 5, 
EDWARDS). All the chemicals, which were air or water sensitive, were stored under inert 
atmosphere. 
Compounds which are not described in the experimental part, were prepared 
according to the literature. 
 
 
8.1.2 NMR-Spectroscopy 
 
1H and 13C NMR spectra were measured on a BRUKER AC 250 (250 or 62.9 MHz, 
respectively) or unity 400 VARIAN (400 or 100 MHz, respectively). All two-dimensional 
spectra (COSY, TOCSY, HSQC, HMBC, NOESY) were measured on BRUKER AMX 400 
(400 or 100 MHz, respectively) or BRUKER AMX 600 (600 or 150 MHz, respectively). As 
solvents were used chloroform-d or benzene-d6. TMS (δ = 0) was used as an internal 
standard. Data are reported as follows: chemical shift [multiplicity (s = singlet, d = doublet, 
t = triplet, m =multiplet, br = broadened), coupling constant (Hz), integration, peak 
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assignment]. For the 13C NMR spectra the signal multiplicity is determined by means of 
the APT or DEPT-135 technique: + for CH or CH3, - for CH2, # for C. 
 
 
8.1.3 Mass Spectrometry 
 
Mass spectra were recorded on a Triple-Stage-Quadrupol Spectrometer TSQ-70 from 
the FINNIGAN-MAT (Bremen) or on an Intectra AMD 402 mass spectrometer. High-
resolution mass spectra were measured on an Intectra AMD MAT-711A mass 
spectrometer from the same firm. The used mass spectrometric ionization methods were 
electron-impact (EI), fast-atom bombardment (FAB) or field-desorption (FD). FT-ICR-mass 
spectrometry and HR-FT-ICR mass spectra were measured on an APEXTM II 
spectrometer from the firm BRUKER DALTONIK (Bremen) with electrospray ionization 
method (ESI). Some of the mass spectra were measured also on a FINNIGAN MAT SFQ 
710 C (Electrospray ionization 4.5 kV, Tcapillary = 250°C, solvent methanol/water = 90/10). 
Significant fragments are reported as follows: m/z (relative intensity). 
 
 
8.1.4 Infrared Spectroscopy 
 
Infrared spectra (IR) were recorded on a FT-IR-430 spectrometer from the firm JACSO 
or on a FT-IR-1000 from the firm PERKIN ELMER. The percent transmittance (T%) of liquid 
or oily substances was measured in film between potassium bromide tablets. Solid 
substances were pulverized with potassium bromide and percent reflection (R%) was 
measured. Absorption band frequencies are reported in cm-1. 
 
 
8.1.5 Polarimetry 
 
Optical rotations were measured on a JASCO Polarimeter P-1020. They are reported 
as follows: [α]temperatureD (concentration, solvent). The unit of c is g/100 ml. As a solvent was 
used anhydrous CH2Cl2. For the measurement was used the sodium D line = 589 nm. 
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8.1.6 Melting Points 
 
Melting points were taken with a BÜCHI B-540 apparatus or BOETIUS-melting point-
microscope and were not corrected. 
 
 
8.1.7 Elemental Analysis 
 
Elemental analyses were recorded with a LECO CHNS-932 or a HEREAUS 
INSTRUMENTS ELEMENTAL ANALYSIS system Vario EL. 
 
 
8.1.8 Chromatographic Methods 
 
Analytical thin-layer chromatography (TLC) was performed on pre-coated silica gel 60 
F254 plates (MERCK) or Polygram Sil G/UV254 (MACHEREY-NAGEL), and pre-coated 
aluminum oxide ALOX N/UV254 (MACHEREY-NAGEL). The compounds were visualised by 
UV254 light and the chromatography plates were developed with an aqueous solution of 
molybdophosphorous acid or aqueous solution of potassium permanganate (heating on a 
hot-plate). For preparation of the molybdate solution were used 20 g ammonium 
molybdate [(NH4)6Mo7O24 x 4H2O] and 0.4 g Cer(SO4)2 x 4H2O dissolved in 400 ml 10% 
H2SO4. The potassium permanganate solution was prepared from 2.5 g KMnO4 and 12.5 
g Na2CO3 in 250 ml H2O. 
Flash column chromatography was performed using J. T. BAKER flash silica gel (40-
63 µm, 230-400 mesh ASTM) or silica gel 60 M (40-63 µm) from the firms MERCK and 
MACHEREY-NAGEL, and aluminum oxide Typ 507 C neutral (0.05-0.15 mm, pH 7.0±0.5) 
from the firm FLUKA.  
Gaschromatography was performed on a CHROMPACK CP 9000 using a flame 
ionization detector, and carrier gas H2. For GC-MS coupled chromatography, GC-system 
from Series 6890 with an Injector Series 7683 and MS-detector Series 5973 from the 
HEWLETT PACKARD was used, with EI method, and carrier gas He. 
Analytical HPLC was performed on a HEWLETT PACKARD HP 1100 system. 
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8.2 General Procedures for Preparation of Epothilone Analogues 
 
 
D-Arabinose di-1-propyl dithioacetal (2):[95] 
 
HO
OH OH
OH SPr
SPr
 
 
 
D-Arabinose (50 g, 0.33 mol) was dissolved in concentrated hydrochloric acid (51 ml) 
in a 1l three-necked flask with mechanical stirring and ice cooling. To the cold, stirred 
solution was added a slow stream of propyl mercaptan (60.4 ml, 50.7 g, 0.66 mol). The 
solution quickly thickened and solidified, and a white solid mass was obtained within 10 
min. After 1 min, chilled water was layered on top of the precipitate, which prevents 
discoloration. The reaction mixture was allowed to remain in the ice bath for 5 min. 
Thereafter the resulting white mass was broken up to small pieces, mixed with additional 
water (200 ml) and stirred until a homogeneous slurry was obtained, which was filtered 
under suction. The white cake was washed with chilled water and the resulting moist solid 
was recrystallized by dissolving it in hot iso-propanol (300 ml) and adding water (500 ml). 
Filtration, washing with cold water and drying over potassium hydroxide in vacuum 
desiccator for 45 h gave the dithioacetal 2 as fine, white needles 67.3 g (71% yield). - 
m.p.: 131.4 – 131.7°C (lit. [95]: 131.0 – 131.5°C). 
MS (EI): m/z (%) = 284 (5) [M+], 163 (100). 
 
 
2,3-4,5-Di-O-isopropylidene-D-arabinose di-1-propyl dithioacetal (3): 
 
O
O
O
O
SPr
SPr
 
 
 
D-Arabinose di-1-propyl dithioacetal (2) (67.3 g, 0.24 mol) was suspended in freshly 
distilled acetone (600 ml). The mechanically stirred mixture was cooled to 0°C and 
concentrated sulphuric acid (9 ml) was added dropwise. After 10 min of stirring at 0°C the 
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reaction mixture was allowed to reach room temperature and was stirred for additional 18 
h, during which time the colour changed from colorless to yellow. Thereafter the solution 
was neutralized by addition of powdered, anhydrous sodium carbonate (21 g) and the 
vigorously stirring was continued for 2 days. The resulting suspension was filtered and the 
filtrate was evaporated under reduced pressure. The residue was taken up in toluene (300 
ml), dried over MgSO4, filtered again, and concentrated in vacuo to provided 85.1 g (99% 
yield) of 2,3-4,5-Di-O-isopropylidene-D-arabinose di-1-propyl dithioacetal (3) as a straw-
colored syrup. The crude material is suitable for the next step without further purification. - 
TLC (n-hexane/ethyl acetate, 4:1): Rf = 0.86. 
1H NMR (250 MHz, CDCl3): δ = 0.98, 1.00 (2 t, J = 7.3 Hz each, 3 H each, propyl-CH3), 
1.32, 1.36, 1.40, 1.44 (4 s, 3 H each, isopropylidene-CH3), 1.55-1.69 (m, 4 H, 
SCH2CH2CH3), 2.59-2.75 (m, 4 H, SCH2CH2CH3), 4.24-4.28 [m, 1 H, CHCH(SPr)2], 3.91-
4.15 (m, 5 H, CH2, 3 CH). 
13C NMR (62.9 MHz, CDCl3): δ = 13.6 (propyl-CH3), 22.7 (SCH2CH2CH3), 25.3, 26.6, 27.1, 
27.3 (isopropylidene-CH3), 33.0, 33.3 (SCH2CH2CH3), 53.0 [CH(SPr)2], 67.8 (OCH2), 77.2, 
79.6, 84.5 (OCH), 109.7, 110.2 (isopropylidene-C). 
MS (EI): m/z (%) = 364 (5) [M+], 231 (20), 163 (100), 143 (50). 
 
 
2-Deoxy-4,5-O-isopropylidene-D-erythro-pent-1-enose di-1-propyl dithioacetal (4): 
 
O
O
OH
SPr
SPr
 
 
 
To a solution of potassium tert-butoxide (13.9 g, 124 mmol) in absolute THF (300 ml) 
and anhydrous DMSO (150 ml) at room temperature and inert atmosphere was added 
dropwise over period of 40 min a solution of 3 (30 g, 82 mmol) in THF (150 ml). After 
stirring for 1 h at room temperature, the brown reaction mixture was poured onto ice (600 
g). The aqueous layer was extracted with ethyl acetate (4 x 400 ml) and the combined 
organic layers were washed once with ice-cold water (400 ml), brine, dried over MgSO4, 
filtered and concentrated under reduced pressure. The residue was purified by flash 
column chromatography (petroleum ether/ethyl acetate, 4:1) to yield 20 g (80%) of 4 as a 
yellow oil. - TLC (petroleum ether/ethyl acetate, 4:1): Rf = 0.56. 
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1H NMR (250 MHz, benzene-d6): δ = 0.79, 0.81 (2 t, J = 7.3 Hz each, 3 H each, propyl-
CH3), 1.24, 1.39 (2 s, 3 H each, isopropylidene-CH3), 1.41-1.51 (m, 4 H, SCH2CH2CH3), 
2.27 (br, 1 H, OH), 3.37-2.80 (m, 4 H, SCH2CH2CH3), 3.80-4.15 (m, 3 H, OCH2, CHOH), 
5.00-5.07 (m, 1 H, CH2CHO), 6.11 [d, J = 8.1 Hz, 1 H, CHC(SPr)2]. 
13C NMR (62.9 MHz, benzene-d6): δ = 13.3 ( +, propyl-CH3), 22.4, 23.4 (2 -, 
SCH2CH2CH3), 25.4, 26.6 (2 +, isopropylidene-CH3), 35.0, 35.4 (2 -, SCH2CH2CH3), 65.8 ( 
-, OCH2), 70.4 ( +, CHOH), 78.6 ( +, CH2CHO), 109.4 ( #, isopropylidene-C), 135.0 [ -, 
CHC(SPr)2], 135.8 [ #, C(SPr)2]. 
IR (neat): v~ = 3454 cm-1 (OH), 2961 cm-1 (alkyl), 1583 cm-1 (C=C). 
MS (EI): m/z (%) = 306 (2) [M+], 291 (3), 205 (100). 
 
 
2-Deoxy-4,5-O-isopropylidene-D-erythro-pentose di-1-propyl dithioacetal (5): 
 
O
O
SPr
SPrOH
 
 
 
To a stirred suspension of lithium aluminium hydride (6.63 g, 175 mmol) in anhydrous 
THF (450 ml) was added at room temperature dropwise over period of 1 h a solution of 4 
(13.3 g, 43 mmol) in THF (120 ml). After 4.5 h of stirring at room temperature, the reaction 
mixture was cooled to 0°C and quenched by careful addition of ice-cold water (60 ml). 
Then the resulting mixture was neutralized by addition of 1M aqueous hydrochloric acid 
(420 ml) and was stirred vigorously at ambient temperature over night. Thereafter the bulk 
of THF was removed on the rotatory evaporator and the rest was extracted with ethyl 
acetate (3 x 250 ml). The combined organic layers were washed with brine (200 ml), dried 
over MgSO4, filtered, and concentrated in vacuo. The residue was purified by flash column 
chromatography (petroleum ether/ethyl acetate, 2:1) to give 12.95 g (98%) of the 
compound 5 as colorless oil. - TLC (petroleum ether/ethyl acetate, 2:1): Rf = 0.66. 
1H NMR (250 MHz, CDCl3): δ = 0.96 (t, J = 7.3 Hz, 6 H, propyl-CH3), 1.32, 1.38 (2 s, 3 H 
each, isopropylidene-CH3), 1.52-1.66 (m, 4 H, SCH2CH2CH3), 1.81-1.95 [m, 2 H, 
CH2CH(SPr)2], 2.45-2.71 [m, 5 H, CH(SPr)2], 3.87-4.02 (m, 4 H, OCH2, OCH, CHOH). 
13C NMR (62.9 MHz, CDCl3): δ = 13.7 ( +, propyl-CH3), 22.7, 22.8 (2 -, SCH2CH2CH3), 
25.3, 26.6 (2 +, isopropylidene-CH3), 31.9, 32.5 (2 -, SCH2CH2CH3), 39.0 [ -, 
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CH2CH(SPr)2], 48.8 [ +, CH(SPr)2], 65.6 ( -, OCH2), 70.0 ( +, CHOH), 78.4 ( +, OCH), 
109.3 ( #, isopropylidene-C). 
IR (neat): v~ = 3465 cm-1 (OH), 2961 cm-1 (alkyl). 
MS (EI): m/z (%) = 308 (10) [M+], 233 (15), 215 (10), 175 (50), 157 (55), 89 (100). 
 
 
2-Deoxy-3-O-(4-methoxybenzyl)-4,5-O-isopropylidene-D-erythro-pentose di-1-propyl 
dithioacetal (6a): 
 
O
O
SPr
SPrOPMB
 
 
 
To a solution of alcohol 5 (7.17 g, 23 mmol) in dry DMF (250 ml) was added at once 
sodium hydride (60% mineral oil dispersion, 1.96 g, 49 mmol) and the resulting 
suspension was stirred at ambient temperature for 3 h. Thereafter the reaction mixture 
was cooled to 0°C and freshly distilled p-methoxybenzyl chloride (3.80 ml, 28 mmol) was 
added dropwise over a period of 10 min. The brown solution was allowed to reach room 
temperature and was stirred for 16 h. Then the reaction mixture was poured into ice-cold 
water (700 ml) and extracted with ethyl acetate (3 x 400 ml). The combined organic layers 
were washed with water (4 x 150 ml), and brine (1 x 150 ml), dried over MgSO4, filtered 
and evaporated under reduced pressure. The yellow crude product was purified by flash 
chromatography (petroleum ether/ethyl acetate, 6:1) to afford 6a as colorless oil (9.76 g, 
99% yield). - TLC (petroleum ether/ethyl acetate, 6:1): Rf = 0.61. - [α]25D = +1.3 (c 0.25, 
CHCl3). 
1H NMR (250 MHz, CDCl3): δ = 0.97, 0.98 (2 t, J = 7.4 Hz each, 3 H each, propyl-CH3), 
1.34, 1.43 (2 s, 3 H each, isopropylidene-CH3), 1.53-1.64 (m, 4 H, SCH2CH2CH3), 1.89-
1.96 [m, 2 H, CH2CH(SPr)2], 2.46-2.62 [m, 5 H, CH(SPr)2], 3.79 (s, 3 H, OCH3), 3.81-4.11 
(m, 4 H, OCH2, OCH, CHOPMB), 4.54, 4.69 (2 d, J = 11.1 Hz each, 2 H, PMB-CH2), 6.86, 
7.25 (2 d, J = 8.7 Hz each, 2 H each, aromatic-CH). 
13C NMR (62.9 MHz, CDCl3): δ = 13.7, 13.8 (propyl-CH3), 22.8 (SCH2CH2CH3), 25.3, 26.5 
(isopropylidene-CH3), 31.5, 32.5 (SCH2CH2CH3), 39.0 [CH2CH(SPr)2], 48.2 [CH(SPr)2], 
55.3 (OCH3), 66.1 (OCH2), 73.2 (PMB-CH2), 76.6 (CHOPMB), 78.4 (OCH), 109.2 
(isopropylidene-C), 113.8, 129.5 (aromatic-CH), 130.7, 159.3 (aromatic-C). 
IR (neat): v~ = 2960 cm-1 (alkyl), 1613 cm-1, 1514 cm-1 (C=C). 
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MS (EI): m/z (%) = 428 (10), [M+], 352 (5), 307 (5), 276 (2), 217 (10), 121 (100). 
HRMS (EI): calc. for C22H36O4S2: 428.20557, found: 428.20588. 
 
 
2-Deoxy-3-O-(4-methoxybenzyl)-4,5-O-isopropylidene-D-erythro-pentose (7): 
 
O
O
OPMBO
H
 
 
 
To a solution of the p-methoxybenzyl ether 6a (9.81 g, 23 mmol) in acetonitrile (320 
ml) and water (64 ml) was added calcium carbonate (10.61 g, 106 mmol) and mercuric (II) 
chloride (25 g, 92 mmol). The heterogeneous reaction mixture was stirred vigorously at 
ambient temperature for 4.5 h. Then the mixture was filtered through a pad of Celite and 
washed several times with acetonitrile. The filtrate was concentrated in vacuo and the 
residue was dissolved in diethyl ether (1 l). This ether solution was washed with 1M 
potassium iodide solution (4 x 120 ml) and once with brine (240 ml), dried over MgSO4, 
filtered, and the solvent was removed under reduced pressure to afford 5.66 g of aldehyde 
7 (84% yield) as a pale yellow liquid. The crude material is suitable for the next step 
without further purification. - TLC (petroleum ether/ethyl acetate, 1:1): Rf = 0.64. 
1H NMR (250 MHz, CDCl3): δ = 1.32, 1.39 (2 s, 3 H each, isopropylidene-CH3), 2.72-2.69 
(m, 2 H, CH2CHO), 3.78 (s, 3 H, OCH3), 3.81-3.87 (m, 1 H, CHOPMB), 4.02-4.15 (m, 3 H, 
OCH2, OCH), 4.49, 4.56 (2 d, J = 11.1 Hz each, 2 H, PMB-CH2), 6.86, 7.21 (2 d, J = 8.7 
Hz each, 2 H each, aromatic-CH), 9.79 (t, J = 2.0 Hz, 1 H, CHO). 
13C NMR (62.9 MHz, CDCl3): δ = 25.1, 26.5 (isopropylidene-CH3), 45.9 (CH2CHO), 55.3 
(OCH3), 66.9 (OCH2), 72.3 (PMB-CH2), 75.0 (CHOPMB), 76.6 (OCH), 109.7 
(isopropylidene-C), 113.9, 129.6 (aromatic-CH), 129.8, 159.5 (aromatic-C), 200.6 (CHO). 
IR (neat): v~ = 2987 cm-1 (alkyl), 2730 cm-1, 1725 cm-1 (CHO), 1612 cm-1, 1514 cm-1 (C=C). 
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(5-Carboxypentyl)triphenylphosphonium bromide (8):[101] 
 
P
OH
O
Br
 
 
 
A solution of triphenylphosphine (6.72 g, 25.6 mmol) and 6-bromohexanoic acid (5 g, 
256 mmol) in absolute toluene (70 ml) was heated to reflux (140°C oil bath) under inert 
atmosphere for 24 h during which time the mixture became inhomogeneous. Thereafter 
the reaction mixture was cooled to ambient temperature under an atmosphere of argon 
and the solvent removed under reduced pressure. The glasslike heavy oil was triturated 
with dry chloroform and diluted with diethyl ether, which resulted in the formation of a 
white solid. After recrystallization from chloroform / diethyl ether (1:10) and drying under 
vacuum for several hours, the pure salt 8 (7.87 g, 67% yield) was obtained as a white 
crystalline solid. - m.p.: 192.4 – 192.6°C (lit. [101]: 188.0 – 191.0°C). 
1H NMR (250 MHz, CDCl3): δ = 1.28-1.78 [m, 6 H, (CH2)3CH2COOH], 2.20-2.35 (m, 2 H, 
CH2COOH), 3.32-3.53 (m, 2 H, Ph3PCH2), 7.62-7.79 (m, 15 H, aromatic-CH), 8.87 (br, 1 
H, COOH). 
13C NMR (62.9 MHz, CDCl3): δ = 22.1 [ -, CH2(CH2)3COOH], 22.9 ( -, Ph3PCH2), 24.1 ( -, 
CH2CH2COOH), 29.7 [ -, CH2(CH2)2COOH], 34.3 ( -, CH2COOH), 117.4, 118.8 (2 #, 
aromatic-C), 130.7, 133.7, 135.2 (3 +, aromatic-CH), 175.8 ( #, COOH). 
IR (KBr): v~ = 2938 cm-1 (alkyl), 1705 cm-1 (COOH). 
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(6Z,9S)-9-[(4R)-2,2-Dimethyl-1,3-dioxolan-4-yl]-9-[(4-methoxybenzyl)oxy]-6-nonenoic acid 
(9): 
 
O
O COOH
PMBO
 
 
 
A suspension of (5-carboxypentyl)triphenylphosphonium bromide (8) (4.35 g, 10 
mmol) in absolute THF (20 ml) was treated dropwise over period of 15 min with 1M 
solution of sodium bis(trimethylsilyl)amide in THF (21 ml, 21 mmol). The resulting red 
colored reaction mixture was stirred for 30 min at ambient temperature and then cooled to 
–60°C. Thereafter was added slowly the aldehyde 7 (5.66 g, 19 mmol) dissolved in 10 ml 
of THF. After complete addition, the reaction mixture was warmed up to –50°C and stirred 
for additional 15 min and then was allowed slowly to reach room temperature and to stir 
for 1 h more. Thereafter the solvent was removed in vacuo and the residue was dissolved 
in ethyl acetate (160 ml), and washed several times with saturated aqueous solution of 
NaHCO3 (15 x 100 ml). The combined aqueous layers were acidified to pH 2 using 
concentrated hydrochloric acid and extracted with ethyl acetate (3 x 500 ml), dried over 
MgSO4, filtered and evaporated under reduced pressure. The crude material was purified 
by flash column chromatography (petroleum ether/ethyl acetate, 1:1) to give the acid 9 
(3.69 g, 99% yield) as yellow oil. - TLC (petroleum ether/ethyl acetate, 1:1): Rf = 0.63. - 
[α]22.4D = +27.1 (c 1.00, CH2Cl2). 
1H NMR (250 MHz, CDCl3): δ = 1.33, 1.41 (2 s, 3 H each, isopropylidene-CH3), 1.36-1.45 
[m, 2 H, CH2(CH2)2COOH], 1.57-1.69 (m, 2 H, CH2CH2COOH), 2.03-2.11 [m, 2 H, 
CH2(CH2)3COOH], 2.26-2.37 (m, 4 H, CH2COOH, CH2CH=CH), 3.48-3.55 (m, 2 H, 
CHOPMB), 3.79 (s, 3 H, OCH3), 3.83-3.90 (m, 1 H, OCH), 3.97-4.15 (m, 2 H, OCH2), 4.50, 
4.57 (2 d, J = 11.1 Hz each, 2 H, PMB-CH2), 5.41-5.55 (m, 2 H, olefin-CH), 6.86, 7.24 (2 
d, J = 8.7 Hz each, 2 H each, aromatic-CH). 
13C NMR (62.9 MHz, CDCl3): δ = 24.4 ( -, CH2CH2COOH), 25.4, 26.7 ( +, isopropylidene-
CH3), 27.0 [ -, CH2(CH2)3COOH], 29.0 ( -, CH2CH=CHCH2CH2), 33.9 ( -, CH2COOH), 55.3 
( +, OCH3), 66.6 ( -, OCH2), 72.2 ( -, PMB-CH2), 77.6 ( +, OCH), 78.9 ( +, CHOPMB), 
109.1 ( #, isopropylidene-C), 113.8 ( +, aromatic-CH), 125.2 ( +, olefin-CH), 129.4 ( +, 
aromatic-CH), 130.6 ( #, aromatic-C), 131.7 ( +, olefin-CH), 159.2 ( #, aromatic-C), 179.4 ( 
#, COOH). 
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IR (neat): v~ = 2936 cm-1 (alkyl), 2680 cm-1, 1738 cm-1, 1709 cm-1 (COOH), 1613 cm-1, 
1586 cm-1, 1514 cm-1 (C=C). 
MS (EI): m/z (%) = 392 (1) [M+], 377 (3), 334 (3), 291 (10), 273 (12), 121 (100). 
HRMS (EI): calc. for C22H32O6: 392.21989, found: 392.21630. 
 
 
Methyl (6Z,9S,10R)-10-hydroxy-9-[(4-methoxybenzyl)oxy]-6-dodecenoate (10): 
 
HO
OH
OPMB
COOMe 
 
 
To a solution of acid 9 (826 mg, 2.11 mmol) in methanol (40 ml) was added at once 
cupric(II) chloride dihydrate (1.96 g, 11.5 mmol) and the green reaction mixture was 
refluxed for 1.5 h. The reaction was cooled to ambient temperature and 2.6 g NaHCO3 
was added. After the evolution of carbon dioxide ceased, 20 ml of water was added and 
the resulting blue precipitate was filtered off trough a pad of Celite and the pad was 
washed several times with ethyl acetate. The combined filtrate was washed once with 
brine (70 ml) and dried over anhydrous MgSO4, filtered, and concentrated in vacuo. 
Purification by flash column chromatography (ethyl acetate) gave 439 mg (57% yield) of 
diol 10 as colorless oil. - TLC (ethyl acetate): Rf = 0.56. 
1H NMR (250 MHz, CDCl3): δ = 1.30-1.42 [m, 2 H, CH2(CH2)2COOMe], 1.55-1.67 (m, 2 H, 
CH2CH2COOMe), 1.97-2.10 [m, 2 H, CH2(CH2)3COOMe], 2.26-2.48 (m, 4 H, CH2COOMe, 
CH2CH=CH), 2.52, 2.80 (2 br, 1 H each, 2 OH), 3.49-3.58 (m, 1 H, CHOPMB), 3.64 (s, 3 
H, COOCH3), 3.69-3.74 (m, 3 H, CH2OH, CHOH), 3.78 (s, 3 H, OCH3), 4.42, 4.58 (2 d, J = 
11.1 Hz each, 2 H, PMB-CH2), 5.38-5.52 (m, 2 H, olefin-CH), 6.85, 7.23 (2 d, J = 8.7 Hz 
each, 2 H each, aromatic-CH). 
13C NMR (62.9 MHz, CDCl3): δ = 24.6 (CH2CH2COOMe), 27.1 [CH2(CH2)3COOMe], 28.4 
(CH2CH=CH), 29.0 [CH2(CH2)2COOMe], 33.9 (CH2COOMe), 51.6 (COOCH3), 55.3 
(OCH3), 63.5 (CH2OH), 72.1 (PMB-CH2), 72.4 (CHOH), 80.5 (CHOPMB), 114.0 (aromatic-
CH), 125.2 (olefin-CH), 129.5 (aromatic-CH), 130.2 (aromatic-C), 131.9 (olefin-CH), 159.4 
(aromatic-C), 174.3 (COOCH3). 
IR (neat): v~ = 3446 cm-1 (OH), 2935 cm-1 (alkyl), 1739 cm-1 (C=O), 1612 cm-1, 1586 cm-1, 
1514 cm-1 (C=C). 
MS (FAB): m/z (%) = 367 (60) [M+H+], 307 (100), 289 (75). 
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Methyl (6Z,9S)-9-[(4-methoxybenzyl)oxy]-10-oxo-6-decenoate (11): 
 
OHC
OPMB
COOMe 
 
 
The diol 10 (300 mg, 0.82 mmol) was dissolved in 60% aqueous acetonitrile (7.5 ml) 
and treated with sodium(meta)periodate (263 mg, 1.23 mmol); a white precipitate was 
formed immediately. The reaction mixture was stirred at ambient temperature for 1.5 h 
and filtered through a glass funnel. The filtrate was mixed with water (10 ml) and extracted 
thoroughly with chloroform (5 x 10 ml). The combined organic layers were washed once 
with water (20 ml), dried with MgSO4, filtered, and concentrated under reduced pressure 
to afford aldehyde 11 (268 mg, 98% yield) as colorless syrup. The crude material is 
suitable for the next step without further purification. - TLC (petroleum ether/ethyl acetate, 
1:1): Rf = 0.71. 
1H NMR (250 MHz, CDCl3): δ = 1.28-1.41 [m, 2 H, CH2(CH2)2COOMe], 1.54-1.66 (m, 2 H, 
CH2CH2COOMe), 1.95-2.06 [m, 2 H, CH2(CH2)3COOMe], 2.24-2.30 (m, 2 H, 
CH2COOMe), 2.36-2.45 (m, 2 H, CH2CH=CH), 3.64 (s, 3 H, COOCH3), 3.70-3.77 (m, 1 H, 
CHOPMB), 3.78 (s, 3 H, OCH3), 4.50, 4.58 (2 d, J = 11.5 Hz each, 2 H, PMB-CH2), 5.33-
5.54 (m, 2 H, olefin-CH), 6.86, 7.26 (2 d, J = 8.7 Hz each, 2 H each, aromatic-CH), 9.60 
(d, J = 2.1 Hz, 1 H, CHO). 
13C NMR (62.9 MHz, CDCl3): δ = 24.6 (CH2CH2COOMe), 27.0 [CH2(CH2)3COOMe], 28.4 
(CH2CH=CH), 28.9 [CH2(CH2)2COOMe], 33.9 (CH2COOMe), 51.5 (COOCH3), 55.3 
(OCH3), 72.3 (PMB-CH2), 82.8 (CHOPMB), 114.0 (aromatic-CH), 123.3 (olefin-CH), 129.4 
(aromatic-CH), 129.7 (aromatic-C), 132.8 (olefin-CH), 159.6 (aromatic-C), 174.1 
(COOCH3), 203.4 (CHO). 
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Dimethyl (3,3,3-trifluoro-2,2-dihydroxypropyl)phosphonate (13):[93] 
 
P
CF3
O HO OH
CH3O
CH3O  
 
 
To a cooled (–78°C) solution of dimethyl methylphosphonate (2.00 ml, 18.5 mmol) in 
anhydrous THF (40 ml) was added dropwise over period of 5 min a 2.7M solution of n-
butyllithium in heptane (7 ml, 18.5 mmol). The resulting mixture was stirred at the same 
temperature for 35 min and 2,2,2-trifluoroethyl trifluoroacetate (3.71 ml, 27.7 mmol) was 
added rapidly (1-2 s). The reaction mixture was stirred for additional 15 min at –78°C and 
was then allowed to warm to room temperature and diluted with diethyl ether (250 ml) 
followed by the addition of 3% aqueous hydrochloric acid (10 ml). The layers were 
separated and the organic phase was washed with saturated aqueous solution of 
NaHCO3 (10 ml) and brine (10 ml), dried over MgSO4, filtered and concentrated on 
rotatory evaporator to give 4.42 g of 13 (100% yield) as a pale yellow oil. The crude 
product was suitable for the next step without further purification and was used 
immediately. - TLC (ethyl acetate): Rf = 0.68. 
1H NMR (250 MHz, CDCl3): δ = 2.33 (d, J = 19.2 Hz, 1 H, CH2), 3.82 (d, J = 11.2 Hz, 1 H, 
CH2), 5.50 (s, 6 H, CH3). 
 
 
p-Acetamidobenzenesulfonyl azide (14):[93] 
 
S N3
O
O
HN
O
H3C
-
 
 
 
A suspension of sodium azide (3.0 g, 46 mmol) and dry acetone (500 ml) was cooled 
to 0°C (ice bath) and N-acetylsulfonyl chloride (10.5 g, 45 mmol) was added slowly, 
portionwise over a period of 10 min. The reaction mixture was stirred at 0°C for 2 h and 
was then allowed to warm up to room temperature and to stir for additional 72 h. 
Thereafter the resulting slurry was filtered off through a glass funnel and the filtrate was 
concentrated under reduced pressure to give the desired product 14(10.8 g, 100% yield) 
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as a yellow oil which solidified on standing. The crude product was suitable for the next 
step without further purification. 
1H NMR (250 MHz, CDCl3): δ = 2.23 (s, 3H, CH3), 7.78, 7.87 (2 d, J = 9.0 Hz each, 4 H, 
aromatic-CH), 8.09 (s, 1H, HN). 
 
 
Dimethyl (diazomethyl)phosphonate (15):[93] 
 
P H
O
CH3O
CH3O N2  
 
 
The crude 13 (4.42 g, 18.5 mmol) was dissolved in dry acetonitrile (45 ml) and treated 
with p-acetamidobenzenesulfonyl azide (14) (4.46 g, 18.5 mmol). The resulting solution 
was cooled to 0°C and treated slowly over a period of 5 min with absolute triethylamine 
(2.58 ml, 18.5 mmol). Thereafter the reaction mixture was allowed to warm to room 
temperature and stirred for 18 h. The solvent was removed under reduced pressure and 
the residual orange oily solid was suspended in chloroform and filtered through a coarse 
glass frit to remove the p-acetamidobenzenesulfonamide, which was washed with several 
small portions of chloroform. Then the resulting filtrate was concentrated in vacuo and the 
crude product was purified by flash column chromatography (ethyl 
acetate/dichloromethane, 4:1) to afford 2.42 g of 15 (87% yield) as an intensive yellow-
colored mobile liquid. - TLC (ethyl acetate/dichloromethane, 4:1): Rf = 0.58. 
1H NMR (250 MHz, CDCl3): δ = 3.70, 3.75 (2 s, 6 H, CH3), 3.72, 3.76 (2 s, 1 H, N2CH). 
 
 
Methyl (6Z,9S)-9-[(4-methoxybenzyl)oxy]-6-undecen-10-ynoate (16): 
 
OPMB
H COOMe 
 
 
A magnetically stirred slurry of potassium tert-butoxide (96 mg, 0.85 mmol) in 
absolute THF (2 ml) was cooled to –78°C and was added dropwise over a period of 5 min 
to a solution of dimethyl (diazomethyl)phosphonate (15) (128 mg, 0.85 mmol) in THF (2.5 
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ml). The reaction mixture was stirred at –78°C for 30 min and during this time the color 
turned from yellow to brown, indicating formation of the anion of 15. Subsequently, the 
aldehyde 11 (259 mg, 0.78 mmol) dissolved in THF (2.5 ml) was added slowly over 2 min 
and nitrogen evolution was an evident. The resulting reaction mixture was stirred at –78°C 
for 26 h and was then allowed to warm up to room temperature. The stirring was 
continued for an additional 4 h. Thereafter the reaction mixture was quenched with water 
(30 ml) and extracted with dichloromethane (3 x 40 ml). The combined organic layers 
were washed with brine (30 ml), dried over anhydrous MgSO4, filtered and the solvent was 
removed on the rotatory evaporator to provide the product 16 as a pale yellow oil (245 mg, 
96% yield), which was used without further purification in the next step. - TLC (petroleum 
ether/ethyl acetate, 6:1): Rf = 0.41. 
1H NMR (250 MHz, CDCl3): δ = 1.30-1.42 [m, 2 H, CH2(CH2)2COOMe], 1.55-1.67 (m, 2 H, 
CH2CH2COOMe), 2.01-2.09 [m, 2 H, CH2(CH2)3COOMe], 2.25-2.31 (m, 2 H, 
CH2COOMe), 2.46-2.51 (m, 3 H, alkyne-CH, CH2CH=CH), 3.65 (s, 3 H, COOCH3), 3.89 
(s, 3 H, OCH3), 4.01-4.07 (m, 1 H, CHOPMB), 4.44, 4.72 (2 d, J = 11.4 Hz each, 2 H, 
PMB-CH2), 5.40-5.55 (m, 2 H, olefin-CH), 6.87, 7.28 (2 d, J = 8.7 Hz each, 2 H each, 
aromatic-CH). 
13C NMR (62.9 MHz, CDCl3): δ = 24.6 (CH2CH2COOMe), 27.1 [CH2(CH2)3COOMe], 29.0 
[CH2(CH2)2COOMe], 33.7 (CH2CH=CH), 34.0 (CH2COOMe), 51.5 (COOCH3), 55.3 
(OCH3), 67.9 (CHOPMB), 70.2 (PMB-CH2), 74.0 (alkyne-CH), 82.7 (alkyne-C), 113.8 
(aromatic-CH), 124.4 (olefin-CH), 129.7 (aromatic-CH), 129.9 (aromatic-C), 132.3 (olefin-
CH), 159.3 (aromatic-C), 174.1 (COOCH3). 
IR (neat): v~ = 3284 cm-1 (alkyne-CH), 3010 cm-1 (alkyl), 2111 cm-1 (C≡C), 1739 cm-1 
(C=O), 1613 cm-1, 1586 cm-1, 1514 cm-1 (C=C). 
MS (ESI): m/z (%) = 369 (50) [M+K+], 353 (100) [M+Na+], 331 (50) [M+H+]. 
HRMS (FT-ICR-ESI): calc. for C20H27O4: 331.1897990, found: 331.1903858. 
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(6Z,9S)-9-[(4-Methoxybenzyl)oxy]-6-undecen-10-ynoic acid (17): 
 
OPMB
H COOH 
 
 
The methyl ester 16 (240 mg, 0.73 mmol) was dissolved in 14 ml of a mixture of THF-
water-methanol (6:3:2). To this solution was added at once lithium hydroxide monohydrate 
(180 mg, 4.29 mmol). The reaction mixture was stirred at ambient temperature for 18 h 
and thereafter was diluted with water (8 ml). Then the pH value of the solution was 
adjusted to 2-3 by adding of 1M aqueous hydrochloric acid. The aqueous phase was 
extracted with ethyl acetate (4 x 20 ml) and the combined organic layers were washed 
with water (30 ml) and brine (30 ml), dried over MgSO4, filtered, and concentrated under 
reduced pressure. Purification by flash column chromatography (petroleum ether/ethyl 
acetate, 1:1) gave the expected acid 17 (176 mg, 77% yield) as colorless oil. - TLC 
(petroleum ether/ethyl acetate, 1:1): Rf = 0.63. 
1H NMR (250 MHz, CDCl3): δ = 1.32-1.45 [m, 2 H, CH2(CH2)2COOH], 1.51-1.68 (m, 2 H, 
CH2CH2COOH), 2.02-2.10 [m, 2 H, CH2(CH2)3COOH], 2.29-2.36 (m, 2 H, CH2COOH), 
2.47-2.51 (m, 3 H, alkyne-CH, CH2CH=CH), 3.79 (s, 3 H, OCH3), 4.01-4.08 (m, 1 H, 
CHOPMB), 4.44, 4.73 (2 d, J = 11.4 Hz each, 2 H, PMB-CH2), 5.41-5.56 (m, 2 H, olefin-
CH), 6.86, 7.28 (2 d, J = 8.7 Hz each, 2 H each, aromatic-CH). 
13C NMR (62.9 MHz, CDCl3): δ = 24.3 (CH2CH2COOH), 27.1 [CH2(CH2)3COOH], 28.9 
[CH2(CH2)2COOH], 33.7 (CH2CH=CH), 33.9 (CH2COOH), 55.3 (OCH3), 67.8 (CHOPMB), 
70.2 (PMB-CH2), 74.1 (alkyne-CH), 82.7 (alkyne-C), 113.8 (aromatic-CH), 124.4 (olefin-
CH), 129.7 (aromatic-CH), 129.8 (aromatic-C), 132.3 (olefin-CH), 159.3 (aromatic-C), 
179.5 (COOH). 
IR (neat): v~ = 3290 cm-1 (alkyne-CH), 2934 cm-1 (alkyl), 2111 cm-1 (C≡C), 1708 cm-1 
(COOH), 1612 cm-1, 1586 cm-1, 1514 cm-1 (C=C). 
MS (EI): m/z (%) = 316 (5) [M+], 135 (80), 121 (100). 
HRMS (EI): calc. for C19H24O4: 316.16746, found: 316.16137. 
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(4S)-4-Benzyl-3-{(6Z,9S)-9-[(4-methoxybenzyl)oxy]-6-undecen-10-ynoyl}-1,3-oxazolidin-2-
one (18): 
 
OPMB
H
O
O O
N
Bn
 
 
 
Method A: To a stirred solution of acid 17 (171 mg, 0.54 mmol) in dry THF (3.5 ml) at 
–15°C was added anhydrous triethylamine (144 µl, 1.04 mmol) followed by trimethylacetyl 
chloride (72 µl, 0.59 mmol). After 20 min of stirring the reaction mixture was allowed to 
warm up to 0°C (over 15 min) and then was recooled to –78°C. In a separate flask was 
dissolved (4S)-4-benzyl-1,3-oxazolidin-2-one (37) (96 mg, 0.58 mmol) in absolute THF (5 
ml) and the resulting solution was cooled to –70°C, and treated dropwise with a 2.7M 
solution of n-butyllithium in heptane (218 µl, 0.59 mmol). After the reaction mixture was 
stirred for 15 min the yellow solution was taken up in a syringe and added to the white 
slurry prepared as described above. The resulting mixture was stirred for 1.5 h at –78°C 
and quenched with 1M aqueous solution of NaHSO4 (2.2 ml). Then the reaction mixture 
was allowed to reach room temperature and concentrated under reduced pressure. The 
residue was extracted with ethyl acetate (3 x 4 ml) and the combined organic extracts 
were washed with brine (5 ml), dried over MgSO4, filtered, and concentrated in vacuo. 
Purification by flash column chromatography (petroleum ether/ethyl acetate, 2:1) provided 
134 mg of the oxazolidinone 18 (52% yield) as a thick colorless oil. - TLC (petroleum 
ether/ethyl acetate, 2:1): Rf = 0.52. - [α]26.6D = -1.1 (c 1.00, CH2Cl2). 
 
Method B: A magnetically stirred slurry of potassium tert-butoxide (871 mg, 7.76 
mmol) in absolute THF (20 ml) was cooled to –78°C and added dropwise over a period of 
10 min to a solution of dimethyl (diazomethyl)phosphonate (15) (1.16 g, 7.76 mmol) in 
THF (25 ml). The reaction mixture was stirred at –78°C for 30 min and during this time the 
colour turned from yellow to brown, indicating formation of the anion of 15. Subsequently 
the aldehyde 21 (3.38 g, 7.05 mmol) dissolved in THF (25 ml) was added slowly over 10 
min and nitrogen evolution was evident. The resulting reaction mixture was stirred at –
78°C for 17 h and then allowed to warm up to room temperature (over 1 h). Stirring was 
continued for an additional 4 h. Thereafter the reaction mixture was quenched with water 
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(250 ml) and extracted with dichloromethane (3 x 150 ml). The combined organic layers 
were washed with brine (250 ml), dried over anhydrous MgSO4, filtered and the solvent 
was removed on the rotatory evaporator. Purification by flash column chromatography 
(petroleum ether/ethyl acetate, 2:1) provided 2.01 g of the oxazolidinone 18 (60% yield) as 
a thick colorless oil. - TLC (petroleum ether/ethyl acetate, 2:1): Rf = 0.52. - [α]26.6D = -1.1 (c 
1.00, CH2Cl2). 
 
 
1H NMR (250 MHz, CDCl3): δ = 1.31-1.43 [m, 2 H, CH2(CH2)2CO], 1.56-1.68 (m, 2 H, 
CH2CH2CO), 1.99-2.07 [m, 2 H, CH2(CH2)3CO], 2.41-2.46 (m, 3 H, alkyne-H, CH2CH=CH), 
2.68 (dd, 2J = 13.3 Hz, 3J = 9.6 Hz, 1 H, C6H5CH2), 2.76-2.88 (m, 2 H, CH2CO), 3.21 (dd, 
2J = 13.3 Hz, 3J = 3.2 Hz, 1 H, C6H5CH2), 3.72 (s, 3 H, OCH3), 3.96-4.15 (m, 3 H, 
CHOPMB, oxazolidinone-CH2), 4.38 (d, 1 H, J = 11.3 Hz, PMB-CH2), 4.53-4.61 (m, 1 H, 
oxazolidinone-CH), 4.66 (d, 1 H, J = 11.3 Hz, PMB-CH2), 5.35-5.51 (m, 2 H, olefin-CH), 
6.80 (d, 2 H, J = 8.6 Hz, PMB-CH), 7.11-7.29 (m, 7 H, aromatic-CH). 
13C NMR (62.9 MHz, CDCl3): δ = 24.0 (CH2CH2CO), 27.3 [CH2(CH2)3CO], 29.0 
[CH2(CH2)2CO], 33.7 (CH2CH=CH), 35.4 (CH2CO),38.0 (C6H5CH2), 55.2 (oxazolidinone-
CH), 55.3 (OCH3), 66.2 (oxazolidinone-CH2), 67.9 (CHOPMB), 70.2 (PMB-CH2), 74.0 
(alkyne-CH); 82.8 (alkyne-C), 113.8 (PMB-aromatic-CH), 124.4 (olefin-CH), 129.0, 129.4, 
129.6 (aromatic-CH), 130.0 (PMB-aromatic-C), 132.3 (olefin-CH), 135.4 (aromatic-C), 
153.5 (oxazolidinone-CO), 159.3 (PMB-aromatic-C), 173.2 (amide-CO). 
IR (neat): v~ = 3283 cm-1 (alkyne-CH), 2934 cm-1 (alkyl), 2110 cm-1 (C≡C), 1784 cm-1, 1699 
cm-1 (C=O), 1612 cm-1, 1585 cm-1, 1514 cm-1 (C=C). 
MS (FD): m/z (%) = 475 (100) [M+]. 
HRMS (FT-ICR-ESI): calc. for C29H34NO5 [M+H+]: 476.24315, found: 476.2300; 
   calc. for C29H33NO5Na [M+Na+]: 498.22509, found: 498.2140; 
   calc. for C29H33NO5K [M+K+]: 514.19903, found: 514.1903. 
EXPERIMENTAL PART 102 
(4S)-4-Benzyl-3-{(6Z,9S)-9-[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]-9-[(4-
methoxybenzyl)oxy]-6-nonenoyl}-1,3-oxazolidin-2-one (19): 
 
O
O
OPMB
O
O O
N
Bn
 
 
 
A magnetically stirred solution of acid 9 (13.7 g, 35 mmol) in anhydrous THF (200 ml) 
was cooled to –15°C under argon, and was treated with dry triethylamine (9.24 ml, 67 
mmol) followed by dropwise addition of trimethylacetyl chloride (4.70 ml, 38 mmol). 
Thereafter the resulting slurry was stirred for 20 min and was allowed to warm up to 0°C 
(over 15 min) and was again recooled to –78°C. In a separate flask a solution of (4S)-4-
benzyl-1,3-oxazolidin-2-one (37) (6.8 g, 39 mmol) in absolute THF (350 ml) was cooled to 
–70°C and treated dropwise with a 2.5M solution of n-butyllithium in hexane (15,4 ml, 39 
mmol). After being stirred for 15 min, the yellow reaction mixture was transported via 
double needle to a dropping funnel and added dropwise over 30 min to the white slurry 
prepared as described above. Then the resulting reaction mixture was stirred for 2.5 h at –
78°C and quenched with 1M aqueous solution of NaHSO4 (140 ml). Thereafter the 
reaction mixture was allowed to reach room temperature and the bulk of THF was 
removed under reduced pressure. The residue was extracted with ethyl acetate (3 x 150 
ml) and the combined organic extracts were washed with brine (100 ml), dried over 
MgSO4, filtered, and concentrated in vacuo. Pure oxazolidinone 19 (15.1 g, 78% yield) 
was obtained by flash column chromatography (petroleum ether/ethyl acetate, 2:1) as 
colorless oil. - TLC (petroleum ether/ethyl acetate, 2:1): Rf = 0.52. . - [α]22.0D = +53.3 (c 
1.00, CH2Cl2). 
1H NMR (250 MHz, CDCl3): δ = 1.27, 1.34 (2 s, 3 H each, isopropylidene-CH3), 1.38-1.44 
[m, 2 H, CH2(CH2)2CO], 1.58-1.67 (m, 2 H, CH2CH2CO), 2.00-2.08 [m, 2 H, 
CH2(CH2)3CO], 2.27-2.30 (m, 2 H, CH2CH=CH), 2.68 (dd, 2J = 13.3 Hz, 3J = 9.6 Hz, 1 H, 
C6H5CH2), 2.82-2.90 (m, 2 H, CH2CO), 3.22 (dd, 2J = 13.3 Hz, 3J = 3.2 Hz, 1 H, C6H5CH2), 
3.42-3.49 (m, 1 H, CHOPMB), 3.72 (s, 3 H, OCH3), 3.77-3.82 (m, 1 H, OCH), 3.92-4.01 
(m, 2 H, OCH2), 4.07-4.12 (m, 2 H, oxazolidinone-CH2), 4.44, 4.52 (2 d, J = 11.1 Hz each, 
2 H, PMB-CH2), 4.56-4.61 (m, 1 H, oxazolidinone-CH), 5.37-5.50 (m, 2 H, olefin-CH), 6.79 
(d, J = 8.7 Hz, 2 H, aromatic-CH), 7.12-7.30 (m, 7 H, aromatic-CH). 
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13C NMR (62.9 MHz, CDCl3): δ = 24.0 (CH2CH2CO), 25.4, 26.7 (isopropylidene-CH3), 27.2 
[CH2(CH2)3CO], 29.1 (CH2CH=CHCH2CH2), 35.5 (CH2CO), 38.0 (C6H5CH2), 55.2 
(oxazolidinone-CH), 55.3 (OCH3), 66.2 (oxazolidinone-CH2), 66.6 (OCH2), 72.2 (PMB-
CH2), 77.3 (OCH), 79.0 (CHOPMB), 109.0 (isopropylidene-C), 113.8 (PMB-aromatic-CH), 
125.2 (olefin-CH), 127.4, 129.0, 129.4 (aromatic-CH), 130.7 (PMB-aromatic-C), 131.8 
(olefin-CH), 135.4 (aromatic-C), 153.5 (oxazolidinone-CO), 159.2 (PMB-aromatic-C), 
173.2 (amide-CO). 
IR (neat): v~ = 2934 cm-1 (alkyl), 1783 cm-1, 1699 cm-1 (C=O), 1613 cm-1, 1586 cm-1, 1514 
cm-1 (C=C). 
MS (EI): m/z (%) = 551 (1) [M+], 493 (2), 432 (3), 337 (10), 121 (100). 
HRMS (EI): calc. for C32H41NO7: 551.28830, found: 551.29155. 
 
 
(4S)-4-Benzyl-3-{(6Z,9S,10R)-10,11-dihydroxy-9-[(4-methoxybenzyl)oxy]-6-undecenoyl}-
1,3-oxazolidin-2-one (20): 
 
O
O O
N
Bn
HO
OH
OPMB
 
 
 
To a solution of oxazolidinone 19 (5.00 g, 9.06 mmol) in methanol (170 ml) was 
added at once cupric(II) chloride dihydrate (1.96 g, 11.5 mmol). The resulting green 
reaction mixture was refluxed for 1.5 h and then allowed to cool to ambient temperature 
and 9.76 g NaHCO3 was added. After the evolution of carbon dioxide had ceased, 85 ml 
of water was added and the resulting blue precipitate was filtered off trough a pad of 
Celite and washed intensively with ethyl acetate. The combined filtrate was washed once 
with brine (300 ml) and dried over anhydrous MgSO4, filtered, and concentrated under 
reduced pressure. Purification by flash column chromatography (diethyl ether/ethanol, 
10:0.5) gave 4.07 g (88% yield) of diol 20 as colorless oil. - TLC (diethyl ether/ethanol, 
10:0.5): Rf = 0.56. - [α]25.0D = +50.0 (c 1.00, CH2Cl2). 
1H NMR (250 MHz, CDCl3): δ = 1.41-1.50 [m, 2 H, CH2(CH2)2CO], 1.63-1.75 (m, 2 H, 
CH2CH2CO), 2.07-2.15 [m, 2 H, CH2(CH2)3CO], 2.31-2.49 (m, 2 H, CH2CH=CH), 2.74 (dd, 
2J = 13.3 Hz, 3J = 9.6 Hz, 1 H, C6H5CH2), 2.88-2.96 (m, 2 H, CH2CO), 3.27 (dd, 2J = 13.3 
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Hz, 3J = 3.2 Hz, 1 H, C6H5CH2), 3.55-3.61 (m, 1 H, CHOPMB), 3.65-3.74 (m, 3 H, CH2OH, 
CHOH), 3.78 (s, 3 H, OCH3), 4.13-4.18 (m, 2 H, oxazolidinone-CH2), 4.44, 4.60 (2 d, J = 
11.1 Hz each, 2 H, PMB-CH2), 4.64-4.68 (m, 1 H, oxazolidinone-CH), 5.44-5.53 (m, 2 H, 
olefin-CH), 6.86 (d, J = 8.7 Hz, 2 H, aromatic-CH), 7.17-7.36 (m, 7 H, aromatic-CH). 
13C NMR (62.9 MHz, CDCl3): δ = 23.8 (CH2CH2CO), 27.2 [CH2(CH2)3CO], 28.4 
(CH2CH=CH), 28.9 [CH2(CH2)2CO], 35.4 (CH2CO), 38.0 (C6H5CH2), 55.2 (oxazolidinone-
CH), 55.3 (OCH3), 63.5 (CH2OH), 66.3 (oxazolidinone-CH2), 72.2 (PMB-CH2), 72.4 
(CHOH), 80.6 (CHOPMB), 113.9 (PMB-aromatic-CH), 125.2 (olefin-CH), 127.4, 129.0, 
129.4, 129.5 (aromatic-CH), 130.2 (PMB-aromatic-C), 132.0 (olefin-CH), 135.3 (aromatic-
C), 153.8 (oxazolidinone-CO), 159.4 (PMB-aromatic-C), 173.4 (amide-CO). 
IR (neat): v~ = 3413 cm-1 (OH), 2933 cm-1 (alkyl), 1781 cm-1, 1700 cm-1 (C=O), 1612 cm-1, 
1586 cm-1, 1514 cm-1 (C=C). 
MS (FD): m/z (%) = 511 (100) [M+], 177 (10). 
 
 
(2S,4Z)-10-[(4S)-4-Benzyl-2-oxo-1,3-oxazolidin-3-yl]-2-[(4-methoxybenzyl)oxy]-10-oxo-4-
decenal (21): 
 
O
O O
N
Bn
OHC
OPMB
 
 
 
The diol 20 (3.98 g, 7.78 mmol) was dissolved in 60% aqueous acetonitrile (73 ml) 
and treated with sodium(meta)periodate (2.49 g, 11.7 mmol); a white precipitate was 
formed immediately. The reaction mixture was stirred at room temperature for 3.5 h and 
filtered through a glass funnel. The filtrate was mixed with water (100 ml) and extracted 
thoroughly with chloroform (4 x 100 ml). The combined organic layers were washed once 
with water (200 ml), dried over anhydrous MgSO4, filtered, and concentrated under 
reduced pressure to afford aldehyde 21 (3.58 g, 96% yield) as colorless high viscose oil. 
The crude material is suitable for the next step without further purification. - TLC 
(petroleum ether/ethyl acetate, 1:1): Rf = 0.57. - [α]21.0D = +19.8 (c 1.00, CH2Cl2). 
1H NMR (250 MHz, CDCl3): δ = 1.40-1.49 [m, 2 H, CH2(CH2)2CO], 1.62-1.74 (m, 2 H, 
CH2CH2CO), 2.03-2.12 [m, 2 H, CH2(CH2)3CO], 2.43-2.48 (m, 2 H, CH2CH=CH), 2.75 (dd, 
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2J = 13.3 Hz, 3J = 9.6 Hz, 1 H, C6H5CH2), 2.83-2.95 (m, 2 H, CH2CO), 3.28 (dd, 2J = 13.3 
Hz, 3J = 3.2 Hz, 1 H, C6H5CH2), 3.74-3.77 (m, 1 H, CHOPMB), 3.79 (s, 3 H, OCH3), 4.12-
4.22 (m, 2 H, oxazolidinone-CH2), 4.52, 4.59 (2 d, J = 11.3 Hz each, 2 H, PMB-CH2), 4.62-
4.69 (m, 1 H, oxazolidinone-CH), 5.39-5.55 (m, 2 H, olefin-CH), 6.87 (d, J = 8.7 Hz, 2 H, 
aromatic-CH), 7.18-7.36 (m, 7 H, aromatic-CH), 9.62 (d, J = 2.1 Hz, 1 H, CHO). 
13C NMR (62.9 MHz, CDCl3): δ = 23.9 (CH2CH2CO), 27.1 [CH2(CH2)3CO], 28.4 
(CH2CH=CH), 28.9 [CH2(CH2)2CO], 35.4 (CH2CO), 38.0 (C6H5CH2), 55.2 (oxazolidinone-
CH), 55.3 (OCH3), 66.2 (oxazolidinone-CH2), 72.3 (PMB-CH2), 82.9 (CHOPMB), 114.0 
(PMB-aromatic-CH), 123.4 (olefin-CH), 127.4, 129.0, 129.4, (aromatic-CH), 129.7 (PMB-
aromatic-C), 132.8 (olefin-CH), 135.4 (aromatic-C), 153.5 (oxazolidinone-CO), 159.6 
(PMB-aromatic-C), 173.2 (amide-CO), 203.3 (CHO). 
IR (neat): v~ = 2935 cm-1 (alkyl), 1719 cm-1 (CHO), 1790 cm-1, 1732 cm-1, 1699 cm-1 (C=O), 
1612 cm-1, 1585 cm-1, 1514 cm-1 (C=C). 
MS (FD): m/z (%) = 479 (100) [M+], 451 (80). 
 
 
(4S)-4-Benzyl-3-[(6Z,9S)-9-hydroxy-6-undecen-10-ynoyl]-1,3-oxazolidin-2-one (22): 
 
OH
H
O
O O
N
Bn
 
 
 
The p-methoxybenzyl ether 18 (900 mg, 1.89 mmol) was dissolved in acetonitrile (30 
ml) and cooled to 0°C. To this solution was added ceric ammonium nitrate (3.11 g, 5.68 
mmol) dissolved in water (9 ml). The yellow reaction mixture was stirred at 0°C for 5 min 
and then was allowed to reach room temperature. After 1 h of stirring the mixture was 
diluted with ethyl acetate (115 ml) and the layers were separated. The organic phase was 
dried over MgSO4, filtered, and concentrated on the rotatory evaporator. Purification of the 
residue by flash column chromatography (petroleum ether/ethyl acetate, 3:2) gave 668 mg 
(99% yield) of the alcohol 22 as colorless oil, which solidified on standing. - TLC 
(petroleum ether/ethyl acetate, 3:2): Rf = 0.45. – m.p.: 87 - 88°C. - [α]26.8D = +37.9 (c 1.10, 
CH2Cl2). 
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1H NMR (250 MHz, CDCl3): δ = 1.43-1.52 [m, 2 H, CH2(CH2)2CO], 1.64-1.73 (m, 2 H, 
CH2CH2CO), 2.08-2.14 [m, 2 H, CH2(CH2)3CO], 2.40-2.53 (m, 3 H, alkyne-H, CH2CH=CH), 
2.75 (dd, 2J = 13.3 Hz, 3J = 9.6 Hz, 1 H, C6H5CH2), 2.89-2.97 (m, 2 H, CH2CO), 3.27 (dd, 
2J = 13.3 Hz, 3J = 3.3 Hz, 1 H, C6H5CH2), 4.13-4.19 (m, 2 H, oxazolidinone-CH2), 4.38-
4.44 (m, 1 H, CHOH), 4.61-4.69 (m, 1 H, oxazolidinone-CH), 5.51-5.64 (m, 2 H, olefin-
CH), 7.18-7.36 (m, 5 H, aromatic-CH). 
13C NMR (62.9 MHz, CDCl3): δ = 23.9 (CH2CH2CO), 27.2 [CH2(CH2)3CO], 28.9 
[CH2(CH2)2CO], 35.4 (CH2CO), 35.5 (CH2CH=CH), 38.0 (C6H5CH2), 55.2 (oxazolidinone-
CH), 61.9 (CHOH), 66.3 (oxazolidinone-CH2), 73.2 (alkyne-CH); 84.4 (alkyne-C), 123.7 
(olefin-CH), 127.4, 129.0, 129.5 (aromatic-CH), 133.7 (olefin-CH), 135.3 (aromatic-C), 
153.6 (oxazolidinone-CO), 173.4 (amide-CO). 
IR (neat): v~ = 3503 cm-1 (OH), 3285 cm-1 (alkyne-CH), 2932 cm-1 (alkyl), 2116 cm-1 (C≡C), 
1786 cm-1, 1701 cm-1 (C=O), 1604 cm-1, 1584 cm-1 (C=C). 
MS (EI): m/z (%) = 356 (2) [M+], 338 (1), 178 (100), 117 (90), 91 (55). 
HRMS (EI): calc. for C21H25NO4: 355.17836, found: 355.17625. 
 
 
(4S)-4-Benzyl-3-{(6Z,9S)-9-[(triisopropylsilyl)oxy]-6-undecen-10-ynoyl}-1,3-oxazolidin-2-
one (23): 
 
OTIPS
H
O
O O
N
Bn
 
 
 
A mixture of 22 (730 mg, 2.06 mmol), imidazol (350 mg, 5.14 mmol) and 
dimethylaminopyridine (50 mg, 0.41 mmol) in anhydrous dichloromethane (20 ml) was 
cooled to 0°C and stirred for 30 min. Thereafter triisopropylsilyl chloride (0.66 ml, 3.08 
mmol) was added and the reaction mixture allowed to warm slowly to room temperature, 
and to stir under an atmosphere of argon until complete consumption of the starting 
material (3 days). The reaction mixture was quenched by addition of saturated aqueous 
solution of NaCl (15 ml) followed by separation of the layers. The organic layer was 
washed with 1M aqueous hydrochloric acid (2 x 15 ml), saturated solution of NaHCO3 (15 
ml), brine (15 ml), dried over MgSO4, filtered, and concentrated under reduced pressure. 
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Flash column chromatography (petroleum ether/ethyl acetate, 5:1) provided 998 mg of 23 
(95% yield) as colorless oil. - TLC (petroleum ether/ethyl acetate, 5:1): Rf = 0.53. - [α]25.4D 
= +31.7 (c 1.00, CH2Cl2). 
1H NMR (250 MHz, CDCl3): δ = 1.03-1.17 (m, 21 H, TIPS), 1.42-1.48 [m, 2 H, 
CH2(CH2)2CO], 1.67-1.73 (m, 2 H, CH2CH2CO), 2.07-2.13 [m, 2 H, CH2(CH2)3CO], 2.39-
2.40 (m, 2 H, CH2CH=CH, alkyne-H), 2.45-2.50 (m, 1 H, CH2CH=CH), 2.75 (dd, 2J = 13.3 
Hz, 3J = 9.6 Hz, 1 H, C6H5CH2), 2.88-2.97 (m, 2 H, CH2CO), 3.28 (dd, 2J = 13.3 Hz, 3J = 
3.3 Hz, 1 H, C6H5CH2), 4.13-4.19 (m, 2 H, oxazolidinone-CH2), 4.42-4.46 (m, 1 H, 
CHOTIPS), 4.62-4.70 (m, 1 H, oxazolidinone-CH), 5.45-5.54 (m, 2 H, olefin-CH), 7.18-
7.36 (m, 5 H, aromatic-CH). 
13C NMR (62.9 MHz, CDCl3): δ = 12.3 (TIPS-CH), 18.0 (TIPS-CH3), 24.0 (CH2CH2CO), 
27.4 [CH2(CH2)3CO], 29.2 [CH2(CH2)2CO], 35.5 (CH2CO), 36.9 (CH2CH=CH), 38.0 
(C6H5CH2), 55.2 (oxazolidinone-CH), 62.8 (CHOTIPS), 66.2 (oxazolidinone-CH2), 72.3 
(alkyne-CH); 85.5 (alkyne-C), 124.6 (olefin-CH), 127.4, 129.0, 129.5 (aromatic-CH), 132.1 
(olefin-CH), 135.4 (aromatic-C), 153.5 (oxazolidinone-CO), 173.2 (amide-CO). 
IR (neat): v~ = 3290 cm-1 (alkyne-CH), 2944 cm-1 (alkyl), 2113 cm-1 (C≡C), 1790 cm-1, 1699 
cm-1, (C=O), 1605 cm-1 (C=C). 
MS (EI): m/z (%) = 511 (1) [M+], 468 (100), 157 (40), 117 (40), 91 (75). 
HRMS (EI): calc. for C30H45NO4Si: 511.311755, found: 511.313806. 
 
 
(4S)-4-Benzyl-3-propionyl-1,3-oxazolidin-2-one (24):[114] 
 
NO
O
Bn
O
 
 
 
Compound 37 (10 g, 56 mmol) was dissolved in absolute THF (170 ml). The resulting 
solution was cooled to –78°C and treated dropwise over a period of 10 min with a 2.7M 
solution of n-butyllithium in heptane (21 ml, 56.6 mmol). Thereafter, the yellow reaction 
mixture was treated with propionyl chloride (5.4 ml, 62 mmol) and stirred for 1 h at –78°C. 
Then the reaction mixture was allowed to warm to ambient temperature over 1 h and 
quenched with saturated aqueous solution of ammonium chloride (35 ml), which resulted 
in the formation of a white precipitate. The bulk of THF was removed under reduced 
pressure and the residue taken up in water (20 ml) and extracted with dichloromethane (2 
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x 50 ml). The combined organic layers were washed with 1M aqueous solution of sodium 
hydroxide (50 ml), brine (50 ml), dried over MgSO4, filtered and evaporated on the rotatory 
evaporator to a afford thick yellow oil (13.47 g), which was placed in a refrigerator over 
night to crystallize. The resulting crystalline solid was pulverized and triturated with a 
minimum quantity of cold hexane (50 ml). After filtration and drying for several hours with 
a vacuum pump, 12.91 g (98% yield) of the desired product 24 was obtained as a 
colorless crystalline solid. – m.p.: 43.9 – 44.4°C (lit. [114]: 44 – 46°C). 
1H NMR (250 MHz, CDCl3): δ = 1.19 (t, J = 7.3 Hz, 3 H, CH3), 2.76 (dd, 2J = 13.4 Hz, 3J = 
9.6 Hz, 1 H, C6H5CH2), 2.85-3.07 (m, 2 H, CH2CH3), 3.29 (dd, 2J = 13.4 Hz, 3J = 3.3 Hz, 1 
H, C6H5CH2), 4.12-4.23 (m, 2 H, oxazolidinone-CH2), 4.62-4.71 (m, 1 H, oxazolidinone-
CH), 7.19-7.36 (m, 5 H, aromatic-CH). 
13C NMR (62.9 MHz, CDCl3): δ = 8.3 (CH3), 29.2 (CH2CH3), 38.0 (C6H5CH2), 55.2 
(oxazolidinone-CH), 66.3 (oxazolidinone-CH2), 127.4, 129.0, 129.5 (aromatic-CH), 135.4 
(aromatic-C), 153.5 (oxazolidinone-CO), 174.1 (amide-CO). 
MS (EI): m/z (%) = 234 (80) [M+H+], 233 (100) [M+], 91 (30). 
 
 
(S)-Phenylalanol (36):[114] 
 
OH
NH2
O  
 
 
L-Phenylalanine (40 g, 0.24 mol) was dissolved in absolute THF (120 ml) and was 
treated by dropwise addition over a 25 min period with boron trifluoride etherate (31 ml, 
0.24 mol). After complete addition, the reaction mixture was heated to reflux for 2 h and 
the resulting solution became colorless and homogeneous. Thereafter to the vigorously 
refluxed reaction mixture was added carefully and dropwise over a 35 min period borane-
dimethyl sulphide complex (26.4 ml, 0.28 mol). During the course of the addition there 
was continuous evolution of dimethyl sulphide and hydrogen gas, and the solution turns 
from orange to light brown. Because of the vigorous exothermic reaction, which occurs, 
heating was reduced so that the reaction mixture could the whole time maintained at 
gentle reflux. Thereafter the reaction mixture was stirred for additional 6 h under reflux 
and was then allowed to cool to ambient temperature. The excess borane was quenched 
by the slowly addition of a 1:1 mixture of THF / water (30 ml) followed by addition of 5M 
aqueous solution of sodium hydroxide (180 ml). The resulting two-phase mixture was 
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heated to reflux for additional 12 h, cooled to room temperature and filtered through a 
glass funnel. The residual solid was washed with small portions of THF and the filtrate 
was concentrated under reduced pressure to remove the bulk of the THF. The resulting 
slurry was then extracted with dichloromethane (4 x 100 ml) and the combined organic 
layers were dried over anhydrous MgSO4, filtered, and concentrated in vacuo. The 
crystalline solid residue was recrystallized from boiling ethyl acetate (145 ml) to give 28.5 
g (78% yield) of the desired product 36 as white needles. – m.p.: 91 - 92°C (lit. [114]: 88.5 – 
91°C). 
1H NMR (250 MHz, CDCl3): δ = 2.47-2.56 (m, 4 H, NH2, OH, C6H5CH2), 2.78 (dd, 2J = 13.4 
Hz, 3J = 5.2 Hz, 1 H, C6H5CH2), 3.05-3.15 (m, 1 H, NH2CH), 3.37 (dd, 2J = 10.8 Hz, 3J = 
7.2 Hz, 1 H, CH2OH), 3.63 (dd, 2J = 10.8 Hz, 3J = 7.2 Hz, 1 H, CH2OH), 7.16-7.33 (m, 5 H, 
aromatic-CH). 
13C NMR (62.9 MHz, CDCl3): δ = 40.6 (C6H5CH2), 54.3 (NH2CH), 66.0 (CH2OH), 126.5, 
128.6, 129.3 (aromatic-CH), 138.6 (aromatic-C). 
MS (EI): m/z (%) = 152 (100) [M+H+], 120 (85), 91 (70), 60 (90). 
 
 
(4S)-4-Benzyl-1,3-oxazolidin-2-one (37):[114] 
 
O
HN
O
 
 
 
A mixture of (S)-Phenylalanol (36) (26.1 g, 0.17 mol), anhydrous potassium carbonate 
(2.4 g, 0.017 mol) and diethyl carbonate (43.4 ml, 0.36 mol) was placed into a round 
bottom flask equipped with a VIGREUX column and distillation head, and heated to 135°C 
with an oil bath. The distillation receiver was cooled in an ice bath and the ethanol (21 ml) 
formed in the reaction over 1.5 h of stirring was collected. After the distillation of ethanol 
had ceased, the reaction mixture was allowed to cool to room temperature under an 
atmosphere of argon and was then diluted with dichloromethane (130 ml), and washed 
with water (130 ml). The resulting organic phase was dried over anhydrous MgSO4, 
filtered, and concentrated on the rotatory evaporator to afford 37.8 g of the crude material 
which was recrystallized from a hot 2:1 mixture of ethyl acetate / hexane (105 ml) to give 
23.5 g of pure 37 (77% yield) as fine white crystals. – m.p.: 87.9 – 88.3°C (lit. [114]: 84.5 – 
86.5°C). 
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1H NMR (250 MHz, CDCl3): δ = 2.78-2.95 (m, 2 H, C6H5CH2), 4.02-4.15 (m, 2 H, CH2O), 
4.35-4.45 (m, 1 H, NHCH), 6.21 (br. s, 1 H, NH), 7.13-7.36 (m, 5 H, aromatic-CH). 
13C NMR (62.9 MHz, CDCl3): δ = 41.4 (C6H5CH2), 53.8 (NHCH), 69.6 (CH2O), 127.2, 
129.0, 129.1 (aromatic-CH), 136.0 (aromatic-C), 159.7 (CO). 
MS (EI): m/z (%) = 177 (30) [M+], 92 (100), 86 (70). 
 
 
5-[(Triisopropylsilyl)oxy]-1-pentanol (39): 
 
HO OTIPS 
 
 
To a suspension of sodium hydride (2.81 g, 117 mmol, washed with hexane) in 
anhydrous THF (230 ml) at room temperature was added 1,5-pentanediol (12.3 ml, 117 
mmol). The resulting reaction mixture was stirred at ambient temperature for 45 min 
during which time a large amount of an opaque white precipitate has formed. 
Subsequently, the triisopropylsilyl chloride (25.0 ml, 117 mmol) was added dropwise over 
5 min and the vigorous stirring was continued for additional 45 min. Thereafter the 
homogeneous white reaction mixture was poured into diethyl ether (1.1 l), washed with 
10% aqueous potassium carbonate (600 ml) and brine (400 ml), dried over MgSO4, 
filtered, and concentrated on the rotatory evaporator to afford 28.3 g of crude material as 
a pale yellow oil. The purification was made by flash column chromatography (petroleum 
ether/ethyl acetate, 2/1) to give 18.6 g (65% yield) of monosilylated alcohol 39 as 
colorless mobile oil. - TLC (petroleum ether/ethyl acetate, 2:1): Rf = 0.47. 
1H NMR (250 MHz, CDCl3): δ = 0.96-1.04 (m, 21 H, TIPS), 1.30-1.39 [m, 2 H, 
CH2(CH2)2OH], 1.43-1.56 (m, 4 H, HOCH2CH2CH2CH2CH2OTIPS), 1.78 (br, 1 H, OH), 
3.53-3.62 (m, 4 H, CH2OH, CH2OTIPS). 
13C NMR (62.9 MHz, CDCl3): δ = 12.1 (TIPS-CH), 18.0 (TIPS-CH3), 22.1 [CH2(CH2)2OH], 
32.6, 32.7 (CH2CH2OH, CH2CH2OTIPS), 63.0 (CH2OH), 63.3 (CH2OTIPS). 
IR (neat): v~ = 3341 cm-1 (OH), 2941 cm-1, 2866 cm-1 (alkyl). 
MS (EI): m/z (%) = 217 (20) [M+], 131 (40), 119 (70), 103 (60), 69 (100). 
HRMS (EI): calc. for C11H25O2Si: 217.162377, found: 217.163187. 
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5-[(Triisopropylsilyl)oxy]pentanal (40): 
 
OHC
OTIPS
 
 
 
Freshly distilled oxalyl chloride (4.31 ml, 49 mmol) was dissolved in anhydrous 
dichloromethane (100 ml). The solution was cooled to –78°C and then absolute DMSO 
(6.97 ml, 98 mmol), dissolved in 20 ml of dichloromethane was added dropwise; gas 
evolution was evident. The colorless reaction mixture was stirred for 30 min and then 
treated dropwise over a period of 25 min with a solution of alcohol 39 (10.3 g, 42 mmol) in 
dichloromethane (100 ml). After the mixture was stirred for 1.5 h at –78°C, absolute 
triethylamine (16.8 ml, 121 mmol) was added dropwise. Thereafter the resulting thick 
reaction mixture was allowed to warm slowly to room temperature over 3 h and was 
quenched with water (110 ml). The layers were separated and the aqueous phase was 
extracted with dichloromethane (3 x 100 ml). The combined organic layers were washed 
with 1M aqueous hydrochloric acid (120 ml) then with water (120 ml) followed by 
saturated aqueous solution of NaHCO3 (120 ml) and at the end again with water (120 ml), 
dried over MgSO4, filtered and concentrated under reduced pressure. Purification of the 
residue by flash column chromatography (petroleum ether/diethyl ether, 10:1) gave 9.5 g 
(87% yield) of the aldehyde 40 as colorless mobile liquid. - TLC (petroleum ether/diethyl 
ether, 10:1): Rf = 0.42. 
1H NMR (250 MHz, CDCl3): δ = 0.98-1.09 (m, 21 H, TIPS), 1.52-1.61 (m, 2 H, 
CH2CH2CHO), 1.66-1.78 (m, 2 H, CH2CH2OTIPS), 2.45 (dt, 3J1 = 1.8 Hz, 3J2 =7.4 Hz, 2 H, 
CH2CHO), 3.69 (t, J = 6.0 Hz, 2 H, CH2OTIPS), 9.75 (t, J = 1.8 Hz, 1 H, CHO). 
13C NMR (62.9 MHz, CDCl3): δ = 12.0 (TIPS-CH), 18.0 (TIPS-CH3), 18.7 (CH2CH2CHO), 
32.3 (CH2CH2OTIPS), 43.7 (CH2CHO), 62.9 (CH2OTIPS), 202.6 (CHO). 
IR (neat): v~ = 2943 cm-1, 2867 cm-1 (alkyl), 2715 cm-1, 1729 cm-1 (CHO). 
MS (EI): m/z (%) = 215 (50) [M+], 173 (90), 103 (100), 75 (80). 
HRMS (EI): calc. for C11H23O2Si: 215.146726, found: 215.148025. 
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(4S)-4-Benzyl-3-{(2S,3R)-3-hydroxy-2-methyl-7-[(triisopropylsilyl)oxy]heptanoyl}-1,3-
oxazolidin-2-one (41): 
 
NO
O
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O
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The oxazolidinone 24 (2.80 g, 12 mmol) was dissolved in anhydrous dichloromethane 
(60 ml) and cooled to –78°C. Titanium tetrachloride (1.30 ml, 12 mmol) was added 
dropwise and the resulting mixture was stirred for 10 min. Thereafter the reaction mixture 
was treated dropwise with (-)-sparteine (6.90 ml, 30 mmol) and the dark red solution was 
stirred at –78°C for 2 h. A solution of 5-[(triisopropylsilyl)oxy] pentanal (40) (9.13 g, 35 
mmol) in dichloromethane (20 ml) was added dropwise and stirring was continued at –
78°C for 1.5 h. The reaction was quenched at –78°C with half-saturated aqueous solution 
of ammonium chloride (60 ml) and was allowed to warm up to room temperature, during 
which time the colour changed to yellow and a precipitate was formed. The resulting 
mixture was filtered through a pad of Celite and the salts were washed with several small 
portions of dichloromethane. Thereafter the layers were separated and the aqueous 
phase was extracted with dichloromethane (3 x 60 ml). The combined organic extracts 
were washed with brine (80 ml), dried over anhydrous MgSO4, filtered and the solvent was 
removed under reduced pressure. Purification by flash column chromatography 
(petroleum ether/ethyl acetate, 5:1) afforded 5.78 g of alcohol 41 (98% yield) as a 
colorless oil. - TLC (petroleum ether/ethyl acetate, 5:1): Rf = 0.28. - [α]22.1D = +39.4 (c 
1.00, CH2Cl2). 
1H NMR (250 MHz, CDCl3): δ = 0.93-1.05 (m, 21 H, TIPS), 1.19 (d, J = 7.0 Hz, 3 H, CH3), 
1.34-1.53 (m, 6 H, 3 CH2), 2.48 (br, 1 H, OH), 2.71 (dd, 2J = 13.3 Hz, 3J = 9.4 Hz, 1 H, 
C6H5CH2), 3.18 (dd, 2J = 13.3 Hz, 3J = 3.3 Hz, 1 H, C6H5CH2), 3.62 (t, J = 6.2 Hz, 2 H, 
CH2OTIPS), 3.69 (dq, 3J1 = 7.0 Hz, 3J2 = 2.7 Hz, 1 H, CHCH3), 3.87-3.90 (m, 1 H, CHOH), 
4.09-4.20 (m, 2 H, oxazolidinone-CH2), 4.60-4.67 (m, 1 H, oxazolidinone-CH), 7.12-7.30 
(m, 5 H, aromatic-CH). 
13C NMR (62.9 MHz, CDCl3): δ = 10.4 (CH3), 12.1 (TIPS-CH), 18.1 (TIPS-CH3), 22.4 
[CH2(CH2)2OTIPS], 32.9 (CH2CH2OTIPS), 33.7 [CH2(CH2)3OTIPS], 37.9 (C6H5CH2), 42.2 
(CHCH3), 55.1 (oxazolidinone-CH), 63.3 (CH2OTIPS), 66.2 (oxazolidinone-CH2), 71.5 
(CHOH), 127.5, 129.0, 129.4 (aromatic-CH), 135.1 (aromatic-C), 153.0 (oxazolidinone-
CO), 177.6 (amide-CO). 
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IR (neat): v~ = 3525 cm-1 (OH), 2942 cm-1, 2866 cm-1 (alkyl), 1784 cm-1, 1697 cm-1 (C=O). 
MS (FD): m/z (%) = 491 (5) [M+], 448 (100) [M+ - i-Pr]. 
MS (EI): m/z (%) = 492 (2) [M+H+], 448 (100) [M+ - i-Pr], 430 (5), 173 (70). 
HRMS (EI): calc. for C24H38NO5Si [M+ - i-Pr]: 448.25193, found: 448.23909. 
 
 
(2S,3R)-3-Hydroxy-N-methoxy-N,2-dimethyl-7-[(triisopropylsilyl)oxy]heptanamide (42): 
 
N
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O
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A suspension of N,O-dimethylhydroxylamine hydrochloride (8.95 g, 91.8 mmol) in 
anhydrous THF (30 ml) was cooled to –30°C and treated dropwise, over a period of 10 
min with a 2M solution of trimethylaluminium in heptane (45.9 ml, 91.8 mmol), and 
vigorous gas evolution was observed. After complete addition, the clear reaction mixture 
was allowed to warm to ambient temperature and to stir for 15 min. The resulting 
aluminium amide solution was recooled to –10°C and the aldol adduct 41 (5.15 g, 10.5 
mmol) dissolved in absolute THF (30 ml) was added slowly over a 10 min period (gas 
evolution). Stirring was continued for 17 h and then the reaction mixture was warmed to 
0°C, and stirred for additional 5 h. Thereafter the reaction mixture was transferred 
carefully by cannula into a rapidly stirred and cooled to 0°C, 1:1 mixture of 
dichloromethane / 0.1M aqueous solution of NaHSO4 (440 ml), and the resulting two-
phase mixture was stirred at 0°C for 1.5 h. After diluting with dichloromethane (700 ml) 
and water (300 ml), the layers were separated, and the aqueous layer was extracted with 
dichloromethane (3 x 200 ml). The combined organic layers were washed with brine (550 
ml), dried over MgSO4, filtered, and concentrated in vacuo. The resulting crude material 
was purified by flash column chromatography (diethyl ether/petroleum ether, 5:1) to 
provide 3.28 g of pure amide 42 (83% yield) as colorless oil. - TLC (diethyl 
ether/petroleum ether, 5:1): Rf = 0.40. - [α]23.0D = +3.0 (c 1.00, CH2Cl2). 
1H NMR (250 MHz, CDCl3): δ = 0.93-1.06 (m, 21 H, TIPS), 1.12 (d, J = 6.7 Hz, 3 H, CH3), 
1.28-1.53 (m, 6 H, 3 CH2), 2.80 (br, 1 H, OH), 3.13 (s, 3 H, NCH3), 3.58-3.65 (m, 6 H, 
OCH3, CH2OTIPS, CH2CH3), 3.76-3.82 (m, 1 H, CHOH). 
13C NMR (62.9 MHz, CDCl3): δ = 10.0 (CH3), 12.0 (TIPS-CH), 18.0 (TIPS-CH3), 22.3 
[CH2(CH2)2OTIPS], 32.0 (NCH3), 33.0 (CH2CH2OTIPS), 33.7 [CH2(CH2)3OTIPS], 38.6 
(CHCH3), 61.5 (OCH3), 63.3 (CH2OTIPS), 71.5 (CHOH). 
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IR (neat): v~ = 3455 cm-1 (OH), 2942 cm-1, 2866 cm-1 (alkyl), 1640 cm-1 (C=O). 
MS (EI): m/z (%) = 376 (5) [M+H+], 332 (100) [M+ - i-Pr]. 
HRMS (EI): calc. for C16H36NO4Si [M+ - i-Pr]: 332.22571, found: 332.21851 
 
 
(2S,3R)-N-Methoxy-3-(methoxymethoxy)-N,2-dimethyl-7-[(triisopropylsilyl)oxy] 
heptanamide (43): 
 
N
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A mixture of the alcohol 42 (3.14 g, 8.38 mmol) in absolute dichloromethane (17 ml) 
and diisopropylethylamine (13.27 ml, 77.5 mmol) was cooled to 0°C. Chloromethyl methyl 
ether (2.92 ml, 38.5 mmol) was added dropwise and the reaction mixture was stirred at 
0°C for 1 h, and then allowed to warm to ambient temperature and to stir 16 h longer. 
Thereafter water (50 ml) was added and the two phases were separated. The aqueous 
layer was extracted with dichloromethane (3 x 80 ml) and the combined organic extracts 
were washed with 1M aqueous hydrochloric acid (3 x 50 ml), water (50 ml), brine (50 ml), 
dried over anhydrous MgSO4, filtered and concentrated under reduced pressure. The 
residue was purified by flash column chromatography (diethyl ether/petroleum ether, 5:1) 
to give the ether 43 (3.39 g, 97% yield) as colorless easy mobile oil. - TLC (diethyl 
ether/petroleum ether, 5:1): Rf = 0.58. - [α]22.0D = +2.7 (c 1.00, CH2Cl2). 
1H NMR (250 MHz, CDCl3): δ = 0.95-1.05 (m, 21 H, TIPS), 1.12 (d, J = 6.9 Hz, 3 H, CH3), 
1.28-1.53 (m, 6 H, 3 CH2), 2.95-3.02 (m, 1 H, CHCH3), 3.12 (s, 3 H, NCH3), 3.31 (s, 3 H, 
OCH3), 3.58-3.62 (m, 5 H, NOCH3, CH2OTIPS), 3.69-3.75 (m, 1 H, CHOMOM), 4.59 (s, 2 
H, MOM-CH2). 
13C NMR (62.9 MHz, CDCl3): δ = 11.9 (TIPS-CH), 13.3 (CH3), 18.0 (TIPS-CH3), 21.6 
[CH2(CH2)2OTIPS], 32.3 (NCH3), 32.9 (CH2CH2OTIPS), 33.1 [CH2(CH2)3OTIPS], 39.4 
(CHCH3), 55.8 (OCH3), 61.2 (NOCH3), 63.2 (CH2OTIPS), 79.5 (CHOMOM), 96.6 (MOM-
CH2). 
IR (neat): v~ = 2942 cm-1, 2866 cm-1 (alkyl), 1666 cm-1(C=O), 1039 cm-1 (C-O-C). 
MS (EI): m/z (%) = 376 (100) [M+ - i-Pr], 314 (30). 
HRMS (EI): calc. for C18H38NO5Si [M+ - i-Pr]: 376.251902, found: 376.255542. 
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(2S,3R)-3-(Methoxymethoxy)-2-methyl-7-[(triisopropylsilyl)oxy]heptanal (44): 
 
O
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A cooled (–78°C) solution of WEINREB amide 43 (2.0 g, 4.77 mmol) in dry THF (50 ml) 
was treated dropwise, over a 5 min period, with a 1M solution of diisobutylaluminium 
hydride in hexane (11.9 ml, 11.9 mmol). The reaction mixture was stirred at this 
temperature for 2 h and then acetone (1.2 ml) was introduced. The resulting solution was 
taken up in a syringe and added at 0°C to a vigorously stirred 1:1 mixture of 0.1M 
aqueous ROCHELLE’S salt / diethyl ether (500 ml). After the solution was warmed to room 
temperature and stirred for 30 min, additional diethyl ether (150 ml) and water (100 ml) 
were added, and the layers were separated. The aqueous phase was extracted with 
diethyl ether (3 x 150 ml) and the combined organic extracts were washed with brine (200 
ml), dried over MgSO4, filtered, and concentrated under reduced pressure. Purification 
was performed by flash column chromatography (petroleum ether/diethyl ether, 3:1) to 
give the desired aldehyde 44 (1.70 g, 99% yield) as colorless syrup. - TLC (petroleum 
ether/diethyl ether, 3:1): Rf = 0.53. - [α]25.9D = +3.4 (c 1.00, CH2Cl2). 
1H NMR (250 MHz, CDCl3): δ = 0.98-1.00 (m, 21 H, TIPS), 1.04 (d, J = 7.0 Hz, 3 H, CH3), 
1.29-1.61 (m, 6 H, 3 CH2), 2.48 (dq, 3J1 = 6.8 Hz, 3J2 = 2.9 Hz, 1 H, CHCH3), 3.25 (s, 3 H, 
OCH3), 3.62 (t, J = 6.0 Hz, 2 H, CH2OTIPS), 3.91-3.98 (m, 1 H, CHOMOM), 4.54, 4.62 (2 
d, J = 7.0 Hz each, 2 H, MOM-CH2), 9.71 (s, 1 H, CHO). 
13C NMR (62.9 MHz, CDCl3): δ = 7.7 (CH3), 12.0 (TIPS-CH), 18.0 (TIPS-CH3), 22.3 
[CH2(CH2)2OTIPS], 32.0 (CH2CH2OTIPS), 32.9 [CH2(CH2)3OTIPS], 49.9 (CHCH3), 55.7 
(OCH3), 63.1 (CH2OTIPS), 77.5 (CHOMOM), 96.3 (MOM-CH2), 204.3 (CHO). 
IR (neat): v~ = 2943 cm-1, 2866 cm-1 (alkyl), 2725 cm-1, 1727 cm-1 (CHO), 1039 cm-1 (C-O-
C). 
MS (EI): m/z (%) = 329 (5) [M+-OCH3], 215 (100), 173 (90), 145 (30). 
HRMS (EI): calc. for C18H37O3Si [M+-OCH3]: 329.251187, found: 329.253845. 
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(4S)-4-Benzyl-3-{(2S,6Z,9S)-2-{(1R,2R,3R)-1-hydroxy-3-(methoxymethoxy)-2-methyl-7-
[(triisopropylsilyl)oxy]heptyl}-9-[(triisopropylsilyl)oxy]-6-undecen-10-ynoyl}-1,3-oxazolidin-
2-one (45): 
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To a cooled to –78°C solution of oxazolidinone 23 (500 mg, 0.98 mmol) in dry 
dichloromethane (5 ml) was added dropwise titanium tetrachloride (0.11 ml, 0.98 mmol) 
and the resulting mixture was stirred for 10 min under an argon atmosphere. (-)-Sparteine 
(0.56 ml, 2.45 mmol) was added dropwise and the dark red solution was stirred at –78°C 
for 1.5 h. Thereafter the aldehyde 44 (423 mg, 1.17 mmol) dissolved in anhydrous 
dichloromethane (1 ml) was added dropwise, and the resulting mixture was stirred for 
additional 3 h at –78°C, before it was treated with a half saturated aqueous solution of 
ammonium chloride (7 ml). The reaction mixture was allowed to warm to ambient 
temperature and filtered through a pad of Celite and the salts were washed with small 
portions of dichloromethane. The layers were separated and the aqueous phase was 
extracted with dichloromethane (3 x 5 ml). The combined organic layers were dried over 
MgSO4, filtered, and concentrated under reduced pressure. Purification of the residue by 
flash column chromatography (petroleum ether/diethyl ether, 1:1) gave 165 mg of the 
desired product 45 (20 %) as a colorless oil together with 309 mg (62 %) of recovered 
starting material. - TLC (petroleum ether/diethyl ether, 1:1): Rf = 0.38. - [α]24.1D = +6.5 (c 
1.00, CH2Cl2). 
1H NMR (250 MHz, CDCl3): δ = 0.88 (d, J = 7.1 Hz, 3 H, CH3), 0.94-1.10 (m, 42 H, 2 
TIPS), 1.21-1.64 [m, 9 H, CH=CHCH2CH2, (CH2)3CH2OTIPS, CHCH3], 1.75-1.85 [m, 2 H, 
CH=CH(CH2)2CH2], 1.94-2.08 (m, 2 H, CH=CHCH2), 2.30-2.34 (m, 2 H, alkyne-CH, 
CH2CH=CH), 2.37-2.42 (m, 1 H, CH2CH=CH), 2.60 (dd, 2J = 13.3 Hz, 3J = 9.6 Hz, 1 H, 
C6H5CH2), 3.26-3.34 (m, 4 H, C6H5CH2, OCH3), 3.59-3.64 (m, 3 H, CHOMOM, 
CH2OTIPS), 4.00 (dd, 3J1 = 7.5 Hz, 3J2 = 2.5 Hz, 1 H, CHOH), 4.07-4.19 (m, 3 H, CHCON, 
oxazolidinone-CH2), 4.31-4.41 (m, 1 H, CHOTIPS), 4.54-4.67 (m, 3 H, MOM-CH2, 
oxazolidinone-CH), 5.41-5.46 (m, 2 H, olefin-CH), 7.15-7.31 (m, 5 H, aromatic-CH). 
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13C NMR (62.9 MHz, CDCl3): δ = 7.2 ( +, CH3), 12.0, 12.2 (2 +, TIPS-CH), 18.1 ( +, TIPS-
CH3), 22.2 [ -, CH2(CH2)2OTIPS], 26.7 [ -, CH=CH(CH2)2CH2], 27.9 ( -, CH=CHCH2), 29.1 ( 
-, CH=CHCH2CH2), 31.8 ( -, CH2CH2OTIPS), 33.1 [ -, CH2(CH2)3OTIPS], 36.9 ( -, 
CH2CH=CH), 38.1 ( -, C6H5CH2), 38.2 ( +, CHCH3), 45.9 ( +, CHCON), 55.6 ( +, 
oxazolidinone-CH), 55.9 ( +, OCH3), 62.8 ( +, CHOTIPS), 63.2 ( -, CH2OTIPS), 65.9 ( -, 
oxazolidinone-CH2), 72.3 ( -, alkyne-CH), 74.7 ( +, CHOH), 82.7 ( +, CHOMOM), 85.4 ( #, 
alkyne-C), 96.1 ( -, MOM-CH2), 124.6 ( +, olefin-CH), 127.4, 129.0, 129.4 (3 +, aromatic-
CH), 132.1 ( +, olefin-CH), 135.3 ( #, aromatic-C), 152.9 ( #, oxazolidinone-CO), 176.0 ( #, 
amide-CO). 
IR (neat): v~ = 3515 cm-1 (OH), 3310 cm-1 (alkyne-CH), 2943 cm-1, 2866 cm-1 (alkyl), 2113 
cm-1 (C≡C), 1785 cm-1, 1694 cm-1 (C=O), 1463 cm-1, 1384 cm-1 (C=C), 1036 cm-1 (C-O-C). 
MS (EI): m/z (%) = 829 (2) [M+ - i-Pr], 785 (1) [M+ - 2(i-Pr)], 468 (95), 215 (60), 173 (100). 
MS (ESI): m/z (%) = 895 (50) [M+Na+], 841 (50) [M+-OCH3-], 534 (100). 
HRMS (FT-ICR-ESI): calc. for C49H85NO8Si2Na [M+Na+]: 894.5705930, found: 
894.5692011. 
 
 
(2R,3S,4R,5R)-5-(Methoxymethoxy)-4-methyl-9-[(triisopropylsilyl)oxy]-2-{(4Z,7S)-7-
[(triisopropylsilyl)oxy]-4-nonen-8-ynyl}-1,3-nonanediol (47): 
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The aldol adduct 45 (165 mg, 0.19 mmol) was dissolved in anhydrous THF (2 ml) 
which contained absolute methanol (15 µl). The resulting solution was cooled to 0°C and 
then treated dropwise with a 2M solution of lithium borohydride in THF (0.2 ml, 0.40 
mmol). After being stirred for 4.5 h at 0°C, the reaction mixture was quenched carefully 
with saturated aqueous ammonium chloride solution (4 ml) and the two-phase mixture 
was allowed to reach ambient temperature. The bulk of the THF was removed under 
reduced pressure and the residue extracted with ethyl acetate (3 x 4 ml). The combined 
organic layers were dried over anhydrous MgSO4, filtered, and concentrated on the 
rotatory evaporator. The residue was purified by flash column chromatography (petroleum 
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ether/ethyl acetate, 3:2) to give compound 47 (105 mg, 80% yield) as colorless oil. - TLC 
(petroleum ether/ethyl acetate, 3:2): Rf = 0.54. - [α]25.5D = -22.4 (c 1.00, CH2Cl2). 
1H NMR (250 MHz, CDCl3): δ = 0.89 (d, J = 7.2 Hz, 3 H, CH3), 0.93-1.05 (m, 42 H, 2 
TIPS), 1.19-1.57 [m, 9 H, CH=CHCH2CH2, (CH2)3CH2OTIPS, CHCH3],1.65-1.72 (m, 1 H, 
CHCH2OH), 1.77-1.84 [m, 2 H, CH=CH(CH2)2CH2], 2.00-2.03 (m, 2 H, CH=CHCH2), 2.30-
2.34 (m, 2 H, alkyne-CH, CH2CH=CH), 2.38-2.43 (m, 1 H, CH2CH=CH), 3.32 (s, 3 H, 
OCH3), 3.53-3.55 (m, 1 H, CHOMOM), 3.59-3.69 (m, 4 H, CH2OTIPS, CH2OH), 3.81 (dd, 
3J1 ≈ 3J2 = 5.0 Hz, 1 H, CHOH), 4.36-4.39 (m, 1 H, CHOTIPS), 4.55, 4.62 (2 d, J = 6.8 Hz 
each, 2 H, MOM-CH2), 5.40-5.47 (m, 2 H, olefin-CH). 
13C NMR (62.9 MHz, CDCl3): δ = 8.2 ( +, CH3), 12.0, 12.3 (2 +, TIPS-CH), 18.0 ( +, TIPS-
CH3), 22.3 [ -, CH2(CH2)2OTIPS], 25.1 [ -, CH=CH(CH2)2CH2], 27.7 ( -, CH=CHCH2), 28.0 ( 
-, CH=CHCH2CH2), 31.4 ( -, CH2CH2OTIPS), 33.1 [ -, CH2(CH2)3OTIPS], 36.9 ( -, 
CH2CH=CH), 37.2 ( +, CHCH3), 43.0 ( +, CHCH2OH), 55.9 ( +, OCH3), 62.8 ( +, 
CHOTIPS), 63.1 ( -, CH2OTIPS), 64.3 ( -, CH2OH), 72.3 ( -, alkyne-CH), 77.1 ( +, CHOH), 
82.0 ( +, CHOMOM), 85.5 ( #, alkyne-C), 95.7 ( -, MOM-CH2), 124.6, 132.1 (2 +, olefin-
CH). 
IR (neat): v~ = 3425 cm-1 (OH), 3311 cm-1 (alkyne-CH), 2943 cm-1, 2866 cm-1 (alkyl), 2113 
cm-1 (C≡C), 1464 cm-1 (C=C). 
MS (FD): m/z (%) = 1398 (100) [2M+H+], 699 (80) [M+], 679 (50). 
MS (ESI): m/z (%) = 668 (100) [M+-OCH3-], 1398 (10) [2M+H+]. 
HRMS (FT-ICR-ESI): calc. for C38H75O5Si2 [M+-OCH3-]: 667.5147550, found: 
667.5156360. 
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(2R,6Z,9S)-2-{(1S,2R,3R)-1-Hydroxy-3-(methoxymethoxy)-2-methyl-7-[(triisopropylsilyl) 
oxy] heptyl}-9-[(triisopropylsilyl)oxy]-6-undecen-10-ynyl 4-methylbenzenesulfonate (48): 
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To a solution of diol 47 (105 mg, 0.15 mmol) in anhydrous dichloromethane (1 ml) 
was added at once p-toluenesulfonyl chloride (30 mg, 0.15 mmol), followed by absolute 
triethylamine (22 µl, 0.16 mmol) and catalytic amounts of dimethylaminopyridine (2 mg, 16 
µmol). The resulting reaction mixture was stirred at ambient temperature for 18 h. Then 
the solvent was removed under reduced pressure and the residue was taken up in diethyl 
ether (3 ml), and water (1 ml) was added. The layers were separated and the organic 
phase was washed with water (2 x 1 ml), dried over MgSO4 filtered and concentrated in 
vacuo. The crude material was purified by flash column chromatography (petroleum 
ether/ethyl acetate, 6:1) to give 87 mg of the desired product 48 (68% yield) as colorless 
oil. - TLC (petroleum ether/ethyl acetate, 6:1): Rf = 0.25. - [α]25.8D = -18.7 (c 1.00, CH2Cl2). 
1H NMR (250 MHz, CDCl3): δ = 0.83 (d, J = 7.0 Hz, 3 H, CH3), 0.96-1.08 (m, 42 H, 2 
TIPS), 1.13-1.56 [m, 9 H, CH=CHCH2CH2, (CH2)3CH2OTIPS, CHCH3], 1.67-1.71 (m, 1 H, 
CHCH2OTs), 1.87-1.93 [m, 4 H, CH=CH(CH2)2CH2, CH=CHCH2], 2.31-2.38 (m, 6 H, 
alkyne-CH, CH2CH=CH, Ts-CH3), 3.21 (s, 3 H, OCH3), 3.51-3.59 (m, 1 H, CHOMOM), 
3.60-3.65 (m, 4 H, CH2OTs, CH2OTIPS), 3.93 (dd, 3J1 ≈ 3J2 = 5.0 Hz, 1 H, CHOH), 4.32-
4.41 (m, 1 H, CHOTIPS), 4.54, 4.62 (2 d, J = 6.7 Hz each, 2 H, MOM-CH2), 5.34-5.42 (m, 
2 H, olefin-CH), 7.28, 7.71 (2 d, J = 8.1 Hz each, 4 H, aromatic-CH). 
13C NMR (62.9 MHz, CDCl3): δ = 7.2 ( +, CH3), 12.1, 12.3 (2 +, TIPS-CH), 18.1 ( +, TIPS-
CH3), 21.7 ( +, Ts-CH3), 22.1 [ -, CH2(CH2)2OTIPS], 26.0 [ -, CH=CH(CH2)2CH2], 27.2 ( -, 
CH=CHCH2), 27.8 ( -, CH=CHCH2CH2), 31.5 ( -, CH2CH2OTIPS), 33.1 [ -, 
CH2(CH2)3OTIPS], 36.9 ( -, CH2CH=CH), 37.0 ( +, CHCH3), 41.2 ( +, CHCH2OTs), 56.0 ( 
+, OCH3), 62.8 ( +, CHOTIPS), 63.1 ( -, CH2OTIPS), 70.1 ( -, CH2OTs), 72.3 ( -, alkyne-
CH), 74.3 ( +, CHOH), 82.2 ( +, CHOMOM), 85.5 ( #, alkyne-C), 95.7 ( -, MOM-CH2), 
124.5 ( +, olefin-CH), 127.9, 129.9 (2 +, aromatic-CH), 132.1 ( +, olefin-CH), 133.1, 144.8 
(2 #, aromatic-C). 
IR (neat): v~ = 3502 cm-1 (OH), 3310 cm-1 (alkyne-CH), 2943 cm-1, 2866 cm-1 (alkyl), 2113 
cm-1 (C≡C), 1464 cm-1 (C=C), 1365 cm-1, 1178cm-1 (SO2-OR). 
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MS (FD): m/z (%) = 809 (100) [M+ - i-Pr], 224 (30). 
 
 
(9R,10R,11S,12S,16Z,19S)-19-Ethynyl-3,3,21,21-tetraisopropyl-9-(methoxymethoxy)-
2,10,12,22-tetramethyl-4,20-dioxa-3,21-disilatricos-16-en-11-ol (49): 
 
OTIPS
H
OTIPS
OH OMOM
 
 
 
A mixture of 48 (57 mg, 67 µmol), sodium iodide (50 mg, 0.34 mmol), zinc dust (44 
mg, 0.67 mmol) and glyme (6 ml) was stirred, and heated to reflux for 2.5 h. Then the 
reaction mixture was cooled to ambient temperature and filtered through a small glass 
funnel. The filtrate was diluted with water (4 ml) and extracted with ethyl acetate (3 x 8 
ml). The combined organic extracts were concentrated under reduced pressure to give 45 
mg of the desired product 49 (100% yield) as colorless oil, which was used in the next 
step without further purification. - TLC (petroleum ether/ethyl acetate, 6:1): Rf = 0.51. - 
[α]27.2D = -20.3 (c 1.00, CH2Cl2). 
1H NMR (250 MHz, CDCl3): δ = 0.73 (d, J = 6.7 Hz, 3H, CH2CHCH3), 0.84 (d, J = 7.1 Hz, 3 
H, CHCH3), 0.95-1.10 (m, 42 H, 2 TIPS), 1.19-1.51 [m, 9 H, CH=CHCH2CH2, 
(CH2)3CH2OTIPS, CHCH3], 1.59-1.80 [m, 3 H, CH2CHCH3, CH=CH(CH2)2CH2], 1.92-2.02 
(m, 2 H, CH=CHCH2), 2.32-2.33 (m, 2 H, alkyne-CH, CH2CH=CH), 2.38-2.43 (m, 1 H, 
CH2CH=CH), 3.30-3.33 (m, 4 H, CHOMOM, OCH3), 3.59-3.64 (m, 4 H, CH2OTIPS, 
CHOH), 4.34-4.41 (m, 1 H, CHOTIPS), 4.57, 4.68 (2 d, J = 6.7 Hz each, 2 H, MOM-CH2), 
5.39-5.49 (m, 2 H, olefin-CH). 
13C NMR (62.9 MHz, CDCl3): δ = 5.8 ( +, CHCH3), 12.0, 12.3 (2 +, TIPS-CH), 15.7 ( +, 
CH2CHCH3), 18.0, 18.1 (2 +, TIPS-CH3), 22.1 [ -, CH2(CH2)2OTIPS], 26.8 [ -, 
CH=CH(CH2)2CH2], 27.0 ( -, CH=CHCH2), 28.1 ( -, CH=CHCH2CH2), 31.3 ( -, 
CH2CH2OTIPS), 33.1 [ -, CH2(CH2)3OTIPS], 36.1 ( +, CH2CHCH3), 36.3 ( +, CHCH3), 36.9 
( -, CH2CH=CH), 56.0 ( +, OCH3), 62.9 ( +, CHOTIPS), 63.2 ( -, CH2OTIPS), 72.2 ( -, 
alkyne-CH), 79.6 ( +, CHOH), 83.3 ( +, CHOMOM), 85.6 ( #, alkyne-C), 95.6 ( -, MOM-
CH2), 124.1, 132.9 (2 +, olefin-CH). 
IR (neat): v~ = 3507 cm-1 (OH), 3312 cm-1 (alkyne-CH), 2942 cm-1, 2866 cm-1 (alkyl), 2113 
cm-1 (C≡C), 1463 cm-1, 1383 cm-1 (C=C). 
MS (FD): m/z (%) = 1367 (100) [2M+H+], 640 (80) [M+ - i-Pr]. 
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MS (ESI): m/z (%) = 705 (30) [M+Na+], 651 (40) [M+-OCH3]. 
HRMS (FT-ICR-ESI): calc. for C38H75O4Si2 [M+-OCH3-]: 651.5198404, found: 
651.5208080; calc. for C39H78O5Si2Na [M+Na+]: 705.5279998, found:705.5268340. 
 
 
(1S,2S,6Z,9S)-1-{(1S,2R)-2-(Methoxymethoxy)-1-methyl-6-[(triisopropylsilyl)oxy] hexyl}-2-
methyl-9-[(triisopropylsilyl)oxy]-6-undecen-10-ynyl 2,2,2-trichloroethyl carbonate (50): 
 
OTIPS
H
OTIPS
O OMOMTroc
 
 
 
To a stirred solution of 49 (67 mg, 98 µmol) in anhydrous dichloromethane (2 ml) was 
added absolute pyridine (143 µl, 1.77 mmol) and dimethylaminopyridine (2 mg, 16 µmol). 
The resulting mixture was cooled to 0°C, treated by dropwise addition with 2,2,2-
trichloroethyl chloroformate (79 µl, 0.60 mmol) which resulted in the formation of a white 
precipitate. Thereafter the reaction mixture was allowed to warm to ambient temperature 
and to stir for 18 h. To destroy the excess of the chloroformate, water (2 ml) was added 
carefully and gas evolution was evident. The layers were separated and the aqueous 
phase was extracted with dichloromethane (3 x 2 ml). The combined organic extracts 
were washed once with 1M aqueous hydrochloric acid (2 ml) and water (2 ml), dried over 
MgSO4, filtrated and evaporated on a rotatory evaporator. The crude crystalline material 
was purified by flash column chromatography (petroleum ether/dichloromethane, 5:1 → 
dichloromethane) to give 83 mg of the desired product 50 (99% yield) as colorless oil. - 
TLC (petroleum ether/dichloromethane, 5:1): Rf = 0.15. - [α]23.4D = -3.3 (c 1.00, CH2Cl2). 
1H NMR (250 MHz, CDCl3): δ = 0.86 (d, J = 6.8 Hz, 3H, CH2CHCH3), 0.90 (d, J = 6.9 Hz, 3 
H, CHCH3), 0.95-1.10 (m, 42 H, 2 TIPS), 1.14-1.58 [m, 9 H, CH=CHCH2CH2, 
(CH2)3CH2OTIPS, CHCH3], 1.81-2.08 [m, 5 H, CH2CHCH3, CH=CH(CH2)2CH2, 
CH=CHCH2], 2.30-2.42 (m, 3 H, alkyne-CH, CH2CH=CH), 3.31 (s, 3 H, OCH3), 3.39-3.41 
(m, 1 H, CHOMOM), 3.61 (t, J = 6.1 Hz, 2 H, CH2OTIPS), 4.35-4.41 (m, 1 H, CHOTIPS), 
4.56, 4.58 (2 d, J = 7.0 Hz each, 2 H, MOM-CH2), 4.72-4.77 (m, 3 H, CHOTroc, Troc-
CH2), 5.41-5.45 (m, 2 H, olefin-CH). 
13C NMR (62.9 MHz, CDCl3): δ = 9.9 ( +, CHCH3), 12.0, 12.2 (2 +, TIPS-CH), 16.3 ( +, 
CH2CHCH3), 18.1 ( +, TIPS-CH3), 22.0 [ -, CH2(CH2)2OTIPS], 27.2 [ -, CH=CH(CH2)2CH2], 
27.8 ( -, CH=CHCH2), 30.3 ( -, CH=CHCH2CH2), 31.3 ( -, CH2CH2OTIPS), 33.1 [ -, 
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CH2(CH2)3OTIPS], 34.6 ( +, CH2CHCH3), 36.8 ( +, CHCH3), 36.9 ( -, CH2CH=CH), 55.9 ( 
+, OCH3), 62.8 ( +, CHOTIPS), 63.2 ( -, CH2OTIPS), 72.3 ( -, alkyne-CH), 76.6 ( -, Troc-
CH2), 79.2 ( +, CHOMOM), 85.0 ( +, CHOTroc), 85.5 ( #, alkyne-C), 94.9 ( #, CCl3), 96.0 ( 
-, MOM-CH2), 124.5, 132.4 (2 +, olefin-CH), 154.5 ( #, CO). 
IR (neat): v~ = 3311 cm-1 (alkyne-CH), 2925 cm-1, 2867 cm-1 (alkyl), 2113 cm-1 (C≡C), 1760 
cm-1 (carbonate-CO), 1463 cm-1, 1383 cm-1 (C=C). 
MS (FD): m/z (%) = 881 (100) / 879 (80) [M+Na+]. 
MS (FAB): m/z (%) = 881 (100) / 879 (100) [M+Na+], 859 (20) / 857 (30) [M+]. 
 
 
(1S,2S,6Z,9S)-1-[(1S,2R)-6-Hydroxy-2-(methoxymethoxy)-1-methylhexyl]-2-methyl-9-
[(triisopropylsilyl)oxy]-6-undecen-10-ynyl 2,2,2-trichloroethyl carbonate (51): 
 
OTIPS
H
OH
O OMOMTroc
 
 
 
To a cooled (0°C) solution of silyl ether 50 (83 mg, 97 µmol) in anhydrous THF (1.5 
ml) was added dropwise a mixture of HF.pyridine complex in dry pyridine / THF mixture 
[HF.pyridine complex (228 µl), pyridine (0.62 ml), THF (1.09 ml)]. The resulting reaction 
mixture was allowed to warm to room temperature and to stir at inert atmosphere for 7 h 
(TLC monitoring). Thereafter the reaction was diluted with ethyl acetate (2 ml) and 
quenched by careful addition of saturated aqueous NaHCO3 (2 ml). The layers were 
separated and the aqueous phase was extracted with ethyl acetate (3 x 3 ml). The 
combined organic extracts were washed once with 1M aqueous hydrochloric acid (2 ml) 
and water (2 ml), dried over MgSO4, filtered, and concentrated under reduced pressure. 
Flash column chromatography (petroleum ether/ethyl acetate, 3:2) of the residue provided 
pure alcohol 51 (38 mg, 56% yield) as a colorless oil together with recovered starting 
material 50 (19 mg, 42%). - TLC (petroleum ether/ethyl acetate, 3:2): Rf = 0.48. - [α]25.6D = 
-1.9 (c 1.00, CH2Cl2). 
1H NMR (250 MHz, CDCl3): δ = 0.86 (d, J = 6.8 Hz, 3H, CH2CHCH3), 0.91 (d, J = 6.9 Hz, 3 
H, CHCH3), 1.01-1.09 (m, 21 H, TIPS), 1.14-1.53 [m, 9 H, CH=CHCH2CH2, (CH2)3CH2OH, 
CHCH3], 1.82-2.05 [m, 5 H, CH2CHCH3, CH=CH(CH2)2CH2, CH=CHCH2], 2.31-2.42 (m, 3 
H, alkyne-CH, CH2CH=CH), 3.32 (s, 3 H, OCH3), 3.39-3.44 (m, 1 H, CHOMOM), 3.58 (t, J 
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= 6.3 Hz, 2 H, CH2OH), 4.35-4.41 (m, 1 H, CHOTIPS), 4.53, 4.58 (2 d, J = 7.0 Hz each, 2 
H, MOM-CH2), 4.72-4.77 (m, 3 H, CHOTroc, Troc-CH2), 5.41-5.45 (m, 2 H, olefin-CH). 
13C NMR (62.9 MHz, CDCl3): δ = 10.0 ( +, CHCH3), 12.2 ( +, TIPS-CH), 16.2 ( +, 
CH2CHCH3), 18.0 ( +, TIPS-CH3), 21.8 [ -, CH2(CH2)2OH], 27.1 [ -, CH=CH(CH2)2CH2], 
27.8 ( -, CH=CHCH2), 30.3 ( -, CH=CHCH2CH2), 31.3 ( -, CH2CH2OH), 32.7 [ -, 
CH2(CH2)3OH], 34.7 ( +, CH2CHCH3), 36.9 ( +, CHCH3), 37.0 ( -, CH2CH=CH), 56.0 ( +, 
OCH3), 62.6 ( -, CH2OH), 62.8 ( +, CHOTIPS), 72.3 ( -, alkyne-CH), 76.5 ( -, Troc-CH2), 
79.3 ( +, CHOMOM), 84.8 ( +, CHOTroc), 85.5 ( #, alkyne-C), 94.9 ( #, CCl3), 96.1 ( -, 
MOM-CH2), 124.5, 132.4 (2 +, olefin-CH), 154.5 ( #, CO). 
IR (neat): v~ = 3507 cm-1 (OH), 3310 cm-1 (alkyne-CH), 2942 cm-1, 2867 cm-1 (alkyl), 2113 
cm-1 (C≡C), 1757 cm-1 (carbonate-CO), 1463 cm-1, 1383 cm-1 (C=C). 
MS (FAB): m/z (%) = 725 (4) / 723 (4) [M+Na+], 221 (100). 
 
 
(5R,6S,7S,8S,12Z,15S)-5-(Methoxymethoxy)-6,8-dimethyl-7-{[(2,2,2-trichloroethoxy) 
carbonyl]oxy}-15-[(triisopropylsilyl)oxy]-12-heptadecen-16-ynoic acid (52): 
 
OTIPS
H COOH
O OMOMTroc
 
 
 
The alcohol 51 (33 mg, 47 µmol) was dissolved in acetone (1 ml) and treated with a 
5% aqueous solution of NaHCO3 (0.2 ml). This magnetically stirred heterogeneous 
reaction mixture was cooled to 0°C and treated at once with potassium bromide (1 mg, 8.4 
µmol) followed by TEMPO (8 mg, 49 µmol). Thereafter was added dropwise an aqueous 
sodium hypochlorite solution (30 µl, 59 µmol) and the resulting mixture was vigorously 
stirred at 0°C for 1 h. Then a new portion of sodium hypochlorite (12 µl, 23 µmol) was 
added and stirring continued for additional 2 h. The reaction mixture was quenched with 
5% aqueous solution of NaHCO3 (0.5 ml) and the acetone was removed under reduced 
pressure. The residue was acidified to pH 6 using a 10% aqueous solution of citric acid 
and extracted with ethyl acetate (4 x 2 ml). The combined organic layers were washed 
once with water (2 ml), dried over anhydrous MgSO4, filtered, and concentrated in vacuo. 
The excess of TEMPO was removed by flash column chromatography (petroleum 
ether/ethyl acetate, 4:1) and 34 mg of a mixture of desired acid 52 with an unknown by-
product was obtained (100 % yield) as a pale yellow thick oil. The resulting material was 
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used in the next step without further purification. - TLC (petroleum ether/ethyl acetate, 
4:1): Rf = 0.26. - [α]27.8D = -5.2 (c 1.00, CH2Cl2). 
1H NMR (250 MHz, CDCl3): δ = 0.86 (d, J = 6.9 Hz, 3H, CH2CHCH3), 0.91 (d, J = 6.8 Hz, 3 
H, CHCH3), 1.02-1.10 (m, 21 H, TIPS), 1.13-1.68 (m, 7 H, CH=CHCH2CH2, 
(CH2)2CH2COOH, CHCH3], 1.70-2.08 [m, 5 H, CH2CHCH3, CH=CH(CH2)2CH2, 
CH=CHCH2], 2.38-2.45 (m, 5 H, CH2COOH, alkyne-CH, CH2CH=CH), 3.32 (s, 3 H, 
OCH3), 3.39-3.48 (m, 1 H, CHOMOM), 4.35-4.48 (m, 1 H, CHOTIPS), 4.54, 4.58 (2 d, J = 
7.0 Hz each, 2 H, MOM-CH2), 4.67-4.78 (m, 3 H, CHOTroc, Troc-CH2), 5.41-5.47 (m, 2 H, 
olefin-CH). 
13C NMR (62.9 MHz, CDCl3): δ = 10.1 ( +, CHCH3), 12.3 ( +, TIPS-CH), 16.2 ( +, 
CH2CHCH3), 18.1 ( +, TIPS-CH3), 20.7 ( -, CH2CH2COOH), 27.1 [ -, CH=CH(CH2)2CH2], 
29.7 ( -, CH=CHCH2), 30.1 ( -, CH=CHCH2CH2), 30.7 [ -, CH2(CH2)2COOH], 33.8 ( -, 
CH2COOH), 34.7 ( +, CH2CHCH3), 37.0 ( -, CH2CH=CH), 37.1 ( +, CHCH3), 56.0 ( +, 
OCH3), 62.9 ( +, CHOTIPS), 72.3 ( -, alkyne-CH), 76.5 ( -, Troc-CH2), 79.1 ( +, 
CHOMOM), 84.3 ( +, CHOTroc), 84.4 ( #, alkyne-C), 94.9 ( #, CCl3), 96.2 ( -, MOM-CH2), 
124.5, 132.3 (2 +, olefin-CH), 154.3 ( #, CO), 178.5 ( #, COOH). 
IR (neat): v~ = 3308 cm-1 (alkyne-CH), 2961 cm-1, 2922 cm-1 (alkyl), 2857 cm-1 (COOH), 
2113 cm-1 (C≡C), 1756 cm-1 (carbonate-CO), 1715 cm-1 (COOH). 
MS (FAB): m/z (%) = 739 (2) / 737 (3) [M+Na+], 207 (100). 
 
 
(5R,6S,7S,8S,12Z,15S)-15-Hydroxy-5-(methoxymethoxy)-6,8-dimethyl-7-{[(2,2,2 trichloro 
ethoxy)carbonyl]oxy}-12-heptadecen-16-ynoic acid (53): 
 
OH
H COOH
O OMOMTroc
 
 
 
To a solution of 52 (34 mg, 47 µmol) in anhydrous THF (0.8 ml) was added dropwise 
a 1M solution of tetrabutylammoniumfluoride in THF (0.29 mmol, 290 µl) at 0°C. After 
complete addition, the reaction mixture was allowed to warm up to room temperature and 
stirred for 20 h. Thereafter the mixture was diluted with ethyl acetate (2 ml) and the 
resulting solution was washed once with saturated aqueous solution of ammonium 
chloride (1 ml). The layers were separated and the aqueous phase was extracted 
thoroughly with ethyl acetate (4 x 1 ml). The combined organic layers were washed with 
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brine (1 ml), dried over MgSO4, filtered, and concentrated under reduced pressure. 
Purification by flash column chromatography (petroleum ether/ethyl acetate, 1:1) afforded 
8 mg of compound 53 (30% yield, over two steps) as colorless oil. - TLC (petroleum 
ether/ethyl acetate, 1:1): Rf = 0.46. 
1H NMR (250 MHz, CDCl3): δ = 0.87 (d, J = 6.9 Hz, 3H, CH2CHCH3), 0.93 (d, J = 6.9 Hz, 3 
H, CHCH3), 1.14-1.67 (m, 7 H, CH=CHCH2CH2, (CH2)2CH2COOH, CHCH3], 1.80-2.06 [m, 
5 H, CH2CHCH3, CH=CH(CH2)2CH2, CH=CHCH2], 2.25-2.38 (m, 2 H, CH2COOH), 2.39-
2.63 (m, 3 H, alkyne-CH, CH2CH=CH), 3.32 (s, 3 H, OCH3), 3.37-3.46 (m, 1 H, 
CHOMOM), 4.31-4.35 (m, 1 H, CHOH), 4.52-4.59 (m, 2 H, MOM-CH2), 4.72-4.78 (m, 3 H, 
CHOTroc, Troc-CH2), 5.43-5.52 (m, 2 H, olefin-CH). 
13C NMR (100 MHz, CDCl3): δ = 10.3 (CHCH3), 16.5 (CH2CHCH3), 21.1 (CH2CH2COOH), 
27.2 [CH=CH(CH2)2CH2], 30.1 (CH=CHCH2), 30.6 (CH=CHCH2CH2), 31.1 
[CH2(CH2)2COOH], 34.0 (CH2COOH), 34.9 (CH2CHCH3), 35.9 (CH2CH=CH), 37.3 
(CHCH3), 56.4 (OCH3), 62.2 (CHOH), 66.3 (alkyne-CH), 75.5 (Troc-CH2), 79.2 
(CHOMOM), 84.9 (CHOTroc), 85.0 (alkyne-C), 95.2 (CCl3), 96.4 (MOM-CH2), 123.9, 
134.3 (olefin-CH), 154.9 (CO), 177.8 (COOH). 
MS (ESI): m/z (%) = 559 (100) /557 (80) [M-H+], 443 (35), 425 (35). 
HRMS (FT-ICR-ESI): calc. for C24H36O8Cl3 [M-H+]: 557.1481310, found: 557.1481248. 
 
 
(6R,7S,8S,9S,16S)-16-Ethynyl-6-(methoxymethoxy)-7,9-dimethyl-2-oxooxacyclohexadec-
13-en-8-yl 2,2,2-trichloroethyl carbonate (54): 
 
O
O
H
OMOM
OTroc
 
 
 
To a solution of hydroxy acid 53 (5 mg, 8.9 µmol) in anhydrous THF (0.3 ml) was 
added dropwise absolute triethylamine (4 µl, 28.8 µmol) and the resulting mixture was 
stirred for 10 min at room temperature before 2,4,6-trichlorobenzoyl chloride (2 µl, 12.8 
µmol) was added. The reaction mixture was stirred for 2 h at ambient temperature during 
which time some fine precipitation was obtained. In a separate flask, connected with a 
reflux condenser and under inert atmosphere, was dissolved dimethylaminopyridine (3 
mg, 19.7 µmol) in anhydrous toluene (6 ml) and the resulting solution was heated to 78°C 
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(oil bath). After the temperature was constant, the solution of the mixed anhydride, 
dissolved in additional toluene (0.7 ml) was added slowly to the amine solution over a 
period of 2 h using a syrange pump. Stirring was continued for 1 h at the same 
temperature. Thereafter the reaction mixture was allowed to cool to ambient temperature 
and diluted with diethyl ether (5 ml), washed successively with 1M aqueous hydrochloric 
acid (4 ml), saturated aqueous solution of NaHCO3 (5 ml) and water (5 ml), dried over 
MgSO4, filtered and concentrated under reduced pressure. Purification of the residue by 
flash column chromatography (petroleum ether/diethyl ether, 2:1) gave 4.15 mg of the 
desired macrolacton 54 (86% yield) as colorless oil. - TLC (petroleum ether/diethyl ether, 
2:1): Rf = 0.35. - [α]28.2D = -9.6 (c 0.377, CH2Cl2). 
1H NMR (400 MHz, CDCl3): δ = 0.91 (d, J = 7.0 Hz, 3H, CH2CHCH3), 0.94 (d, J = 6.7 Hz, 3 
H, CHCH3), 1.43-1.70 (m, 7 H, CH=CHCH2CH2, (CH2)2CH2CO, CH=CHCH2], 1.84-2.07 
[m, 5 H, CH2CHCH3, CH=CH(CH2)2CH2, CHCH3], 2.22-2.30 (m, 2 H, CH2CO), 2.38-2.47 
(m, 2 H, alkyne-CH, CH2CH=CH), 2.55-2.64 (m, 1 H, CH2CH=CH), 3.32 (s, 3 H, OCH3), 
3.45-3.50 (m, 1 H, CHOMOM), 4.43-4.46 (m, 1 H, MOM-CH2), 4.59-4.61 (m, 1 H, MOM-
CH2), 4.70-4.77 (m, 2 H, Troc-CH2), 4.79-4.85 (m, 1 H, CHOTroc), 5.31-5.39 (m, 2 H, 
CHOCO, olefin-CH), 5.43-5.52 (m, 1 H, olefin-CH). 
13C NMR (100 MHz, CDCl3): δ = 9.4 (CHCH3), 17.2 (CH2CHCH3), 21.7 (CH2CH2CO), 27.9 
[CH=CH(CH2)2CH2], 29.1 (CH=CHCH2), 29.7 (CH=CHCH2CH2), 30.3 [CH2(CH2)2CO], 34.2 
(CH2CO), 34.8 (CH2CHCH3), 36.3 (CH2CH=CH), 36.5 (CHCH3), 55.9 (OCH3), 62.2 
(CHOCO), 62.7 (alkyne-CH), 73.6 (Troc-CH2), 77.2 (CHOMOM), 85.7 (CHOTroc), 86.5 
(alkyne-C), 95.4 (CCl3), 95.5 (MOM-CH2), 123.6, 133.7 (olefin-CH), 154.8 (carbonate-CO), 
171.7 (lactone-CO). 
MS (ESI): m/z (%) = 565 (100) / 563 (100) [M+Na+]. 
HRMS (FT-ICR-ESI): calc. for C24H35O7Cl3Na [M+Na+]: 563.1335320, found: 
563.1340577. 
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Typical procedure for preparation of the di-n-butylboron triflate:[123, 124] 
 
B O S
O
O
CF3
 
 
 
To a Gringard solution, prepeared from magnesium (17 g, 0.7 mol) and n-butyl 
bromide (75 ml, 0.7 mol) in anhydrous diethyl ether (250 ml) was added dropwise a 
solution of boron triflouride etherate (8.8 ml, 0.07 mol) in dry diethyl ether (23 ml) at a rate 
sufficient to cause gentle refluxing (40 min). After complete addition, the resulting mixture 
was refluxed for 2.5 h and then cooled to room temperature under an atmosphere of 
argon. Subsequently, a solution of concentrated hydrochloric acid (45 ml) in water (135 
ml) was added carefully. The ether layer was separated, washed with water (100 ml); 
saturated aqueous solution of NaHCO3 (100 ml), and again with water (100 ml), dried over 
MgSO4, filtered and the solvent was removed by distillation under inert atmosphere. The 
residue was distilled under reduced pressure to provide 9.79 g (78% yield) of pure tri-n-
butylborane with b.p.: 106-110°C / 20 Torr (lit. [123]: 108-110°C / 20 Torr) as a colorless 
mobile liquid that undergoes oxidation rapidly in the air.  
Trifluoromethanesulfonic acid (4.31 ml, 0.05 mmol) was added dropwise to the tri-n-
butylborine (8.86 g, 0.05 mmol) at room temperature under argon and the color changed 
to dark yellow (exothermic reaction). The reaction mixture was stirred for 3 h and then 
distilled in vacuum under inert atmosphere to afford 12.3 g (92% yield) of di-n-butylboron 
triflate with b.p.: 40-42°C / 0.7 Torr (lit. [124]: 37°C / 0.12 Torr) as a colorless to pale yellow 
liquid. According to the literature [124] the product was stored as a 1M solution in 
dichloromethane. 
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8.3 General Procedures for Preparation of Cyclohexenylamines 
 
 
4-Pentenal (58): 
 
CHO 
 
 
Procedure according to the literature.[132,133] Purification by distillation provided 58 as a 
colorless liquid (3.9 g, 40%) with b.p.: 100-105°C (lit.:[133] 104°C). 
1H NMR (400 MHz, CDCl3): δ = 2.36-2.40 (m, 2 H, CH2), 2.52-2.56 (m, 2 H, CH2), 5.00-
5.08 (m, 2 H, olefinic-H), 5.77-5.86 (m, 1 H, olefinic-H), 9.77 (t, J = 1.7 Hz, 1 H, CHO). − 
IR (neat): v~ = 1737 cm-1, 1642. 
 
 
Typical procedure for preparation of N1-(allyl-4-pentenyl)-carbamates (59a, 59b): 
 
N
O
R
H
59a (R = BnO)
59b (R = tBuO)  
 
 
Under inert atmosphere a stirred solution of aldehyde 58 (1.0 g, 12 mmol), 
allyltrimethylsilane (1.37 g, 12 mmol) and carbamate (12 mmol) in 20 ml dichloromethane 
was cooled to 0-5°C. At this point borontrifluoride etherate (1.48 ml, 12 mmol) was added 
at once. After 30 min of stirring the reaction mixture was allowed to warm up to room 
temperature and stirred for 12 h. Then the mixture was poured into saturated aqueous 
NaHCO3 and diluted with 30 ml toluene. The organic phase was washed with brine, dried 
(Na2SO4) and evaporated in vacuo. The crude product was purified by flash column 
chromatography on silica gel. 
 
N1-(1-allyl-4-pentenyl)-benzylcarbamate (59a): Chromatography  (eluent: 
heptane/ethyl acetate; 7:1) provided 59a as a white solid (1.87 g, 60%). − TLC 
(heptane/ethyl acetate, 7:1): Rf = 0.41. − m.p.: 26-28°C. − 1H NMR (400 MHz, CDCl3): δ = 
1.44-1.61 (m, 2 H, CH2), 2.06-2.17 (m, 2 H, CH2), 2.19-2.30 (m, 2 H, CH2), 3.71-3.74 (m, 1 
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H, CH), 4.57 (d, J = 7.4 Hz, 1 H, NH), 4.93-5.04 (m, 4H, olefinic H), 5.07 (s, 2 H, aryl-
CH2), 5.70-5.83 (m, 2 H, olefinic-H), 7.29-7.36 (m, 5 H, aryl-H). − 13C NMR (50 MHz, 
CDCl3): δ = 30.1, 33.8, 39.4 (3 CH2), 50.3 (CH), 66.5 (aryl-CH2), 115.0, 117.9 (2 olefinic-
CH2), 128.0, 128.5 (5 aryl-CH), 134.0 (olefinic-CH), 136.6 (aryl-CH), 137.8 (olefinic-CH), 
155.9 (CO). − MS (EI): m/z (%): 218 (15) [M+ - allyl], 174 (20), 91 (100). − C16H21NO2 
(259.35): calc. C 74.10, H 8.10, N 5.40; found C 73.96, H 7.82, N 5.42. 
 
N1-(1-allyl-4-pentenyl)-tert-butylcarbamate (59b): Chromatography (petroleum 
ether/ethyl acetate; 5:1) provided 59b as a colorless oil (1.3 g, 48%).− TLC (petroleum 
ether/ethyl acetate, 5:1): Rf = 0.51. − 1H NMR (400 MHz, CDCl3): δ = 1.43 (s, 9 H, tert-
butyl), 1.46-1.58 (m, 2 H, CH2), 2.03-2.40 (m, 4 H, CH2), 3.64 (m, 1 H, CH), 4.33 (s, 1 H, 
NH), 4.94-5.09 (m, 4 H, olefinic-H), 5.71-5.85 (m, 2 H, olefinic-H). − 13C NMR (100 MHz, 
CDCl3): δ = 29.4 (C(CH3)3), 31.2, 34.9, 40.5 (3 CH2), 50.7 (CH), 64.8 (C(CH3)3), 115.9, 
118.7 (2 olefinic-CH2), 135.5, 139.2 (2 olefinic-CH), 156.8 (CO). − MS (ESI): m/z (%): 248 
(100) [M + Na]+. − C13H23NO2 (225.33): calc. C 69.30, H 10.29, N 6.22; found C 69.01, H 
9.94, N 6.38. 
 
 
N4-Benzyl-1,7-octadien-4-amine (59c): 
 
N
H
Bn
 
 
 
Under inert atmosphere, freshly distilled benzylamine (1.29 g, 12 mmol) was 
combined with 4Å molecular sieves (1.08 g) and cooled to 0°C. Thereafter the aldehyde 
58 (1 g, 12 mmol) was added dropwise and the reaction mixture stirred for 1 h and then 
was allowed to warm up to room temperature and stirred for additional 30 min. Anhydrous 
diethyl ether (3 ml) was added and the organic layer separated. The aqueous layer was 
extracted with ether and the combined organic layers were washed with brine, dried 
(Na2SO4) and concentrated in vacuo. The obtained crude 4-pentenyl-(benzyl)-imine was 
used without further purification. To a stirred solution of crude 4-pentenyl-(benzyl)-imine in 
absolute methanol-chloroform (1/1 : v/v, 32 ml) was added a 0.3M solution of 
trifluoroacetic acid in absolute methanol (44 ml, 13 mmol) followed by allyltributyl 
stannane (4.48 g, 14 mmol). The reaction mixture was stirred 48 h at room temperature, 
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and thereafter was quenched with 1M hydrochloric acid and extracted with hexane/ethyl 
ether (4/1). Then the pH of the resulting solution was adjusted to pH = 7 with 1M solution 
of potassium hydroxide and the aqueous phase was again extracted with ether. The last 
organic layer was dried (K2CO3), filtered, and concentrated under reduced pressure. The 
residue was purified by flash column chromatography on aluminum oxide (eluent: 
petroleum ether/ethyl acetate; 5:1) to provide 59c as a brown liquid (0.65 g, 25% from the 
aldehyde 58, > 99% by GC area % analysis). − TLC (aluminum oxide plate; petroleum 
ether/ethyl acetate, 5:1): Rf = 0.79. 
1H NMR (400 MHz, CDCl3): δ = 1.50-1.58 (m, 2 H, CH2), 2.09-2.29 (m, 4 H, CH2), 2.62-
2.67 (m, 1 H, CH), 3.76 (s, 2 H, aryl-CH2), 4.92-5.09 (m, 4 H, olefinic-H), 5.73-5.84 (m, 2 
H, olefinic-H), 7.20-7.35 (m, 5 H, aryl-H). 
13C NMR (125 MHz, CDCl3): δ = 30.0, 33.2, 38.3 (3 CH2), 51.1 (aryl-CH2), 44.8 (CH), 
114.4, 117.2 (2 olefinic-CH2), 126.8, 128.1, 128.3 (5 aryl-CH), 135.6, 138.8 (2 olefinic-
CH), 140.8 (aryl-C). 
MS (ESI): m/z (%): 216 (100) [M + H]+. 
 
 
N1-(1-Allyl-4-pentenyl)-N1-benzyl-2,2,2-trifluoracetamide (59d): 
 
N
O
F3C
Bn
 
 
 
A stirred solution of amine 59c (100 mg, 0.46 mmol) and triethylamine (278 mg, 2.78 
mmol) in dichloromethane (2 ml) was cooled to -10°C and treated with trifluoracetic acid 
anhydride (293 mg, 1.39 mmol) in a dropwise fashion. The reaction mixture was stirred for 
10 min, and then allowed to warm up to room temperature and stirred for additional 1½ h. 
Thereafter the reaction was quenched by addition of phosphate puffer pH 7 (3 ml) and 
methanol (6 ml) and stirring was continued for 15 min. Most of the solvent was removed 
under reduced pressure and the residue was extracted three times with ether and the 
combined extract was washed with a saturated solution of NaHCO3, 1M hydrochloric acid 
and brine. The combined organic layer was dried (Na2SO4), filtered, and evaporated and 
the crude product was purified by flash column chromatography on silica gel (eluent: 
petroleum ether/ethyl acetate; 5:1) to afford 59d as a colorless liquid (130 mg, 90%, >98% 
by GC area % analysis). − TLC (petroleum ether/ethyl acetate, 5:1): Rf = 0.68. 
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1H NMR (400 MHz, CDCl3): δ = 1.56-1.89 (m, 4 H, CH2), 2.30-2.33 (m, 2 H, CH2), 3.58-
4.03 (m, 1 H, CH), 4.41-4.72 (m, 2 H, aryl-CH2), 4.83-5.08 (m, 4 H, olefinic-H), 5.52-5.64 
(m, 2 H, olefinic-H), 7.26-7.37 (m, 5 H, aryl-H). 
13C NMR (100 MHz, CDCl3): δ = 31.1, 31.6, 31.7, 33.0, 37.1, 39.3, 46.7, 52.5, 58.9, 60.6, 
116.3, 116.5, 118.9, 119.7, 128.6, 129.4, 129.7, 129.8, 134.3, 135.7, 136.5, 137.8, 138.1, 
138.5, 159.3, 159.6. 
MS (EI): m/z (%): 311 (M+), 270 (M+ - allyl). 
- C17H20F3NO (311.20): calc. C 65.61, H 6.43, N 4.50; found C 65.98, H 6.28, N 4.50. 
 
 
General procedure for preparation of cyclohexenylamines (63a, b, d) using RCM: 
 
N
R1
R2
63a (R1 = H; R2 = Cbz)
63b (R1 = H, R2 = Boc)
63d (R1 = Bn, R2 = F3CCO) 
 
 
Under inert atmosphere a solution of diene (0.5 mmol) in absolute and degassed 
dichloromethane (90 ml) and ruthenium carbene 60 (14 mg, 0.015 mmol, 3 mol%), was 
stirred for 24 h at room temperature. Subsequently, the solvent was removed in vacuo 
and the residue purified by flash column chromatography on silica gel. 
 
N1-(3-cyclohexenyl)benzylcarbamate (63a): Chromatography (eluent: heptane/ethyl 
acetate; 7:1) provide 63a as a white crystals (212 mg, 95%). − TLC (heptane/ethyl 
acetate, 7:1): Rf = 0.26. − m.p.: 61-63°C. − 1H NMR (400 MHz, CDCl3): δ = 1.49-1.59 (m, 
2 H, CH2), 1.86-1.98 (m, 2 H, CH2), 2.12-2.13 (m, 2 H, CH2), 2.38 (d, J = 15.6 Hz, 1 H, 
NH), 3.84 (s, 1 H, CH), 5.08 (s, 2 H, aryl-CH2), 5.58-5.67 (m, 2 H, olefinic-H), 7.29-7.35 
(m, 5 H, aryl-H). − 13C NMR (100 MHz, CDCl3): δ = 23.3, 28.1, 31.9 (3 CH2), 46.1 (CH), 
66.5 (aryl-CH2), 124.3, 127.1 (2 olefinic-CH), 128.16, 128.21, 128.6 (5 aryl-CH), 136.7 
(aryl-C), 158.8 (CO). − IR (KBr): v~ = 3322 cm-1, 1687, 1542. − MS (ESI): m/z (%): 254 
(100) [M + Na]+. − C14H17NO2 (231.16): calc. C 72.70, H 7.41, N 6.06; found C 72.93, H 
7.54, N 6.13. 
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N1-(3-cyclohexyl)tert-butylcarbamate (63b): Chromatography (eluent: petroleum 
ether/ethyl acetate; 5:1) provide 63b as a pale violet crystals (160 mg, 91%). − TLC 
(petroleum ether/ethyl acetate, 5:1): Rf = 0.57. − m.p.: 53-55°C. − 1H NMR (400 MHz, 
CDCl3): δ = 1.29-1.60 (m, 2 H, CH2), 1.44 (s, 9 H, tert-butyl), 1.80-1.89 (m, 2 H, CH2), 
2.06-2.18 (m, 2 H, CH2), 2.37 (dd, J = 1.5, 17.2 Hz, 1 H, NH), 3.77 (s, 1 H, CH), 5.56-5.69 
(m, 2 H, olefinic-H). − 13C NMR (100 MHz, CDCl3): δ = 24.6 (CH2), 29.4 (C(CH3)3), 33.1, 
45.0 (2 CH2), 47.5 (CH), 81.5 (C(CH3)3), 125.6, 128.1 (2 olefinic-CH), 157.5 (CO). − IR 
(KBr): v~ = 3315 cm-1, 1676, 1534. − MS (EI): m/z (%): 141 (57) [M+ - C(CH3)3], 80 (100), 
57 (100). − MS (ESI): m/z (%): 220 (30) [M + Na]+, 198 (10) [M + H]+. − C11H19NO2 
(197.13): calc. C 67.02, H 9.64, N 7.11; found C 66.85, H 9.64, N 6.92. 
 
N1-benzyl-N1-(3-cyclohexenyl)-2,2,2-trifluoracetamide (63d): Chromatography 
(eluent: petroleum ether/ethyl acetate; 5:1) provide 63d as a pale yellow oil which 
solidified on standing (82 mg, 98%). − TLC (petroleum ether/ethyl acetate, 5:1): Rf = 0.68. 
− m.p.: 39-40°C (lit.:[68] 41-44°C). − 1H NMR (400 MHz, CDCl3): δ = 1.67-1.78 (m, 2 H, 
CH2), 1.88-2.39 (m, 4 H, CH2), 4.02-4.21 (m, 1 H, CH), 4.62 (s, 2 H, aryl-CH2), 5.49-5.65 
(m, 2 H, olefinic-H), 7.18-7.36 (m, 5 H, aryl-H). − C15H16F3NO (283.17): calc. C 63.62, H 
5.69, N 4.94; found C 63.39, H 6.02, N 4.91. 
 
 
8-Bromo-2-oxa-4-azabicyclo[3.3.1]nonan-3-one (65a): 
 
Br
N O
O
H
 
 
 
To a cooled to -78°C solution of cyclohexenylamine 63b (20 mg, 0.10 mmol) in 
dichloromethane (2 ml) was added at once N-bromosuccinimide (22 mg, 0.12 mmol) 
under inert atmosphere. After 18 h of stirring at this temperature the reaction mixture was 
allowed to warm up to room temperature. The reaction was controlled by TLC and after 
complete consumption of the starting material (3 days), the reaction mixture was 
quenched by addition of saturated aqueous Na2SO3. The mixture was diluted with ether, 
washed with brine and saturated aqueous NaHCO3, dried (Na2SO4), and concentrated to 
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give a pale yellow oil which solidified on standing. Recrystallization from pentane/ether 
provided 65a as a white crystals (13 mg, 60%). − m.p.: 157°C. 
1H NMR (400 MHz, CDCl3): δ = 1.69 (d, J = 13.6 Hz, 1 H), 1.92-2.01 (m, 3 H, CH2), 2.28-
2.38 (m, 1 H), 2.53 (dd, J = 2.9, 13.8 Hz, 1 H), 3.64 (s, br., 1 H, CHN), 4.46 (s, 1 H, CHBr), 
4.64 (s, 1 H, CH-O), 6.04 (s, br., 1 H, NH). 
13C NMR (100 MHz, CDCl3): δ = 24.0, 24.7, 26.9 (3 CH2), 45.2 (CNH), 48.1 (CHBr), 75.4 
(C-O), 154.0 (C=O). 
MS (ESI): m/z (%): 244 (40) [M + Na]+, 221 (98) [M + H]+. 
 
 
8-Iodo-2-oxa-4-azabicyclo[3.3.1]nonan-3-one (65b): 
 
I
N O
O
H
 
 
 
To a stirred suspension of cyclohexenylamine 63b (20 mg, 0.10 mmol), potassium 
carbonate (28 mg, 0.20 mmol) in anhydrous diethyl ether (3 ml) was added at once iodine 
(52 mg, 0.20 mmol) at room temperature. The reaction was controlled by TLC and after 
complete consumption of the starting material (3 days) ethyl acetate (10 ml) and saturated 
aqueous Na2SO3 (10 ml) was added. The layers were separated and the aqueous layer 
was extracted with ethyl acetate. The combined organic layer was washed with brine, 
dried (Na2SO4), filtered, and the solvent was evaporated in vacuo. Flash column 
chromatography (eluent: ethyl acetate/ethanol; 10:1) afford 65b as a pale yellow crystals 
(20 mg, 74%). − TLC (ethyl acetate/ethanol, 10:1): Rf = 0.46. − m.p.: 158-162°C. 
1H NMR (400 MHz, CDCl3): δ = 1.65-1.80 (m, 1 H), 1.92-2.05 (m, 3 H, CH2), 2.18-2.30 (m, 
1 H), 2.67 (d, J = 12.0 Hz, 1 H), 3.62 (s, br., 1 H, CHN), 4.69 (s, 1 H, CHI), 4.62 (s, 1 H, 
CH-O), 6.48 (s, br., 1 H, NH). 
13C NMR (100 MHz, CDCl3): δ = 25.9, 27.3, 28.6 (3 CH2), 28.7 (CHI), 46.2 (CNH), 77.8 (C-
O), 155.7 (C=O). 
IR (KBr): v~ = 3232 cm-1, 3114, 2942, 1732. 
MS (ESI): m/z (%): 290 (100) [M + Na]+, 268 (45) [M + H]+. 
- C7H10INO2 (266.99): calc. C 31.48, H 3.77, N 5.24; found C 31.62, H 4.07, N 4.96. 
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1H- and 13C-NMR spectra of compound 18. 
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1H- and 13C-NMR spectra of compound 19. 
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1H- and 13C-NMR spectra of compound 22.
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1H- and 13C-NMR spectra of compound 23.
OTIPS
H
O
O O
N
Bn
23
APPENDIX 150 
 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
0.
93
1.
04
1.
18
1.
21
1.
34
1.
39
1.
45
1.
50
1.
53
2.
49
2.
68
2.
71
2.
73
2.
77
3.
15
3.
17
3.
21
3.
22
3.
59
3.
62
3.
65
3.
68
3.
69
3.
70
3.
71
4.
13
4.
14
4.
16
4.
60
4.
64
4.
66
4.
67
7.
12
7.
15
7.
20
7.
24
7.
27
7.
31
 
 
 
180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chloroform-d
10
.4
8
12
.0
7
18
.0
6
22
.3
9
32
.9
1
33
.7
3
37
.8
8
42
.2
2
55
.1
5
63
.3
3
66
.2
1
71
.5
2
77
.0
5
12
7.
47
12
9.
02
12
9.
46
13
5.
11
15
3.
04
17
7.
59
 
 
 
1H- and 13C-NMR spectra of compound 41. 
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1H- and 13C-NMR spectra of compound 43. 
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1H- and 13C-NMR spectra of compound 44. 
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1H- and 13C-NMR spectra of compound 45.
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1H- and 13C-NMR spectra of compound 49.
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1H-NMR spectra of compounds 53 and 54.
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